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 Semaphorins and plexins were initially identified as cell surface receptors 
that function in guiding neuronal axons to their destination. The expression of 
semaphorins and plexins has also been seen in many non-neuronal tissues as well. 
Recent evidence suggests that these axon guidance molecules could function in 
regulating various hallmarks of cancer such as proliferation, tumor angiogenesis, 
invasion and metastasis. Nevertheless, very little has been known about their 
function in glioma progression.  
 The transmembrane protein, Sema5A, has been shown to exhibit 
contradictory functions in different cancer types. It could either elicit oncogenic 
effects or behave as a tumor suppressor. Published reports from our laboratory 
have shown a significant downregulation of Sema5A protein level in high-grade 
glioblastomas. In this study, we analyzed the levels of Sema5A mRNA in human 
glioma biopsies and we found no significant difference in Sema5A mRNA levels 
in different grades of glioma. We also analyzed the Sema5A gene is gliomas so as 
to identify mutations or alternative splice isoforms of Sema5A. Our results 
indicate the presence of a number of novel alternative splice variants of Sema5A 
in gliomas which translate into truncated proteins that are rapidly targeted for 
degradation. No mutations were identified in the Sema5A gene in gliomas. We 
also identified that microRNA-21, a microRNA that is involved in regulating 
many oncogenic signaling pathways, was able to target Sema5A for degradation 
in a post-transcriptional manner. These findings indicate that these mechanisms 
VIII 
 
would contribute to the downregulation of Sema5A protein that was observed in 
high-grade glioblastomas.  
 By using MTS assays and flow cytometry we were able to confirm an anti-
proliferative role of Sema5A in human glioma cell lines. It was observed that 
forced expression of Sema5A in glioma cell lines was able to induce a G0-G1 cell 
cycle arrest with a large percentage of cells stuck in the G1 cell cycle phase. We 
investigated the signaling pathways that link Sema5A to the tumor suppressive 
role in gliomas. It was observed that Sema5A enhanced phosphorylation of cyclin 
D1 which resulted in increased degradation of cyclin D1. A significant reduction 
in levels of phosphorylated Erk1/2 was also observed upon ectopic expression of 
Sema5A in glioma cell lines.  
 All these results indicate that Sema5A plays an important role in inhibiting 
glioma cell proliferation. The downregulation of Sema5A protein observed in 
high-grade gliomas could be accounted for by the presence of alternative splice 
isoforms of Sema5A seen in gliomas as well as miR-21 mediated degradation of 
Sema5A. These findings highlight the need for further explorations of Sema5A as 
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1.1 Glioblastoma and malignant gliomas 
1.1.1 Pathology, risk factors and treatment of gliomas 
Gliomas are one of the most malignant types of cancers mostly due to the 
poor prognosis and also because of the repercussions on the quality of life and 
cognitive functions. Glioblastomas and malignant gliomas are the most common 
primary brain tumors, accounting for 80% of patients with an annual incidence 
rate of 6.02 per 100,000 population new diagnoses per year (Ostrom, Gittleman et 
al. 2013). This type of cancer is commonly seen in older patients aged between 60 
and 80 years old and with increased aging of the population the numbers of 
patients are estimated to increase (Ostrom, Gittleman et al. 2013). Patients mostly 
present with symptoms such as headache, nausea/vomiting, cognition changes, 
personality changes, gait imbalance, aphasia, seizures, hemiparesis and visual 
field defects (Forsyth and Posner 1993; Glantz, Cole et al. 2000). Usually the 
manifestation of symptoms is swift, resembling a stroke. Magnetic resonance 
imaging (MRI) of the brain with and without contrast is the diagnostic tool of 
choice when a brain tumor is suspected (Bradley, Waluch et al. 1984). Malignant 
brain tumors enhance with gadolinium and they usually have central areas of 
necrosis (Fig 1.1). Further on they are mostly surrounded by white matter edema. 
Unfortunately, unlike other cancers early diagnosis and treatment does not 




Fig 1.1.  Magnetic resonance imaging (MRI) studies highlighting the typical features 
of glioblastomas. MRI of the brain of a patient with glioblastoma in the right temporal lobe. (A) 
Axial T1-weighted MRI which shows a right temporal tumor with poorly defined boundaries,    
(B) reveals a heteregenously mass with central areas of necrosis, (C) Fluid attenuated inversion 
recovery sequence shows areas of enhanced signal which extend beyond the areas of contrast 














Malignant gliomas arise in a multistep fashion involving successive and 
accumulative genetic alterations that result from environmental and intrinsic 
factors. A family history of glioma is rarely observed but many rare hereditary 
syndromes such as Li-Fraumeni, neurofibromatosis type 1 and type 2 and Cowden 
syndromes are associated with increased risk of glioma (Hottinger and Khakoo 
2007; Gu, Liu et al. 2009). With the recent onset of genome-wide association 
studies, a few susceptibility variants had been identified such as 20q13.3 (RTEL), 
5p15.33 (TERT), 9p21.3 (CDKN2BAS), 7p11.2 (EGFR), 8q24.21 (CCDC26) and 
11q23.3 (PHLDB1), unfortunately these genes are only weakly associated with 
glioma and they could possibly reflect the different molecular subsets of glioma 
(Shete, Hosking et al. 2009; Rajaraman, Melin et al. 2012).  
A well-established environmental risk factor for glioma development is 
ionizing radiation. This association was revealed in individuals exposed to atomic 
bombs and nuclear weapons testing as well as in children receiving cranial 
irradiation for cancer therapy (Bondy, Scheurer et al. 2008).  
The first line of treatment for high-grade gliomas includes surgery 
followed by adjuvant radiotherapy and chemotherapy using drugs such as 
temozolomide. However, a majority of patients are inoperable because of the 
location of the tumor, widespread invasion of the tumor in the brain or the 
patient’s poor physical health. The most successful chemotherapeutic drug for 
gliomas, temozolomide, is a DNA alkylating agent which is administered orally in 
combination with radiotherapy. The use of this treatment protocol was validated 
in a randomized phase 3 study that showed including temozolomide as first line of 
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treatment increased the median survival time of patients from 12 months to 15 
months (Soffietti, Kocher et al. 2013). Another US Federal Food and Drug 
Administration (FDA) approved agent for first-line treatment is Gliadel, 
biodegradable polymers containing the alkylating agent carmustine, which is 
implanted into the patient’s brain post tumor resection (Westphal, Hilt et al. 
2003). Bevacizumab, a VEGF monoclonal antibody that targets angiogenesis is 
currently under study for use as treatment in glioblastoma (Gilbert 2013; 
Wolfgang Wick 2013).  
After the initial treatment, almost all glioblastoma patients experience 
tumor recurrence within 7 to 10 months. Unfortunately, none of the treatments 
available have shown improved survival and only benefit a few patients overall. 
This critical phenomenon highlights the heterogeneous nature of glioblastomas as 
well as the necessity for establishing individualized treatments.  
 
1.1.2 Classification of gliomas 
Histopathological Classification – In 2007, the World Health Organization 
(WHO) classified gliomas into astrocytomas, oligodendrogliomas and 
ependymomas and others based on presenting morphology (Louis, Ohgaki et al. 
2007). These were further classified into 4 grades which are determined by 
pathological assessment of the tumor: 
WHO grade I: Pilocytic astrocytomas, these are clearly defined pediatric gliomas 
and due to their defined margins these are easier to surgically excise.  
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WHO grade II:  Low grade gliomas such as astrocytomas, oligodendroglioma, 
and mixed astrocytoma usually occur in young adults in the second through fifth 
decades of life. These gliomas tend to be benign and have a better prognosis for 
the patients. Unfortunately, due to the highly infiltrative tendencies of these 
tumors, recurrences tend to occur and these low grade tumors manifest 
progressively into more aggressive high-grade gliomas.  
WHO grade III: These are the malignant types of gliomas and they include 
anaplastic astrocytomas, anaplastic oligodendrogliomas and anaplastic mixed 
oligoastrocytoma. Grade III tumors grow much more swiftly than grade II 
gliomas and they infiltrate into the brain parenchyma with tentacle-like 
projections and they deem surgical resection to be challenging.  
WHO grade IV: Glioblastoma multiforme (GBM) is the most malignant and 
aggressive of high-grade gliomas. Almost 90% of GBMs arise rapidly de novo in 
older patients with no clinical or histological presence of a less malignant 
precursor tumor and these are known as primary GBMs. Secondary GBMs arise 
from low-grade gliomas such as diffuse astrocytomas or anaplastic astrocytomas. 
These are usually observed in younger patients and are preferentially localized in 
the frontal lobe. Secondary GBMs tend to have a better prognosis than primary 
GBMs. Based on histology it is difficult to segregate primary and secondary 
GBMs but they do have characteristically different genetic and epigenetic 
signatures. 
  
Molecular Classification – Due to considerable amount of heterogeneity in 
patients with high grade gliomas, a classification solely based on histopathology 
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seems highly insufficient. This classification provides diagnostic information 
based on a population and is unable to provide insight into individual patient care. 
In the era of GWAS studies and next gen-sequencing, targeted therapies would be 
the key to treat patients with glioma. With this in mind, a huge amount of effort 
has been made to add-on new information about the molecular signature of 
gliomas so as to segregate them into novel classifications through which treatment 
modalities could emerge.  
Phillips’ classification:  Back in 2006, a microarray analysis performed on 76 
high-grade glioma patients had identified a 35 gene signature in grade III and 
grade IV astrocytomas (Phillips, Kharbanda et al. 2006). This glioma signature 
classifies patients into proneural, proliferative and mesenchymal subclasses. In 
proneural tumors, neuron-associated markers were upregulated and they had 
significantly longer survival times. While in proliferative type there is an 
upregulation of proliferation-associated genes such as proliferating cell nuclear 
antigen and topoisomerase II α. Finally the mesenchymal gliomas had an 
overexpression of angiogenesis-associated markers such as VEGF, VEGFR1, 
VEGFR2 and endothelial cell adhesion molecule I. Proliferative and 
mesenchymal subtypes have shorter survival times. Interestingly, upon tumor 
recurrence the gliomas tend to shift towards the mesenchymal subtype. Phillips et 
al. also identified an association between tumor grade and the gene signature 
classification; grade III anaplastic astrocytomas were predominantly clustered to 
the proneural subclass while GBMs were a mix of all the three subtypes.  
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Classification of the Cancer Genome Atlas (TCGA): TCGA analyzes more than 
500 primary, untreated GBM samples at the DNA, mRNA, miRNA and exome 
levels (Verhaak, Hoadley et al. 2010). The “classical” subclass is characterized by 
highly proliferative cells, shows gains in chromosome 7 followed by losses in 
chromosome 10 as well as frequent losses in chromosome 9p21.3. The above 
chromosomal events give rise to amplification of the EGFR gene and losses in 
PTEN and CDK2A gene loci. The classical GBM are sensitive to radiotherapy 
and chemotherapies probably due to the p53-induced DNA damage response 
which is still functional in these patients. Neural precursor genes and stem cell 
marker genes are all upregulated in the classical subtype of GBMs. The second 
“mesenchymal” subtype is associated with an expression profile of genes 
involved in the mesenchyme and angiogenesis and there was overexpression of 
many genes such as c-Met and genes for astrocytic markers such as CD44 and 
MERTK as well as genes in the NFκB pathways. Frequent inactivation of the 
NF1, TP53 and PTEN genes are characteristic of this subtype. The tumors 
categorized in this subtype are sensitive to chemo and radiotherapies and may 
respond well to drugs against PI3K and angiogenesis. The “proneural” subclass 
has an expression profile resembling genes activated during neuronal 
development such as upregulation of oligodendrocytic and proneural development 
genes such as OLIG2, NKX-2, SOX2 and DCX. Unique genetic alteration in the 
proneural subtype is mutations in the IDH1 gene. Overexpression and mutations 
in the PDGFRA gene has also been reported in ∼30% of patients in this subclass. 
Inactivating mutations in the TP53 and PIK3CA/PIK3R1 genes and amplification 
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of chromosome 7 and losses in chromosome 10 have been observed too. Patients 
classified into the proneural subtype have a slightly better chance of survival than 
the other GBM subtype though this tumor is the least responsive to classical GBM 
treatment modalities. The fourth and final subtype is the “neural” subtype, this is 
less well defined and the gene expression profile is reminiscent of genes found in 
normal brain tissue, with increased expression of neuronal markers such as 
GABRA1, SLC12A5 and NEFL. These tumors have reduced invasive capabilities 
and do not infiltrate the brain parenchyma as extensively as the other GBM 
subclasses. Their expression profile suggests that these tumor cells are well-
differentiated. A comparison of expression profiles obtained from the four GBM 
subtypes and those obtained from primary astrocytes, neurons, oligodendrocytes 
and microglioa seems to suggest that each of these subtypes have originated from 
different cell types, but this hypothesis requires validation.   
 
Glioma CpG island methylator phenotype (G-CIMP); Toyota and colleagues were 
the first ones to characterize the CpG island methylator phenotype (CIMP) in 
human colorectal cancer to be cancer-specific CpG island hypermethylation of a 
subset of genes in a subpopulation of cancer cells (Toyota, Ahuja et al. 1999). In a 
recent study, the DNA methylation profiles of 272 TCGA GBM samples were 
determined by Noushmehr and colleagues and they identified three distinct DNA 
methylation clusters (Fig 1.2) (Noushmehr, Weisenberger et al. 2010). Cluster I 
was highly similar to the CIMP initially discovered in colorectal cancer and thus 
these tumors were clustered together as G-CIMP. A predominant number of 
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samples classified as G-CIMP possessed a mutant IDH1 and many of the genetic 
alterations commonly observed in GBMs were absent such as amplification of 
EGFR, losses in chromosome 10 and gains in chromosome 7. Correlating both the 
TCGA gene expression profiles and the DNA methylation analysis showed that 
G-CIMP positive tumors were a subpopulation of proneural tumors. Interestingly, 
the G-CIMP positive GBMs showed a better chance of survival when compared 
to other GBMs as well as within proneural GBMs. Retinol binding protein 1 
(RBP1) and G0-G1 switch gene 2 (G0S2) are the two key genes that are subjected 
to epigenetic silencing in the G-CIMP tumors. Epigenetic silencing of RBP1 has 
been reported in many other cancers too and its association with retinoic acid 
receptors has been well-defined as well (Esteller, Guo et al. 2002). Expression of 
G0S2 is regulated by retinoic acid (Kitareewan, Blumen et al. 2008) and the 
protein it encodes promotes apoptosis in transformed cells (Welch, Santra et al. 
2009) and it also inhibits proliferation of haemotopoietic stem cells (Yamada, 
Park et al. 2014) thus suggesting it might have tumor suppressor functions in 
leukemia.  
The methylation analysis and gene expression profiling has helped to 
further classify the most aggressive type of brain tumors and has vastly expanded 
our current understanding of the disease. These tumors represent a heterogeneous 
population with regard to patient prognosis and tumor characteristics. The 
classification of brain tumors to date has relied solely upon histopathological 
features of the tumor, but now molecular tools and rapidly changing technology 
are beginning to classify these tumors based on their unique molecular signature. 
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The next milestone would be for next-generation sequencing to identify more 
unique prognositve and predictive markers for GBM subtypes which would then 















Fig 1.2. G-CIMP Classification of glioblastomas. DNA methylation analysis of 91 
TCGA glioblastomas. Three distinct methylation clusters were identified, with cluster 1 
(red top bar) designated as G-CIMP due to a high frequency of DNA methylation. The 
gene expression profile and mutation status of selected genes (EGFR, IDH1, NF1, PTEN, 
and p53) are shown in the bars below each methylation cluster. IDH1 mutations were 
found exclusively in G-CIMP tumors, and nearly all G-CIMP tumors had a proneural 









1.1.3 Deregulated signaling pathways in glioblastomas 
Glioblastomas are one of the most aggressive and malignant types of 
cancers known to humans with a dismal life expectancy of less than 15 months. 
The genome in glioblastomas is highly mutated and this is characterized by the 
alterations in many classical signaling pathways which involve apoptosis, 
survival, proliferation and motility (Fig 1.3). The mechanisms involved in the 
onset and progression of glioblastomas still largely remains a mystery, 
nevertheless recent research has unearthed some interesting findings with relation 
to the signaling pathways involved in GBM. 
 
 p53 signaling pathway – The most frequently mutated pathway in tumorigenesis 
is the p53 pathway. The p53 protein is a well-characterized tumor suppressor that 
gets activated upon DNA damage as well as upon genotoxic or cytotoxic stresses 
such as apoptosis and cell cycle arrest. Another crucial role for p53 is that it is a 
transcription factor that regulates a myriad of genes involved in tumorigenesis and 
tumor invasion (Huang, Cavenee et al. 2007; Huse and Holland 2010). Mutations 
in the p53 pathways are one of the earliest genetic alterations detected in 
secondary GBMs and these mutations are mostly located at two critical codons 
248 and 273. Mutations in p53 are rarely detected in primary GBMs and the 
mutations are observed to be widely dispersed throughout the gene thus 
suggesting that in primary GBMs p53 mutations are a passenger mutation due to 
genomic instability (Ohgaki, Dessen et al. 2004; Ohgaki and Kleihues 2007). 
Mdm2, an E3 ubiquitin ligase that negatively regulates p53 by transcriptional 
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inhibition and proteasomal degradation (Haupt, Maya et al. 1997; Kubbutat, Jones 
et al. 1997; Itahana, Mao et al. 2007), is observed to be overexpressed in 10% of 
malignant GBMs in those tumors that harbor a wild-type p53 (Reifenberger, 
Ichimura et al. 1996). This suggests that Mdm2 overexpression could be an 
alternative mechanism for tumors to inactivate p53 mediated tumor suppression. 
Likewise, Mdm4 is another regulator of p53 and is also overexpressed in GBMs 
(Riemenschneider, Buschges et al. 1999; Rao, Edwards et al. 2010). Therefore, 
Mdm4 has been highlighted to be of therapeutic value but the mechanism by 
which Mdm4 overexpression regulates GBM onset is still questionable. The 
upstream regulator of p53, ARF (p14ARF), regulates p53 mediated transcriptional 
activities by interacting with Mdm2 and suppressing its E3 ligase activity 
(Kamijo, Weber et al. 1998; Zhang, Xiong et al. 1998). Mutations and 
inactivation of ARF has been frequently observed in both malignant gliomas and 
low-grade gliomas alike (Nakamura, Watanabe et al. 2001). The CDK2A locus 
uniquely encodes two proteins, ARF and INK4a (p16INK4a), which are vital 
regulators of cellular proliferation pathways p53 and pRB, respectively. A 
common genetic alteration in gliomas is the deletion of the CDK2A loci that 
encodes the proteins p16(INK4a)/p14(ARF)/p15(INK4b) (Solomon, Kim et al. 
2008) and interestingly it was also found that co-deletion of ARK and INK4a was 
increased from low- to high-grade gliomas (Labuhn, Jones et al. 2001). These 





pRB pathway – The tumor suppressor retinoblastoma (pRB) plays a critical role 
in blocking cell cycle progression from G1 to S phase by interacting with and 
inhibiting E2F family of transcription factors. The RB gene is located at 13q14.1-
q14.2 and is regulated by cyclin-dependent kinases (CDKs). Mutations in the RB 
gene have been observed in almost 20% of malignant gliomas and 
downregulation of pRB expression has been found in GBMs (Tortosa, Ino et al. 
2000). Interestingly, loss of 13q14.1 loci has been linked with the progression of 
low-grade gliomas to intermediate gliomas (Henson, Schnitker et al. 1994; 
Bahuau, Vidaud et al. 1998). During the G1 phase of the cell cycle, pRB is 
inactivated by Cyclin D/CDK4/CDK6- mediated phosphorylation, which results 
in release of pRB from E2F transcription factors and the consequence is normal 
cell cycle progression into the S phase. Promoter methylation of RB, 
amplification of CDK4 and CDK6 and inactivation of CDKN2A and CDKN2B 
which are CDK4 and CDK6 inhibitors have been frequently observed in 
glioblastomas (Ueki, Ono et al. 1996; Burns, Ueki et al. 1998; Lam, Di Tomaso et 
al. 2000). The end result of these genetic alterations is unchecked cell cycle 
progression and cancer progression.  
 
PI3K-PTEN-Akt-mTOR signaling pathway in glioblastomas – The classical 
PI3K-PTEN-Akt-mTOR pathway is involved in regulating functions such as 
cellular proliferation and survival, cell motility and invasion. Many growth factors 
and their receptors such as EGF and EGFR regulate the phosphatidylinositol 3-
kinase (PI3K) complex and upon activation PI3K generates phosphatidylinositol-
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3,4,5-triphosphate which subsequently activates Akt. As a result, Akt in turn 
activates mTOR which brings together various upstream signaling events into 
triggering multiple downstream signaling targets that participate in cell growth 
and proliferation (Zoncu, Efeyan et al. 2011). Various tumor suppressors such as 
PTEN suppress this pathway. The PI3K complex is the mediator that joins the 
growth factors with cellular differentiation, survival, proliferation and 
metabolism. Hyperactivation and mutation of the PI3K signaling pathway plays 
key roles in gliomagenesis (Parsons, Jones et al. 2008; Akhavan, Cloughesy et al. 
2010). In almost 70% of GBMs alterations in the PI3K pathway is observed, 
either by PTEN deletion or hyperactivation of EGFR and/or VEGFR or PDGFRα 
(Zhi, Song et al. 2009). Overamplification of EGFR is a frequently observed 
genetic alteration in primary glioblastomas (Watanabe, Tachibana et al. 1996; 
Peraud, Watanabe et al. 1997).  
EGFR gene encodes a receptor tyrosine kinase which belongs to the ErbB 
family. Upon binding of growth factors such as EGF and TGFα, EGFR undergoes 
dimerization and a conformational change that activates its inherent kinase 
activity. Thereby resulting in activation of the downstream signaling events such 
as the PI3K-Akt and Ras-MEK pathways (Mizoguchi, Betensky et al. 2006). 
Another frequent mutation in glioblastomas is the EGFRvIII mutant, in which 
exons 2-7 of the EGFR gene are deleted resulting in a truncated extracellular 
domain (Wong, Ruppert et al. 1992). The EGFRvIII mutant exhibits ligand-
independent activity as it is unresponsive to EGF (Ekstrand, Longo et al. 1994). 
These genetic aberrations in EGFR lead to enhanced activity of the PI3K pathway 
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that is responsible for cellular proliferation and subsequently increases glioma 
tumorigenecity.  
The mammalian target of rapamycin (mTOR) are composed of two 
complexes, mTOR complexes 1 and 2 (mTORC1 and mTORC2). These mTOR 
complexes play pivotal roles in gliomagenesis by acting as an upstream regulator 
of PI3K as well as a downstream effector (Akhavan, Cloughesy et al. 2010). 
mTORC1 is oncogenic in nature and it can trigger the translation of various 
oncogenes, inhibit autophagic cell death, promote angiogenesis by upregulating 
HIF1α and regulate lipid uptake by activating sterol regulatory regulatory binding 
protein 1c (SREBP1c). Likewise, mTORC2 is oncogenic too, it has been shown 
to activate Akt and serum/glucocorticoid regulated kinase which stimulates 
glucose uptake, thus enhancing tumor cell survival and proliferation (Zoncu, 
Efeyan et al. 2011).  
A well-known tumor suppressor in gliomas is PTEN and PTEN mutations 
have been involved in the development of many types of cancers including 
GBMs. It is a negative regulator of the PI3K/Akt pathway (Stambolic, Suzuki et 
al. 1998), it blocks Akt signaling by preferentially binding to and reducing the 
intracellular levels of phosphatidylinositol(3,4,5)- triphosphate (PIP3). Thereby 
PTEN can regulate the downstream genes such as mTOR and regulate cell 
proliferation and apoptosis. PTEN has also been reported to regulate glioma cell 
migration by dephosphorylating FAK in integrin complex and thus inhibit 
integrin-regulated invasion and migration (Gu, Tamura et al. 1998; Tamura, Gu et 
al. 1999; Natarajan, Hecker et al. 2003). Interestingly, PTEN can also inhibit 
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glioma migration by dephosphorylating SH2-adaptor protein (Shc) which is 
upstream of Ras thus resulting in suppressing the Ras/MAPK pathway (Gu, 
Tamura et al. 1998). It is noteworthy to mention that complete loss of the 
chromosome 10 where the PTEN gene is located is a frequent genetic alteration in 
primary glioblastomas. A large proportion of glioblastomas and glioma cell lines 
harbor inactivating mutations in the PTEN gene that results in reduced expression 
of PTEN (Furnari, Lin et al. 1997; Li, Yen et al. 1997) thus resulting in aberrant 
Akt signaling and a perfect way for glioma cells to escape apoptosis and promote 
cell cycle progression.  
 
Ras/MAPK signaling pathway in glioblastomas – There are three members of the 
Ras oncogene family – H-Ras, N-Ras and K-Ras. These are G proteins and their 
activation is controlled by its binding to GTP and inactivated by its binding to 
GDP. The GTP-bound Ras then triggers downstream signaling events such as the 
MAPK pathway as well as the PI3K pathway (Moodie, Willumsen et al. 1993). 
Ras plays critical roles in cell proliferation, signal transduction, differentiation, 
apoptosis and tumorigenesis. Increased levels of Ras are frequently observed in 
glioma cell lines and glioma patient biopsies (Guha, Feldkamp et al. 1997), which 
is in stark contrast to several other tumors where Ras is activated by tumor-
inducing mutations. Several receptor tyrosine kinases and growth factors such as 
EGFR and PDGFR can directly bind to Ras and regulate it (Warner, Hack et al. 
1993). Once activated, Ras then activates Raf which goes on to activate MEK and 
ERK. The activation of ERK enables it to translocate to the nucleus and enhance 
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transcription of various cell-cycle related genes (Kapoor and O'Rourke 2003). 
Interestingly, reduced glioma cell proliferation was observed upon suppressing 
Ras activation (Guha, Feldkamp et al. 1997; Feldkamp, Lau et al. 1999) and in 
U87-MG cells administering a Ras inhibitor significantly reduced glioma 
migration too (Goldberg and Kloog 2006). The deregulated signaling pathways in 
gliomas are deemed more complicated due to the extensive cross-talk between the 
Ras and PI3K pathways. Ras can stimulate PI3K by directly binding to it and 
activating PI3K’s antiapoptotic function which serves as a boost to Ras mediated 



























Fig 1.3. Genetic alterations commonly seen in glioblastomas. Dysregulation of 
the RTK-Ras-PI3K pathway is commonly seen in almost 88% of patients, while 
87% show alterations in the p53 pathway, and 78% show alterations in the RB 
pathway. Overall, 74% of patients showed changes in all three pathways. Red 
circles depict activating genetic alterations, with darker red colour representing 
frequently altered genes. Blue circles indicate inactivating alterations, with darker 












1.2 Semaphorins and plexins : Neural guidance molecules 
 
1.2.1 Axon guidance cues 
  With more than 100 billion neurons the human brain is undoubtedly the 
most complex organ in the body. The brain enables us to view, perceive, think, 
and learn and to retain our experiences as memories. It maintains the temperature 
homeostasis, regulates our muscle movements and is the master regulator of the 
body. All these attributes are due to the way the brain is wired. During embryonic 
development, the nervous system is pieced together by various neuronal 
subpopulations connected to each other in a highly specific manner. The first 
axons that grow in the fetal brain known as “pioneers” find themselves in an 
environment devoid of other axons and they traverse their way through 
unchartered territory (Easter, Ross et al. 1993). These pioneer axons then lay 
down the foundation for the “follower” axons to navigate through. The actin 
dynamics as well as the growth cone characteristics of pioneer axons are distinctly 
different from the follower axons which are rapidly growing and less complex 
(Bak and Fraser 2003; Kulkarni, Bak-Maier et al. 2007). Experiments performed 
in zebrafish and mutant mice lacking Pax6 highlighted that neural patterning was 
disrupted upon ablation of early axonal tracts, thus emphasizing that pioneer 
axons recognize guidance molecules specifically distributed throughout the 
nervous system so as to establish topographical organization of the brain 
(Macdonald, Xu et al. 1994; Mastick, Davis et al. 1997).  
How do these pioneer axons navigate through the neuroepithelium and 
forge neuronal paths to reach their target cells? The “fan-shaped” tip of the axon 
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is known as the growth cone and it is pleomorphic enabling the axon to probe 
their environment constantly by extending protrusions known as filopodia and 
lamellipodia (Fig 1.4). The outgrowth of axons occurs by three progressive stages 
(Dent, Gupton et al. 2011): 
1. Protrusion – F actin polymerization at the growth cone border results in 
extension of the growth cone membrane in the forward direction 
2. Engorgement – microtubules move further into the growth cone bringing 
along with it membranous organelles from the central microtubule rich region 
to the peripheral actin region 
3. Consolidation – A cylindrical axonal shaft is formed from the contraction 





























Fig 1.4. Cytoskeletal changes in a growth cone that has been exposed to an axon 
guidance cue with attractive effects. (A) An image depicting a typical growth cone, 
the actin bundles, actin meshwork and the microtubules are depicted in green, blue and 
red, respectively. The attractive guidance cue is depicted in gray in the upper right 
corner of the image. The boxed regions are enlarged in the subsequent images. (B) The 
growth cone is undergoing F actin polymerization at the edge and this is called 
protrusion. (C) This part of the growth cone is the region where the actin and the 
cytoskeleton work cooperatively to result in outgrowth in the forward direction. (D) 
This image depicts the area of the growth cone that is undergoing retraction. The actin 




Molecular concentration gradients of axon guidance cues steer the axonal 
growth cones along the precise trajectory by means of attractive or repulsive cues. 
A large proportion of axon guidance molecules can behave as bidirectional cues 
as well, that is in a contextual manner the same guidance cue can either attract or 
repel axonal growth cones.  
There have been many families of axon guidance molecules and receptors 
identified and the canonical guidance cues are the Ephrins, Slits, Nephrins and 
Semaphorins. These can guide axons at both long and short distances and they 
also play a role in fasciculation or bundling of axons to generate nerve fibres. 
When axons navigate their way, they are bombarded with different guidance 
choices by way of disparate guidance cues. Some cues interact with each other to 
result in a net additive effect while other cues behave dominantly and suppress 
other guidance cues. In motor axons, glial-cell derived neurotrophic factor 
(GDNF) elicits an attractive response while ephrinAs induces a repulsive turning 
of axons, the combinatorial effect of both these guidance cues when added to 
opposite sides of the growth cone results in an amplified attraction response 
(Dudanova, Gatto et al. 2010). Hierarchical interactions between axon guidance 
molecules exist as well. For example, complex crosstalk between semaphorin 3A 
(Sema3A) and semaphorin 3C (Sema3C) in the fetal cortex results in Sema3A 
eliciting a dominant repulsive response while suppressing the Sema3C attractive 
cue. The magnified Sema3A response and the subdued Sema3C response is due to 
the ligands binding to different sets of neuropilin receptors in the growth cone 
membrane (Ruediger, Zimmer et al. 2013). All these interactions of axon 
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guidance cues highlight the degree of complexity and cross talk that exist between 
different ligand and receptors and the molecular mechanisms of these interactions 
are just beginning to be unraveled. 
 
Netrins 
Netrins are a family of evolutionarily conserved secreted proteins that 
function as chemotropic guidance cues for axonal outgrowth. They function as 
bifunctional guidance cues as they can attract certain axons and repel others. 
These 70-80 kDa guidance molecules mediate their functional effects in a 
paracrine manner to nearby axons as well as to long-range axons. There have been 
three secreted netrins (netrin 1, 3 and 4) and 2 GPI-linked netrins (netrin G1 and 
G2) identified in mammals. Mammalian receptors for netrins are deleted in 
colorectal cancer (DCC) and UNC-5 homologues. The netrin receptors are all 
membrane-bound and belong to the immunoglobulin (Ig) superfamily. The DCC 
family of receptors are responsible for netrin’s attractive properties while UNC5 
members mediate repulsion. Experiments performed in Xenopus neurons where 
the extracellular and intracellular domains of DCC and UNC5 were swapped 
(Hong, Hinck et al. 1999; Keleman and Dickson 2001) proved that the 
intracellular domain of netrin receptors was crucial in mediating their attractive 







Ephrins are another important axon guidance molecule which has been 
implicated in various physiological processes. Ephrins are classified into two 
subfamilies: class A ephrins and class B ephrins. The main difference between 
them is that class B ephrins are transmembrane proteins while class A ephrins are 
GPI tethered to the cell membrane. Ephrin ligands need to oligomerize to be 
functional thus suggesting that these axon guidance cues work best at short-range. 
Membrane bound Eph family of receptor tyrosine kinases are the receptors for 
ephrins. Class A ephrins interact preferentially with class A Eph receptors while 
class B ephrins interact with class B Eph receptors (Gale, Holland et al. 1996; 
Himanen, Chumley et al. 2004). Similar to netrins, ephrins are bifunctional as 
axonal repellants and attractants. Ephrins have been implicated in many 
physiological processes such as hindbrain segmentation, topographic mapping 
and synaptic plasticity (Wilkinson 2001; Palmer and Klein 2003). Interestingly, 
Eph and ephrins can transduce bidirectional signaling known as “reverse 
signaling”. They can elicit cytoskeletal changes in both ligand and receptor 
expressing cells and these reverse signals play a critical role in outgrowth of 
dendrites in axons during early development. 
 
Slits 
Initially identified in Drosophila, the secreted Slit ligand and its Robo 
receptor were implicated in repelling developing neurons from re-crossing the 
midline. (Brose, Bland et al. 1999; Kidd, Bland et al. 1999). Robo receptors that 
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belong to the immunoglobulin superfamily bind to secreted 200 kDa glycoprotein 
slits and execute its repellant activities. Three members of the Slit proteins have 
been characterized in vertebrates, Slit1, Slit2 and Slit3. They are all secreted 
proteins and mediate their effects by paracrine signaling mechanisms. As for their 
receptors, the Robo proteins, there have been four Robo receptors identified in 
vertebrates: Robo1, Robo2, Robo3 and Robo4. Slit-Robo interactions have been 
implicated to function as guidance molecules during development of the olfactory 
tract, forebrain, hindbrain and in many non-neural tissues as well (Hinck 2004; 
Andrews, Barber et al. 2007). 
 
Semaphorins 
1.2.2 Semaphorins: Canonical axon guidance cues 
Semaphorins are an evolutionarily conserved family of secreted and 
transmembrane glycoproteins that were initially identified as axon guidance cues 
during neural development. The name “semaphorin” has been derived from the 
word “semaphore”, which means to relay information via a signaling network. 
True to their names, semaphorins play critical roles as a signaling hub involved in 
many physiological and developmental processes. 
 
1.2.3 Genetic and Molecular Features of Semaphorins 
Semaphorins are characterized by a highly conserved 500 amino acid 
“sema domain” through which semaphorins elicit their functional effects and this 
cysteine rich domain also contains critical binding sites for their receptors. It has 
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also been determined that the sema domain is a vital component critical for 
semaphorins to elicit their effects with a characteristic β propeller topology (Love, 
Harlos et al. 2003) They also contain a PSI (plexin, semaphorin and integrin) 
domain that has also been called as MET-related sequence (MRS) (Fig. 1.5A).  
Based on their ectodomain composition, and their expression in 
vertebrates and invertebrates semaphorins have been classified into seven classes 
(Fig 1.5).  Classes 1 and 2 are found in invertebrates, classes 3-7 are the vertebrate 
orthologues. Viral semaphorins have also been identified (class V semaphorins). 
Class 3 semaphorins are secreted glycoproteins while classes 4-7 are cell surface 
bound and they possess additional structural elements such as thrombospondin 
repeats in Class 5 members and a carboxy terminal glycophosphatidylinositol 
(GPI) anchor in Class 7 semaphorins. Some of the transmembrane semaphorins 
such as semaphorin 4B (Sema4B) can be proteolytically cleaved to yield soluble 
proteins (Strongin 2010). Even the soluble semaphorins like class 3 semaphorins 
are synthesized as inactive precursors which are further cleaved into their 
functionally active form. Oligomerization and clustering of semaphorins is highly 
essential for them to transduce their signals.   
The genes encoding semaphorins are ubiquitously spread throughout the 
genome and they are evolutionarily conserved all the way from Drosophila to 
humans. During development, semaphorins are dynamically expressed in the 
nervous system and upon maturity the expression levels decrease. Intriguingly, 
semaphorins expression levels increase upon neuronal injury and altered 
semaphorin levels have been observed in pathological conditions such as 
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tumorigenesis as well. Beyond the nervous system, semaphorin expression has 
also been observed in the immune, vascular, endocrine, and reproductive and 
respiratory systems. Genetic analyses have highlighted the importance of the 
divergent expression patterns of semaphorins during development and adulthood.  
 
1.2.4 Semaphorin receptors 
Members of the plexin and neuropilin families were identified as high 
affinity semaphorin receptors. A certain degree of promiscuity does exist with 
certain semaphorins interacting with several plexin families (for example, plexin-
D1 binds semaphorin 3E (Sema3E) and possibly semaphorin 4A (Sema4A) but 
this interaction could probably be cell-type specific.  
The neuropilin family consists of two glycoproteins, neuropilin-1 (Nrp1) 
and neuropilin-2 (Nrp2). Nrp1 was identified as a receptor to Sema3A (He and 
Tessier-Lavigne 1997; Kolodkin, Levengood et al. 1997) and Nrp2 to semaphorin 
3F (Sema3F) (Chen, Chedotal et al. 1997; Kolodkin, Levengood et al. 1997). As 
neuropilins possess a short intracellular domain, it was highly unlikely that they 
could transduce signals emerging from semaphorin binding (Fig 1.5B). Thus it 
was hypothesized that another protein would be responsible for the signal 
transduction, and thereby plexins were discovered as the missing link (Takahashi, 
Fournier et al. 1999; Tamagnone, Artigiani et al. 1999). 
Plexins were initially discovered in the plexiform layers of the optic 
tectum in Xenopus nervous system thus earning their name “plexins” (Takagi, 
Tsuji et al. 1987; Ohta, Mizutani et al. 1995). Plexins are transmembrane proteins 
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and there are four plexin families identified, plexin-A, plexin-B, plexin-C and 
plexin-D. Plexin-A family consists of plexin-A1, A2, A3 and A4; plexin-B family 
consists of plexin-B1, B2 and B3; plexin-C and –D consist of only one member 
each (Tamagnone, Artigiani et al. 1999) . Similar to semaphorins, plexins possess 
a sema domain in their ectodomains; this behaves as an auto inhibitory domain in 
the resting state of the receptor.  
The extracellular region of plexins also contains an Immunoglobulin-
plexin-transcription (IPT) domain, thus named due to its presence in plexins and 
immunoglobulins alike. Met and Ron receptors have also been shown to contain 
the IPT domain and they have been shown to have a functional importance in 
these proteins. Deletion analysis of IPT domains in Ron resulted in a 
conformational change followed by enhanced receptor activation. Sandwiched 
between the sema domain and IPT domain lies the plexin-semaphorin-integrin 
(PSI) domain. A fairly small domain consisting of only 50 amino acids and this 
domain has been found in many cell signaling molecules including Met and Ron. 
Thereby it is hypothesized that PSI and IPT domains might be crucial components 
involved in receptor activation.  
The intracellular region contains a sex-plexin domain which is conserved 
among different species. The intracellular domains have several putative tyrosine 
phosphorylation sites but they do not possess a tyrosine kinase domain, instead 
they have Ras GTPase activating protein (GAP) and RhoGTPase binding portion 
(RBD) domains (Fig 1.6) through which they interact with a diverse array of 
GTPases (Negishi, Oinuma et al. 2005; Bell, Aricescu et al. 2011). Interestingly, 
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it has been shown that binding of small GTPases to the RBD results in 
dissociation of the GAP domains thereby activating the plexin.  
A unique characteristic of plexin-B family members is the presence of a 
highly conserved proteloytic cleavage site close to the transmembrane domain 
which results in cleavage of plexin-Bs by proprotein convertases. It has also been 
shown that proteloytic processing of plexin-B1 enhances binding of semaphorin 
4D (Sema4D) subsequently resulting in enhanced functional effects (Artigiani, 




















Fig 1.5. The structural features of semaphorins and their receptors. (A) Semaphorins 
have an N-terminal sema domain and a conserved stretch of residues known as the PSI 
domain. Class 4–7 semaphorins are all cell membrane-anchored proteins; class 5 
semaphorins are distinguished by thrombospondin repeats. (B) The structural features of 
the neuropilins. Neuropilins are single-pass transmembrane proteins. (C) The nine 
vertebrate plexins are further classified into four type A and three type B plexins and 
plexins C1 and D1. Plexins are transmembrane receptors distinguished by the presence of 
a split cytoplasmic GTPase-activating protein (GAP) domain. The extracellular regions 
of all plexins harbor a sema domain, PSI and glycine–proline rich motifs, which the 

























Fig 1.6. The semaphorin receptors and their interaction with semaphorins. Shown 
are plexin family members and neuropilins that form complexes with semaphorins. 
Semaphorins that bind to the different plexins and neuropilins are shown. Semaphorin 
names are abbreviated such that for example, semaphorin 3A is abbreviated as s3a. 





1.2.5 Other Semaphorin Interactors 
Additional interactors other than plexins and neuropilins have been 
implicated in semaphorin signaling events. This would explain their ability to 
mediate a vast array of signaling pathways in different cell types. Some of these 
additional interacting molecules associated to plexins are receptor tyrosine 
kinases (RTKs), both cytoplasmic and membrane-bound RTKs such as 
erythroblastic leukaemia viral oncogene homologue 2 (ErbB-2), c-Met, vascular 
endothelial growth factor receptor 2 (VEGFR2), SRC, proline-rich tyrosine kinase 
2 (PYK2), feline sarcoma oncogene (FES), FYN, offtrack kinase (OTK), integrins 
and cell-adhesion molecule L1 as well as dendritic cells related protein triggering 
receptor expressed on myeloid cells 2 (TREM2). Some semaphorins can also 
interact with other proteins distinctly different from plexins, such as in the 
immune system where Sema4D and semaphorin 4A (Sema4A) interact with 
CD72 and T-cell immunoglobulin and mucin domain containing protein 2 (TIM-
2) (Kumanogoh, Watanabe et al. 2000; Kumanogoh, Marukawa et al. 2002).  
The most important interactors are discussed below. 
 
Transmembrane RTKs – As mentioned above, semaphorins can activate RTKs 
that interact with plexins and trigger a signaling cascade. Reports over the past 
decade, have indicated that transmembrane RTKs such as ErbB-2 and c-Met can 
interact with the Sema4D receptor, plexin-B1 (Giordano, Corso et al. 2002; 
Conrotto, Corso et al. 2004; Swiercz, Worzfeld et al. 2008). ErbB-2 belongs to 
the epidermal growth factor receptor (EGFR) family and it is a well-characterized 
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proto-oncogene. Overexpression of ErbB-2 in many types of cancers has been 
observed, most notably in highly aggressive breast cancer (Harari and Yarden 
2000). ErbB-2 gets autophosphorylated upon dimerisation with other members of 
the ErbB family and thereby triggering a vast array of signaling cascades. ErbB-2 
does not have its own ligand but instead it seems to be the preferential binding 
partner of other ErbB family members. c-Met, another RTK, similar to ErbB-2 is 
a proto-oncogene and encodes the hepatocyte growth factor receptor protein 
(HGFR). Upon activation by HGF, the receptor gets tyrosine phosphorylated and 
initiates signaling events involved in invasive growth (Naldini, Vigna et al. 1991). 
c-Met expression is altered in many types of cancer and is correlated with poor 
prognosis. The HGF family of proteins contains two similar family members, Ron 
and c-Met. Ron encodes macrophage stimulating protein (MSP). They are both 
functionally similar too; both induce cell proliferation, migration and survival 
upon ligand binding. The extracellular domains of both proteins contain a sema 
domain along with a MRS and IPT domain and they have been shown to have a 
functional importance in these proteins. Deletion analysis of IPT domains in Ron 
resulted in a conformational change followed by enhanced receptor activation 
(Zhang, Zhou et al. 2010). The binding of these proteins induces tyrosine 
phosphorylation in all plexin-B family members.  
It has been well illustrated by Swiercz et al that upon Sema4D stimulation 
of epithelial cells both plexin-B1 and the RTKs become tyrosine phosphorylated 
and activated (Swiercz, Worzfeld et al. 2008). Intriguingly, they noticed that 
Sema4D stimulation induces pro-migratory and anti-migratory responses in 
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different epithelial cells and this seems to correlate with RhoA activation in these 
complexes. Sema4D induced activation of ErbB-2 results in RhoA activation and 
enhances migration through plexin-B1 and Rho-GEF/LARG complex. While on 
the other hand, activation of the c-Met pathway by Sema4D evokes Rho 
inhibition and is anti-migratory. These findings highlight that plexins can elicit 
radically different and opposing effects depending on the cellular context.  
 
Integrins – Integrins are a family of transmembrane cell-adhesion molecules that 
are involved in interactions between the cell and extracellular matrix (ECM). 
They are glycoproteins that are composed of heterodimers of α and β subunits. 
The specific binding of integrins to the ECM or to receptors in adjacent cells is a 
critical component in many physiological processes from embryogenesis to injury 
repair. They are involved in outside-in signaling where they inform the cell about 
the chemical composition and mechanical status of the ECM (Hynes 2002; 
Miranti and Brugge 2002). This information obtained from integrins allows the 
cell to decide on the proper cellular response to execute such as differentiation, 
migration, survival and motility. The binding of extracellular ligands to integrins 
initiates the formation of a talin-mediated connection (Garcia-Alvarez, de Pereda 
et al. 2003; Tadokoro, Shattil et al. 2003) followed by the recruitment of other 
cytoskeletal related proteins such as paxillin, focal adhesion kinase (FAK), Src-
family kinase and vinculin (Mitra, Hanson et al. 2005; Giannone and Sheetz 
2006; Ziegler, Liddington et al. 2006; Deakin and Turner 2008) . 
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Accumulating evidence indicates that semaphorins and their receptors 
interact with integrins to activate signaling pathways involved in neurite 
outgrowth and angiogenesis but then the exact mechanism is still unclear. Class 3 
semaphorins were the first semaphorins identified to be involved in integrin 
signaling. Sema3 proteins were shown to behave as integrin inhibitory signals, by 
signaling through neuropilin-plexin receptors they could inactivate vascular 
endothelial cell adhesion (Serini, Valdembri et al. 2003; Guttmann-Raviv, 
Shraga-Heled et al. 2007). During embryonic development, Sema3A is expressed 
in vascular endothelial cells and this behaves as an integrin inhibitor thus 
contributing to the plasticity of the vasculature during development (Serini, 
Valdembri et al. 2003). It is interesting to note that during tumor progression in 
mice models, Sema3A was one of the key genes to be lost probably to confer an 
advantage to the growing tumor. Upon delivery of exogenous Sema3A to these 
mice, a reduction in tumor volume followed by endothelial cell apoptosis and 
reduction in blood volume tortuosity was observed (Maione, Molla et al. 2009). 
Nrp1, the co-receptor of class 3 semaphorins has been the most widely studied 
semaphorin receptor for its adhesion properties. It has been shown to form 
complexes with membrane proteins such as α5 integrin and β1 integrin and this 
might be the manner it functions as cell-cell and cell-matrix adhesion molecule 






1.2.6 Regulation of Semaphorin-Receptor Complexes 
In neurons, the binding of semaphorins to plexins activates the Ras 
GTPase activating protein domain in plexins (Oinuma, Ishikawa et al. 2004; 
Wang, He et al. 2012) and triggers downstream signaling by means of tyrosine 
kinases, GTPases and cytoskeletal proteins (Kruger, Aurandt et al. 2005; 
Pasterkamp 2005; Franco and Tamagnone 2008; Zhou, Gunput et al. 2008; 
Derijck, Van Erp et al. 2010). There have been many extrinsic and intrinsic 
signals that can affect semaphorin signaling such as seen in semaphorin 5A 
(Sema5A). Sema5A can exhibit both chemoattractive and chemorepulsive effects 
depending on the presence of heparin sulphate or chondroitin sulphate 
proteoglycans, respectively (Kantor, Chivatakarn et al. 2004).  
A high level of regulatory control of semaphorin-receptor complexes 
converge upon transcriptional and post-transcriptional mechanisms. 
Transcriptional control is a major regulatory mechanism during axon guidance so 
as to ensure appropriate spatiotemporal expression of axon guidance molecules 
(Polleux, Ince-Dunn et al. 2007). For example, Tang and coworkers have 
demonstrated that COUP transcription factor 2 (COUP-TF2) mutant mice had 
decreased Nrp1 and Nrp2 expression levels in Pax6+ cells in the amygdale and 
ChIP assay proved that the neuropilins were direct targets of COUP-TF2 (Tang, 
Rubenstein et al. 2012). This resulted is abnormal cell migration of Pax6+ cells 
and severe defects in amygdala formation.  
All the information obtained about transcriptional control of semaphorin 
signaling has been obtained from neuronal migration experiments; unfortunately 
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it is unclear how transcription factors could regulate semaphorin and their 
receptors in a pathophysiological context such as cancer or neuronal injury. 
Another question to address is how the transcriptional factors are regulated 
themselves.  
Besides transcriptional control, semaphorin receptors can be tightly 
controlled by cis inhibitory binding to their ligands. This kind of inhibitory 
binding has been extensively observed in Ephs, Notch and Delta (Yaron and 
Sprinzak 2012). Recently, class 6 semaphorins and Plexin-A receptors have been 
shown to be involved in cis inhibitory interactions. The neurons of the 
sympathetic nervous system and dorsal root ganglion express plexin-A4, but the 
inhibitory effect of semaphorin 6A (Sema6A) expressed by adjacent cells is only 
observed in the sympathetic neurons (Xu, Fisher et al. 2000; Cheng, Bagri et al. 
2001; Suto, Ito et al. 2005). The reason behind this is the presence of plexin-A4, 
Sema6A and semaphorin 6B (Sema6B) in dorsal root ganglion neurons, wherein 
the Sema6 proteins bind to the plexin in cis thus preventing the Sema6s in 
surrounding cells from interacting in trans with the plexin-A4 (Haklai-Topper, 
Mlechkovich et al. 2010). Similar kind of inhibitory regulation of Sema6s and 
plexin-As has been recognized in hippocampal neurons too.  
MicroRNA (miRNA) mediated regulation of semaphorins seems to be a 
new dimension of receptor regulation that is just beginning to emerge. miRNAs 
are small non-coding RNAs approximately 20-25 nucleotides in length (Bartel 
2009). The long primary miRNAs are transcribed by RNA polII followed by 
cleavage by Drosha (Han, Lee et al. 2004) and cytoplasmic shuttling where they 
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are further processed by Dicer (Ketting, Fischer et al. 2001; Yi, Qin et al. 2003) 
before being recruited into the RISC (RNA-induced silencing complex) to exert 
gene silencing. The mature miRNA binds to its target mRNAs and results in post-
transcriptional gene silencing by either mRNA degradation or translation 
inhibition (Kim 2005; Djuranovic, Nahvi et al. 2012). The spatiotemporal 
regulation of semaphorins seems to be the ideal situation miRNAs could play a 
role. This is still a fairly rudimentary field but some recent evidence seems to 
highlight a very important prospect for miRNAs in semaphorin-receptor control. 
The earliest studies that unearthed a potential link between miRNAs and 
semaphorins were from experiments performed in mature regulatory T cells 
where Dicer was knocked out. A microarray analysis showed multiple 
differentially expressed genes upon Dicer ablation and Nrp1 was one of them 
(Zhou, Jeker et al. 2008). As Nrp1 has been reported previously to negatively 
regulate T regulatory cells, this seemed to hint at a possible link between miRNAs 
and the semaphorin network.  In diseased conditions such as cancer, it has been 
well-known that dysregulation of miRNA expression plays a pivotal role in tumor 
progression and tumor suppression. Liu et al.’s laboratory had demonstrated that 
miR-141 could target Sema6A expression levels in clear cell renal cell 
carcinomas (Liu, Brannon et al. 2010). The overexpression of pre-miR-141 in this 
cancer resulted in a decrease in Sema6A mRNA. Another study performed in 
colorectal cancer highlighted that miR-320a could target the 3’UTR of Nrp1 and 
regulate its expression (Zhang, He et al. 2012). Finally, plexin-B1 was also shown 
to be regulated by miR-124 in cervical cancers, expression of plexin-B1 and miR-
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124 were inversely correlated in cervical carcinoma with plexin-B1 highly 
expressed in cervical tumors and metastasis (Qiang, Wang et al. 2011). In neural 
circuit formation and axon guidance, the data correlating miRNAs and 
semaphorins is rather fragmentary. An interesting question to address would be 
how the miRNAs partake in semaphorin signaling networks and how do they fine 
tune the expression levels of these proteins.  
Published reports over the past few years have illustrated many new and 
unusual mechanisms of semaphorin network regulation. All these findings 
indicate that there are many intriguing questions left to be answered about these 
axon guidance cues both in the developmental context as well as the 
pathophysiological scenario.  
 
1.3 Signaling Mechanism of Semaphorins and Plexins 
1.3.1 Interaction with Rho and Ras small GTPases 
Molecular cues control many physiological processes in various organs of 
the body. For all these biological processes, the signaling occurs mostly through 
networks rather than signaling pathways. Semaphorins and plexins work in a 
similar fashion. Plexins can interact directly with Rho and Ras small GTPases via 
their intracellular domains. The Ras family of GTPases has 200 members and can 
be classified into six families: Rho, Ras, Rab, Arf, Sar and Ran (Colicelli 2004). 
These GTPases behave as on/off switches, shifting between the GDP-bound 
inactive state and the GTP-bound active state. The activated GTPases interact 
with several effector molecules to trigger downstream signaling events essential 
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for many biological processes. Regulatory proteins such as guanine exchange 
factors (GEFs) turn on the switch by catalyzing the change of GDP to GTP, while 
GTPase-activating proteins (GAPs) inactivate the active GTPase (Jaffe and Hall 
2005). Guanine nucleotide dissociation inhibitors (GDI) inhibit both the 
GDP/GTP cycling as well as GTP hydrolysis. Transmembrane plexins can 
directly interact with small GTPases as well as regulate many GTPase regulatory 
proteins too. RhoGTPases are involved in the dynamic regulation of the actin 
cytoskeleton and thereby are involved in motility and cellular polarity. While Ras 
family of GTPases, on the other hand, are activated by growth factor receptors 
and influence interaction with integrins. They play critical roles in many classical 
signaling pathways such as ERK, MAP kinase and PI3K pathways in many 
organs of the body (Fig 1.7).  
 
Rho family small GTPases: Rac1, Cdc42, RhoA and Rnd1 in plexin signaling :  
The Rho family of GTPases have been implicated in playing critical roles during 
neural development, disease and regeneration. Rho GTPases regulate cell 
migration by their involvement in actin reorganization. Sema3A-induced growth 
cone collapse occurs via the neuropilin/plexin-A1 complex and it depends on Rho 
and Rac activity (Jin and Strittmatter 1997; Vastrik, Eickholt et al. 1999; Turner, 
Nicholls et al. 2004). In plexin-A family members the role of Rac1 seems to be 
somewhat different from plexin-B members. Upon Sema3A stimulation, FARP2, 
a Rac1 exchange factor, interacts with plexin-A1 and activates Rac1 to Rac1 
GTPase (Toyofuku, Yoshida et al. 2005). The active Rac1 then binds to RBD of 
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plexin-A1 and results in a conformational change in the plexin which exposes a 
docking site for Rnd1 binding and enhances receptor activity. On the other hand, 
binding of RhoD to plexin-A1 has been demonstrated to inhibit Rnd1 and plexin 
signaling (Zanata, Hovatta et al. 2002). While in the plexin-B family, Rac1 is 
believed to bind more strongly to B-family plexins than A-family plexins. The 
interaction with RBD of plexin-Bs and Rac1 results in activating the receptor by 
either a conformational change (Tong, Chugha et al. 2007) and/or results in 
correct localization of the plexins (Vikis, Li et al. 2002). It has also been 
hypothesized that Rac1 is sequestered by plexin-B1 away from p21 activated 
kinase (PAK) (Vikis, Li et al. 2002) thereby resulting in inhibition of Rac1 
induced PAK activation. PAK is an effector protein that regulates various 
cytoskeletal changes in the cell such as filopodia formation and actin 
polymerization.  
Plexin-B1 binding to RhoA has also been observed (Driessens, Hu et al. 
2001). Plexin-Bs bind to Rho guanine nucleotide exchange factors PDZ-RhoGEF 
and LARG leading to RhoA activation (Fig 1.7) (Swiercz, Kuner et al. 2002). 
This interaction is enhanced by Rnd1 binding (Oinuma, Katoh et al. 2003). 
Swiercz and colleagues also demonstrated that a dominant negative form of PDZ-
RhoGEF was unable to elicit Sema4D mediated growth cone collapse of 
hippocampal neurons. The PDZ domain of PDZ-RhoGEF binds specifically to the 
C-terminal PDZ domain recognition motif in plexins-B family members. A 
mutant form of RhoGEF and LARG with a mutation in the PDZ domain 
eliminated its binding to plexin-B1. It has also been shown that Sema4D 
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stimulation is not necessary for PDZ-RhoGEF and plexin-B1 binding but the PDZ 
motif is essential for membrane localization of plexin-B1 (Swiercz, Kuner et al. 
2002).  
The unusual member of the Rho family of proteins, Rnd1, has also been 
shown to take part in plexin signaling. Rnd1 is involved in many cellular 
processes including regulation of actin cytoskeleton. The GTPase hydrolysis role 
of Rho family of proteins seems to be absent in Rnd1, thereby they are assumed to 
be constitutively active and their function is regulated by their expression levels 
(Chardin 2006). By interacting and activating p190 RhoGAP, Rnd1 plays a role in 
downregulating RhoA (Ishikawa, Katoh et al. 2006). Rnd1 may be sequestered 
away from p190RhoGAP by various proteins (Katoh, Harada et al. 2002; Harada, 
Katoh et al. 2005; Li, Ghavampur et al. 2009) likewise plexins may play a role in 
sequestering Rnd1 thus transiently inactivating the GTPase (Vikis, Li et al. 2002). 
It could also be possible that Rnd1 binding to plexins could inhibit binding of 
plexins to other RhoGTPases (Zanata, Hovatta et al. 2002; Oinuma, Katoh et al. 
2003).  
Similar to other Rho family proteins, Cdc42 plays a role in filopidia 
formation and cell motility. Recent evidence suggests that in the immune system 
plexin-B2 activation downregulates Rac and Cdc42 in macrophages either by 
regulating p190RhoGAP or another GAP protein (Roney, O'Connor et al. 2011). 
The cytoplasmic RBD of plexin-B1 has binding sites for many proteins, 
including Rac1, Rnd1 and RhoD. These proteins are responsible for triggering 
many different signaling pathways within the cell. It is also becoming clear that 
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different plexins have varying binding affinities to small GTPases but the role of 
GTPases in plexin signaling is highly critical and highly complex as well.  
 
Ras family of small-GTPases : The Ras superfamily of GTPases is a family of 
small GTPases that are related to the Ras protein family (such as N-Ras, K-Ras 
and H-Ras). The Ras superfamily is divided into nine families which are further 
classified into subfamilies: Ras, Rap, Rho, Rheb, Rad, Rab, Ran, Rheb, Rit and 
Arf. The Ras family GTPases are involved in the regulation of genes involved in 
cell growth and they are also involved in integrin attachment of the cell. The first 
indication that Ras GTPases might be involved in plexin signaling was from the 
homologous regions found within plexin cytoplasmic domain and Ras GAP 
regulatory proteins (Rohm, Rahim et al. 2000). Negishi et al. was the first to 
illustrate that all human plexins exhibited GAP activity against R-Ras GTPase 
(Saito, Oinuma et al. 2009; Uesugi, Oinuma et al. 2009). What has been known is 
that several GTPases bind to the GAP domains of plexins but how does this 
binding specificity arise and how it is regulated is still debatable. Some 
researchers claim that plexin binding to R-Ras does not inactivate it but it 
possibly sequesters it away from the integrin system thus resulting in cell 
collapse. Evidence from Worzfeld’s laboratory seems to suggest otherwise. The in 
vivo data shows that mutating the two N-terminal arginine residues of the plexin-
B2 GAP domain was sufficient to block R-Ras GAP binding as well as its 
activity. While, a mutant with a mutation in the C-terminal arginine resulted in 
loss of GAP activity but the plexin could still bind to R-Ras GAP (Worzfeld, 
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Swiercz et al. 2014). Thereby, this data seems to suggest that the mode of 
function of plexin GAP domain is due to inactivation of R-Ras rather than the 
sequestration of small GTPases. Interestingly, even though plexins are involved in 
a myriad of physiological processes, mutations in the GAP domain was sufficient 
to completely mimic the phenotype of plexin null mutants with regard to nervous 
system development and cardiovascular development (Worzfeld, Swiercz et al. 
2014).  
Stimulation of GAP activity of plexins results in downregulation of R-Ras 
followed by inhibition of PI3K and dephosphorylation of Akt and GSK-3β in 
growth cone collapse (Ito, Oinuma et al. 2006). Sema4D and plexin-B1 also 
inhibited PI3K and resulted in reduced integrin mediated cell adhesion thus 
enhancing cell migration (Oinuma, Katoh et al. 2006).  
Recent evidence showed that GAP activity against Rap GTPases was 
demonstrated in aqueous solution especially for plexin-C1 and –D1 intracellular 
domains. A constitutively active form of Rap1 eliminated the growth cone 
collapse of Sema3A stimulated neuronal cells (Wang, He et al. 2012). Rap 
GTPases are a subfamily of Ras family of proteins with functions mostly 
involving vesicular transport. Rap proteins have been implicated to be involved in 
axon outgrowth and growth cone collapse in conjunction with other guidance 
molecules as well as being involved in integrin downregulation (Richter, Murai et 
al. 2007). Nevertheless, the downstream signaling mechanism of Rap GTPases is 
unknown with regard to plexins. Plexins appear to be multifunctional and their 
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binding affinities and activities against different Ras GTPase family members 















Fig 1.7. The role of Rho and Ras GTPases in semaphorin signaling. (A) Upregulation 
of Rho activity is observed upon plexin-A1 activation, this leads to an increase in actin 
contractility mediated by ROCK. The direct binding of Rac to the GTPase binding 
domain of plexin could induce a conformational change in the plexin. Sema3A-induced 
dissociation of the FARP2 from the plexin-A1 complex induces recruitment of Rnd1 to 
plexin-A1. The Rnd1/plexin-A1 interaction opens the two R-Ras GAP domains of plexin-
A1 (gray), and leads to inactivation of R-Ras. This event may result in growth-cone 
collapse by inhibiting integrin-mediated adhesion. (B) Rho activity downstream of 
plexin-B1 undergoes transient down-regulation through p190RhoGAP. The PDZ domain 
in the plexin-Bs (orange triangle) interacts with the other PDZ domain containing 
proteins such as Rho GEFs PDZ-RhoGEF and LARG in a semaphorin dependent 





1.3.2 Tyrosine kinases in Semaphorin signal transduction cascade 
Tyrosine phosphorylation is a critical post-translational modification of 
proteins that regulates cell intrinsic signaling in response to extrinsic stimuli such 
as extracellular ligands. This phosphorylation is carried out by tyrosine kinases 
either receptor tyrosine kinases or non-receptor tyrosine kinases. Many of the 
tyrosine kinases are involved in pathways associated with integrin mediated cell 
adhesion, actin cytoskeletal rearrangements, cell motility and axon guidance, 
which are all physiological processes in which semaphorins have been implicated 
too.  
The plexin-tyrosine kinase signaling mechanisms can be classified into 
three types: 
a. Kinase mediated phosphorylation of plexin and its effect on plexin 
signaling; 
b. Phosphorylation of plexin associated proteins by kinases and the effect on 
intracellular signaling; 
c. Downstream effect of plexin signaling on kinases. 
Due to the complex nature of plexin and tyrosine kinase signaling as well as the 
extensive cross-talk and feedback control, it is possible that most kinases might fit 
into more than one of the above-mentioned groups.  
 
Kinase mediated phosphorylation of plexins and its effect on plexin signaling : 
The effect of tyrosine phosphorylation of plexins such as Met, Ron and ErbB-2 
have been discussed above. 
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Phosphorylation of plexin associated kinases and its effect on intracellular 
signaling : Many cytoplasmic kinases have been demonstrated to be involved in 
plexin signaling. The mechanism involved in recruiting and activating these 
plexin associated kinases are largely speculative. The intracellular plexin domain 
might contain recognition motifs such as SH2 and SH3 which are often found in 
cytoplasmic tyrosine kinases and the conformational change after interacting with 
the plexins might be enough to activate them (Moarefi, LaFevre-Bernt et al. 
1997). 
Various studies have shown that cytoplasmic tyrosine kinases such as Fer, 
Fyn and Fes/Fps are involved in the plexin signaling pathway. Fer is believed to 
interact with the intracellular domain of Nrp1 upon Sema3A stimulation and 
results in cell death of cultured cortical neurons (Jiang, Whitehead et al. 2010). 
Nrp1 has also been involved in recruiting Fes and Fak tyrosine kinases to the 
semaphorin receptor complex (Mitsui, Inatome et al. 2002; Bechara, Nawabi et 
al. 2008). Previous studies have elucidated that Fyn and Fes tyrosine kinases 
associate with plexin-A family members in a semaphorin independent manner 
(Mitsui, Inatome et al. 2002; Sasaki, Cheng et al. 2002), and Pyk2 and Src 
kinases interact with plexin-B1 and elicit functional effects in endothelial cells in 
the presence of Sema4D (Basile, Afkhami et al. 2005). The Fes/Fps are also 
involved in signaling to the collapsing response mediator (CRMP) family of 
microtubule regulators which interact with plexin-A family members (Mitsui, 
Inatome et al. 2002; Deo, Schmidt et al. 2004).  Another Src family kinase 
involved in CRMP signaling is Fyn (Buel, Rush et al. 2010), which in response to 
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Sema3A mediated plexin-A2 activation, initiates the Cdk5 phosphorylation 
cascade eventually leading to guiding cortical projections in the cortex (Sasaki, 
Cheng et al. 2002). Furthermore, inhibiting Cdk5 can reduce Sema4D mediated 
RhoA regulation as well as Rho-Rho kinase (ROCK) activity by activation of 
p190 RhoGAP (Lin, Ogiya et al. 2007; Tripathi and Zelenka 2009).  
 
Downstream effect of plexin signaling on kinases : The intracellular signaling 
cascade triggered by semaphorin binding consists of many kinase-initiated 
classical pathways. Stimulation of endothelial cells with Sema4D recruits and 
activates Pyk2, an integrin-related kinase, and Src kinase subsequently triggering 
the PI3K-Akt pathway to induce cell migration (Basile, Afkhami et al. 2005; 
Basile, Gavard et al. 2007). Another study on the same pathway shows Pyk2 acts 
downstream of plexin-B1 by Rho activation of Rho kinase (ROCK). Src is also 
activated by Met but this is a broad scale signaling event that is regulated by 
Ras/Erk and Rac1/p38. The PI3K/Akt pathway is probably involved too most 
likely providing feedback control via GSK-3β (Segarra, Balenci et al. 2006; Fan, 
Meng et al. 2009). Sema4D mediated phosphorylation of plexin-B1 activates Erk 
and the plexin-B1 C-terminus is essential for this activation. Further, LARG 
mediated activation of RhoA stimulated Raf and increased Erk activity towards 
Elk, a transcriptional activator (Aurandt, Vikis et al. 2002; Hirotani, Ohoka et al. 
2002; Perrot, Vazquez-Prado et al. 2002; Swiercz, Kuner et al. 2002). All these 
mechanisms are important players in the downstream signaling pathway elicited 
by plexins.  
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It is true that tyrosine phosphorylation is a key regulatory protein 
modification involved in tightly controlling physiological processes. On the other 
side of the coin, is tyrosine dephosphorylation by phosphatases. There has been 
scanty evidence that plexins can interact with phosphatases, nevertheless the 
importance of it cannot be overlooked. Fuchikawa and colleagues illustrated that 
overexpression of a phosphatase inactive version of Src-homology 2-containing 
protein-tyrosine phosphatase 2 (Shp2), a cytoplasmic tyrosine phosphatase, 
suppressed Sema4D mediated growth cone collapse in retinal neurites. 
Furthermore, as Shp2 has been shown to indirectly associate with ErbB2 and Met, 
it is possible that Shp2 might be one of the phosphatases involved in plexin 
signaling (Fuchikawa, Nakamura et al. 2009). Unfortunately, Fuchikawa et al., 
were unable to show stable binding of Shp2 to plexin-B1 but it could always be 








Fig 1.8. Involvement of tyrosine kinases in semaphorin signalling pathways.            
(A) Semaphorin receptor complexes often include plexin-associated RTKs. For example, 
plexin-B1 and plexin-A1 have been found in association with tyrosine kinases such as 
MET, RON, ERBB2, VEGFR2 or OTK (off-track kinase) in a cell-specific manner. Once 
activated by semaphorins, these RTKs get activated, resulting in mediating effects on cell 
migration, invasive growth and morphogenesis. (B) The intracellular domain of plexins 
might also associate with cytoplasmic tyrosine kinases implicated in signal transduction. 
For example, upon Sema4D binding, integrin-dependent activation of the kinases PYK2 












1.4 Biological functions of Semaphorins and plexins 
1.4.1 Semaphorins and plexins play key roles in axon guidance and neural 
circuit development 
The precise functioning of the nervous system depends upon the correct 
wiring of neuronal circuits established during embryonic development and their 
remodeling upon adulthood. These patterns of neuronal circuitry depend 
predominantly on the attractive and repulsive guidance cues such as semaphorins. 
These guidance cues play a role in controlling the direction of axonal and dendrite 
growth (Polleux, Morrow et al. 2000; Gu, Rodriguez et al. 2003; Fenstermaker, 
Chen et al. 2004) as well as neuronal migration and branching (Marin, Yaron et 
al. 2001; He, Wang et al. 2002; Kerjan, Dolan et al. 2005). They also function in 
defining the pattern of synaptic connectivity (Sahay, Kim et al. 2005; Bouzioukh, 
Daoudal et al. 2006), dendritic spine formation (Morita, Yamashita et al. 2006), 
apoptotic cell death (Ben-Zvi, Yagil et al. 2006), pruning and transport of axons 
(Goshima, Kawakami et al. 1997; Goshima, Hori et al. 1999; Bagri, Cheng et al. 
2003; Li, Sasaki et al. 2004; Liu, Low et al. 2005).  
 
Semaphorins and plexins regulate axonal branching, pathfinding and 
fasciculation : The founding member of the semaphorin family, Sema3A, was 
initially identified for its property of eliciting axonal growth cone collapse in 
sensory neurons in vitro (Luo, Raible et al. 1993). The most studied function of 
semaphorin is that of a chemorepellant for many neuronal cell types. However, in 
certain contexts, they do exhibit attractive functions too.  
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In vitro and in vivo studies have expanded our knowledge of semaphorin function 
in the developing nervous system to a great extent. Being axon guidance 
molecules, semaphorins regulate axonal fasciculation, pathfinding and branching. 
Genetic ablation of semaphorins in vertebrates had brought upon some surprising 
findings. Unlike its potent effect in vitro, the in vivo effect upon deletion of 
semaphorin genes was quite limited. The most severe effects were observed in 
Sema3F and Sema3A mutant embryos, Sema3A mutants displayed severe 
defasciculation and abnormal extension of certain cranial nerves including the 
ophthalmic nerve. Further, abnormal extension of spinal nerve projections and 
sympathetic neuronal projections were altered too (Taniguchi, Yuasa et al. 1997; 
Behar, Mizuno et al. 1999; Ulupinar, Datwani et al. 1999). Sema3F plays a 
similar role but in a different set of cranial nerves such as the oculomotor and 
trochlear nerves (Sahay, Molliver et al. 2003). Assays performed on neurons 
obtained from plexin-A3 and plexin-A4 null mice illustrated that these plexins 
were indeed the functional receptors for class 3 semaphorins. In vitro assays 
performed on sympathetic neurons obtained from plexin-A3 and plexin-A4 
mutant embryos, showed that plexin-A4 was the main signaling receptor involved 
in the repulsive response of sympathetic neurons to Sema3A while plexin-A3 was 
only partially responsible for this function. Plexin-A4 null mice also exhibited 
severe defasciculation of peripheral and sensory motor projections while plexin-
A3 mice showed a modest defasciculation only (Cheng, Bagri et al. 2001; Suto, 
Ito et al. 2005; Yaron, Huang et al. 2005). As for Sema3F mediated axon 
guidance, the sympathetic and hypothalamic neurons of plexin-A3 null mice 
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completely lost their ability of repulsive response to Sema3F thereby implicating 
that Nrp2 might interact with plexin-A3 to trigger Sema3F signaling in these 
types of neurons (Cheng, Bagri et al. 2001).  
With relation to other secreted semaphorins, semaphorin 3B (Sema3B) 
mutant mice exhibit defasciculation and abnormalities in anterior commissure 
(Falk, Bechara et al. 2005). As for transmembrane semaphorins, no defects in 
axon guidance have been reported for Sema4A, semaphorin 4E (Sema4E) and 
Sema5A, while for Sema5A a detailed neuronal connectivity study has not been 
done due to embryonic lethality of Sema5A null mice (Fiore, Rahim et al. 2005). 
As for Sema6A null mice (Leighton, Mitchell et al. 2001), they showed abnormal 
projection of thalamocortical fibres and semaphorin 7A (Sema7A) mutant mice 
exhibited impaired axon extension of the olfactory tract (Pasterkamp, Peschon et 
al. 2003). The lack of severe neuronal phenotypes in semaphorin mutants could 
possibly be due to the possible redundancy among semaphorins as their 
distribution mostly overlaps in the developing nervous system as well as the 
distribution of different coreceptors that are involved in semaphorin-plexin 
signaling. 
Neuropilins are a small family of coreceptors for many secreted 
semaphorins. Nrp1 interacts strongly with Sema3A while Nrp2 binds to Sema3F. 
As discussed above, neuropilin binding to plexin generates a conformational 
change that releases the plexin from autoinhibition (Takahashi and Strittmatter 
2001). It was seen that Nrp1 and Sema3A null mice exhibited almost identical 
axon guidance phenotypes (Kitsukawa, Shimizu et al. 1997; Taniguchi, Yuasa et 
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al. 1997; Gu, Rodriguez et al. 2003) as do Sema3F and Nrp2 mutant mice (Chen, 
Bagri et al. 2000; Giger, Cloutier et al. 2000; Sahay, Kim et al. 2005). The 
neuropilin mutant phenotypes closely resembled those seen in mice with 
mutations in their respective semaphorin ligands that to the plexin mutants and the 
neuropilins were selectively expressed in the neuronal populations affected in 
these mutants.  
The diverse array of ligand-receptor interactions that can trigger 
semaphorin signaling provides an excellent opportunity for diverse semaphorin 
expression patterns in subsets of similar cell types. For example, during the 
development of the vertebrate limb, expression of class 3 semaphorins and 
neuropilins distinguish populations of motor neurons in the hindbrain and spinal 
cord and the repulsive interactions between the semaphorins and neuropilins are 
responsible for the distinct spinal-motor-neuron projections patterns (Huber, 
Kania et al. 2005).  
Research performed on Sema3A and Nrp1 mutant mice illustrated their 
roles in motor axon pathfinding. During early embryogenesis, Nrp1 is expressed 
at the medial and lateral parts of the lateral motor column while Sema3A is 
expressed at the base of the limb where the motor axons assemble and reorganize 
themselves into nerve branches. In Sema3A null mice and mice expressing a 
functionally inactive variant of Nrp1 that is unable to bind to Sema3A (Gu, 
Rodriguez et al. 2003), motor neurons from the lateral motor column did not 
assemble at the plexus region and the motor neuronal projections were 
disorganized and defasciculated. Moreover, the motor column motor neurons 
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misprojected to the dorsal forelimb and ventral forelimb (Huber, Kania et al. 
2005). Whilst in Sema3F or Nrp2 null mice, the medial motor column neurons 
misproject to the dorsal limb while lateral motor column neurons project as 
normal. Thus indicating that sensory and motor neurons are dependent on each 
other on axon pathfinding and they interact partly through Nrp1-mediated 
fasciculation within the developing limb.   
In the developing nervous system, semaphorins have another distinct 
function of regulating axon fasciculation by repulsive axonal interactions that 
enable axons to diverge from nerve fibres and extend along a separate trajectory. 
This has been observed with the Drosophila semaphorin Sema1a and its receptor 
PlexA which is predominantly expressed in a majority of Drosophila motor 
neurons and in the absence of Sema1a and PlexA the motor neurons tend to 
remain hyperfasciculated and fail to reach its designated targets. Overexpression 
of Sema1a, PlexA or other downstream signaling effectors involved in 
semaphorin-mediated axon-axon interaction, resulted in premature defasciculation 
of motor neurons which resulted in abnormal patterning of the motor nerves 
(Winberg, Noordermeer et al. 1998; Yu, Araj et al. 1998; Terman, Mao et al. 
2002; Ayoob, Yu et al. 2004; Terman and Kolodkin 2004).   
The role of plexin-B family members in neural development has been 
elucidated as well. In plexin-B1 null mice, there was no abnormal phenotype 
observed in the nervous system while plexin-B2 mutant mice died postnatal due 




Regulation of axon targeting : Another role of semaphorins and their receptors in 
the developing nervous system is in selectively directing subsets of related 
neuronal cell types to their correct targets. For example, the separation of the 
proprioceptive and cutaneous sensory neurons to the dorsal and ventral spinal 
cord regions requires spatial expression of semaphorin 6C (Sema6C) and Sema6D 
in the proprioceptive neurons and its receptor plexin-A1 is specifically expressed 
in the superficial dorsal horn, a region avoided by the proprioceptive neurons 
(Yoshida, Han et al. 2006). These experiments suggest that plexin-A1 and 
sema6C/6D have specific roles in axon shaft positioning thereby ensuring 
appropriate patterning of sensory neurons in the developing central nervous 
system.   
The projections of the retinal ganglion cells (RGCs) to the optic tectum 
require semaphorin signals as well. During embryogenesis, RGCs have an option 
whether to cross the CNS midline at the optic chiasm or to avoid it, thus 
regulating RGC extensions to their ipsilateral or contralateral targets. A recent 
study by Kuwajima et al. elucidated that Sema6D via its receptors plexin-A1 and 
Nr-CAM stimulated retinal axonal midline crossing (Fig 1.9) (Kuwajima, 
Yoshida et al. 2012). They found that Sema6D and Nr-CAM expression were 
observed in radial glial cells in the midline and plexin-A1 expression was seen in 
chiasm neurons, furthermore plexin-A1 and Nr-CAM were both expressed in 
contralateral retinal ganglion cells. Their experiments demonstrated that Sema6D 
by itself behaves repulsive to contralateral retinal ganglion cells but if it is in 
combination with Nr-CAM and plexin-A1 this surprisingly alters the 
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chemorepulsion to chemoattraction. Their study also showed that Nr-CAM 
interacts with both Sema6D and plexin-A1 and all these 3 molecules are essential 
















Fig 1.9. Retinal midline crossing is controlled by Sema6D via its interaction with 
plexin-A1 and Nr-CAM. Glial cells present in the optic chaism express Sema6D and Nr-
CAM while plexin-A1 is expressed by the chiasm neurons (SSEA1). Nr-CAM and 
plexin-A1 are expressed by crossed RGCs. The receptor complex in cis on RGCs and 
Sema6D leads to repulsion of RGCs, whereas the complex on chiasm cells acting in trans 












Semaphorins and plexins in cellular circuit lamination – Distinct patterns of 
synaptic connectivity in the nervous system are usually organized into individual 
laminae. The most studied of these laminae formation is in the vertebrate retina, 
the RGCs are segregated into amacrine cells and bipolar cells. These cells project 
specific synaptic connections within the synaptic plexus of the inner plexiform 
layer. Recent studies using mouse genetics highlighted the regulation of different 
aspects of retinal lamination by transmembrane semaphorins (Matsuoka, 
Chivatakarn et al. 2011; Matsuoka, Nguyen-Ba-Charvet et al. 2011). During 
postnatal development of the retina, Sema5A and semaphorin 5B (Sema5B) 
expression was observed at the outer neuroblastic layer of the retina and depletion 
of Sema5A and 5B resulted in the amacrine and bipolar cells to abnormally 
project into the outer plexiform layer, inner nuclear layer and outer nuclear layer 
(Fig 1.10). This illustrates that Sema5A and Sema5B constrain the stratification of 
neurites of various retinal cell subtypes within the inner plexiform layer in vivo 
(Matsuoka, Chivatakarn et al. 2011). Interestingly, plexin-A1 and -A3 null mice 
phenocopy the inner retinal lamination defects seen in Sema5A and 5B mutant 
mice thus demonstrating that these receptors mediate the repulsive signals elicited 
by Sema5A and Sema5B. Once these neural processes are constrained to the inner 
plexiform layer, they are then guided by Sema6A to their respective sublaminae. 
The inner plexiform layer is divided into five sublaminae, S1 to S5; Sema6A 
expression is observed in S4-S5 stratified neurites and its receptor plexin-A4 
expression is seen is S1-S3. In wild-type mice, the dopaminergic amacrine cells 
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and M1-type melanopsin intrinsically photoreceptive retinal ganglion cells are 
restrained and stratify within the S1 sublaminae. On the other hand, in  
plexin-A4-/- mutant mice these neural cells extend projections abnormally into 
S4/S5 sublaminae. These findings suggest that Sema6A behaves as a repulsive 
cue for neurites expressing plexin-A4 and that they are essential for the regulation 






















Fig 1.10. Membrane bound semaphorins control laminar neurite stratification in the 
retina. (A) Schematic representation of the embryonic eye. The dotted region is 
magnified in (B) and (C). (B) Expression of Sema5A and Sema5B in the outer 
neuroblastic layer (ONBL) during early postnatal development of the retina is shown to 
restrict the neurites of amacrine cells and RGCs to the inner plexiform layer (IPL) where 
they form synaptic connections. These effects are mediated by the sema5 receptors 
plexin-A1 and -A3. (C) Within the IPL, various sublaminae can be discerned (S1–S5). 
Sema6A is expressed in S4/S5 and these neurites lie adjacent to neurites from the S1–S3 





















Research performed over the past few years has unearthed various new 
and unconventional functions of semaphorins in the nervous system as well as the 
different mechanisms of semaphorin signaling. Emerging evidence also suggest 
aberrant semaphorin expression is involved in nervous-system related disorders as 
well as regeneration failure such as neurodevelopmental and psychiatric disorders. 
Further, semaphorins inhibit axonal regeneration of injured or severed CNS axons 
by creating an environment inhibitory for axon regrowth around injury site 
(Pasterkamp, De Winter et al. 1998; Kaneko, Iwanami et al. 2006). Therefore, 
understanding the intricate details of semaphorin signaling in the nervous system 
will be critical to design treatment modalities for neural injury.  
 
1.5 Multi faceted role of semaphorin signaling in cancer progression 
Despite the fact that semaphorins were originally discovered as axon 
guiding molecules, the expression of semaphorins and their receptors has been 
observed in non-neural tissues as well. As discussed above, they have been known 
to be involved in the development of various organ systems but the trend is for 
their expression levels to decline upon adulthood. Considering their ubiquitous 
expression as well as their critical role during development it is highly likely that 
dysregulation of this primitive signaling pathway would be involved in various 
aspects of cancer biology.  
Semaphorins and their receptors are widely expressed in cancer cells. 
There are certain semaphorins that are overexpressed in numerous cancer types 
especially Sema3C and 3E. To date, there is no known evidence of any genetic 
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alterations of these signaling pathways in cancer cells. Therefore it is speculated 
that abnormal semaphorin signaling cannot initiate tumorigenesis in isolation but 
rather they are critical players in controlling cancer related traits such as tumor 
proliferation, angiogenesis, metastasis and invasion.  On the other hand, certain 
semaphorins exhibit tumor-suppressive functions such as Sema3A, 3B, 3F and 3G 
and they are often seen to be downregulated in cancer cells. It is noteworthy to 
mention that the distinction of being an oncogenic or tumor suppressive 
semaphorin is not clear-cut, there have been some semaphorins like Sema5A that 
have been found to exhibit both pro-tumoral and anti-tumoral functions in 
different cancers. 
  
1.5.1  Oncogenic Semaphorins 
Oncogenic semaphorins are involved in regulation of cancer cell behavior 
such as enhancing invasion and metastasis, increasing proliferation as well as 
favoring tumor cell survival. In addition, they also modulate the tumor cell 
microenvironment by sustaining angiogenesis, and as they have been shown to be 
involved in the immune system they could also regulate the tumor immune 
microenvironment too.  
Sema3C, a soluble semaphorin of the class 3 semaphorins, was initially 
implicated to be involved in multidrug resistance in tumor cells and upon 
treatment with various chemotherapeutic agents as well as X-rays and UV 
irradiation it was observed that Sema3C expression was increased (Yamada, Endo 
et al. 1997; Konno 2001). It was also found to be overexpressed in gastric cancer 
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and metastatic lung adenocarcinoma (Martin-Satue and Blanco 1999) as well as 
being associated with poor prognosis in ovarian cancer patients (Galani, Sgouros 
et al. 2002).  Silencing of Sema3C in gastric cancers suppressed in vivo tumor 
growth and vascularity of the stomach cancers in an orthotopic mouse model 
(Miyato, Tsuno et al. 2012). The molecular mechanisms behind the pro-tumoral 
effects of Sema3C still remain a mystery. It could be possible that epigenetic 
mechanisms such as chromatin modification and chromatin remodeling might be 
involved in transcriptionally regulating Sema3C. In a recent study on colorectal 
cancer, genome-wide DNA methylation analysis of human colon cancer samples 
highlighted that Sema3C promoter was hypomethylated in colorectal cancers 
thereby giving rise to higher Sema3C expression levels in colon cancer samples 
(Irizarry, Ladd-Acosta et al. 2009).  During cardiac development, GATA6, a well-
known oncogene transcriptionally regulates Sema3C, taking this into 
consideration it is quite possible that GATA6 or other transcription factors might 
modulate Sema3C levels (Lepore, Mericko et al. 2006; Kodo, Nishizawa et al. 
2009).  
Sema3E is another semaphorin known to be overexpressed in various 
cancers such as breast, colorectal, ovarian cancers as well as melanoma. In a 
study, Christensen and colleagues had demonstrated that overexpression of 
Sema3E in murine mammary adenocarcinoma cell lines increased the metastatic 
ability of these cell lines (Christensen, Ambartsumian et al. 2005). Another study 
performed on ovarian cancer cells illustrated that Sema3E induced epithelial-to-
mesenchymal (EMT) in these cancer cells (Tseng, Murray et al. 2011). 
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Interestingly, Sema3E can be proteolytically processed to yield a p61-Sema3E 
fragment which has been observed to enhance cancer cell invasion and metastasis 
by activating ErbB-2 tyrosine kinase (Casazza, Finisguerra et al. 2010). On the 
other hand, due to its inherent anti-angiogenic role during embryonic 
development (Sakurai, Gavard et al. 2010) overexpression of Sema3E can also 
decrease tumor volume in animal models of cancer (Casazza, Kigel et al. 2012).  
A class 4 semaphorin, Sema4D, seems to play a dual role in cancer 
progression too. It was shown that Sema4D was involved in cancer cell migration, 
angiogenesis and apoptosis. Being an immune semaphorin, Sema4D is expressed 
in activated B cells and dendritic cells (Ch'ng and Kumanogoh 2010) and thus it 
was found to be downregulated in B cell non-Hodgkin lymphoma (Dorfman, 
Shahsafaei et al. 1998). In solid tumors such as prostate, lung, breast, oral, colon, 
cervical, head and neck cancers and soft tissue cancers it was found to be 
overexpressed (Basile, Castilho et al. 2006; Sun, Zhou et al. 2009; Liu, Yang et 
al. 2014). In breast cancer low expression of the Sema4D receptor, plexin-B1 
correlated with a good prognosis (Worzfeld, Swiercz et al. 2012). In head and 
neck cancer Sema4D was illustrated to be regulated by hypoxia thereby indicating 
a potential pro-angiogenic role for this semaphorin in this type of squamous cell 
carcinoma (Sun, Zhou et al. 2009). A very recent study found that increased 
Sema4D expression in cervical cancer correlated with poor prognosis and it also 
showed that Sema4D enhanced invasiveness in cervical cancer cell lines by 
activating MAPK and Akt pathway (Liu, Yang et al. 2014).  
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A transmembrane semaphorin, Sema6D along with its receptor, plexin-A1 
interacts and activates VEGFR2 mediated signaling (Toyofuku, Zhang et al. 
2004). Malignant pleural mesothelioma cells were shown to express Sema6D and 
plexin-A1 and they were essential for sustaining anchorage-independent growth 
in mesothelioma cells. Sema6D binding to plexin-A1 which then interacts with 
VEGFR2 activates VEGFR2 in these malignant cells thereby inducing a response 
similar to those induced by VEGF activation (Catalano, Lazzarini et al. 2009). 
Sema6D expression was also observed to overexpressed in gastric cancer thus 
suggesting a potential oncogenic role for this semaphorin in gastric cancer (Zhao, 
Chen et al. 2006).    
Among class 5 semaphorins, Sema5A, has been shown to be 
overexpressed in ovarian, gastric, prostate and pancreatic cancers and its 
overexpression correlated with increased invasion and metastasis (Sadanandam, 
Varney et al. 2007; Pan, Lv et al. 2010; Sadanandam, Varney et al. 2010; 
Danielson 2014). In contrast, Li et al. have elucidated a tumor suppressive role for 
Sema5A in glioblastomas and it was observed to inhibit invasion in glioma cells 
by Rho-GDIα mediated inactivation of Rac1 (Li and Lee 2010; Li, Law et al. 
2012). Further on, in non small cell lung carcinoma Sema5A expression level was 
significantly reduced and was associated with poor survival in those patients. The 
reasons for this discrepancy could be due to cell-type specific effects of 





1.5.2 Tumor Suppressive Semaphorins 
Some members of the class 3 semaphorin family such as Sema3F and 
Sema3B were discovered during the search for potential tumor suppressors in a 
region of chromosome 3 which was frequently lost during lung cancer 
progression (Roche, Boldog et al. 1996; Sekido, Bader et al. 1996). These 
semaphorins were shown to play roles in inhibiting cellular proliferation, 
angiogenesis and invasion. Sema3F is downregulated in various types of cancers 
too, such as melanoma, prostate, breast, lung and ovarian cancers (Xiang, Hensel 
et al. 1996; Lerman and Minna 2000; Lantuejoul, Constantin et al. 2003; 
Bielenberg, Hida et al. 2004; Drenberg, Livingston et al. 2009; Staton, Shaw et 
al. 2011). Likewise, Sema3B is also downregulated in some solid tumors such as 
lung, ovarian, breast, prostate and liver tumors (Konno 2001; Ito, Ito et al. 2005; 
Tischoff, Markwarth et al. 2005; Staton, Shaw et al. 2011).  
Sema3F was the first class 3 semaphorin that was identified as an anti-
angiogenic factor (Bielenberg, Hida et al. 2004; Kessler, Shraga-Heled et al. 
2004) as well as being proapoptotic to endothelial cells (Guttmann-Raviv, Shraga-
Heled et al. 2007). Upon re-expression of Sema3F in various cancer cell lines, it 
resulted in complete loss of tumorigenecity in nude mice thereby highlighting 
Sema3F directly affects cancer cell behavior (Xiang, Davalos et al. 2002). 
Recently it was found that reduced expression of Sema3F in lung cancer cells was 
due to the highly active transcriptional repressor, ZEB-1(Clarhaut, Gemmill et al. 
2009). In H157 lung cancer cells Sema3F inhibited various classical signaling 
pathways such as Akt and STAT pathways resulting in the loss of activated αvβ3 
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integrin. Furthermore, it also inhibited HIF-1α expression and consequently 
VEGF levels thus mediating inhibition of hypoxia-induced angiogenesis (Kusy, 
Nasarre et al. 2005; Potiron, Sharma et al. 2007). In MCF-7 cells, Sema3F 
inhibited the attachment and spreading of these breast cancer cells and inhibited 
E-cadherin expression (Nasarre, Constantin et al. 2003; Nasarre, Kusy et al. 
2005). In A375 melanoma cells, Sema3F inhibited integrin-β1-mediated adhesion 
and suppressed metastatic dissemination of these cells (Bielenberg, Hida et al. 
2004). Interestingly, wild-type p53 was shown to induce Sema3F expression and 
the loss of p53 in colorectal cancer cell lines resulted in reduced Sema3F levels 
followed by increased tumor vessel formation and angiogenesis (Futamura, 
Kamino et al. 2007).  
Sema3B, another class 3 member, was shown to inhibit the anchorage-
independent growth of responsive lung cancer cells and induce apoptosis 
(Tomizawa, Sekido et al. 2001). The apoptotic effects were inhibited by VEGF165 
but not by VEGF121 as both neuropilins interact with VEGF165 isoform of VEGF 
and not the VEGF121 splice form (Castro-Rivera, Ran et al. 2004). Thereby, 
suggesting that the apoptotic effects elicited by Sema3B are mediated by 
neuropilins. Stimulation of lung and breast cancer cells with soluble Sema3B 
resulted in cell growth inhibition, increased apoptosis, and was associated with 
reduced Akt phosphorylation, increased cytochrome c release, activation of 
caspase-3, as well as phosphorylation of various proapoptotic proteins such as 
glycogen synthase kinase-3-β (GSK3β), FKHR and MDM2 (Castro-Rivera, Ran 
et al. 2008). Varshavky and colleagues recently demonstrated that Sema3B 
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possesses anti-angiogenic properties too (Varshavsky, Kessler et al. 2008). It was 
found that Sema3B can also induce the expression of interleukin-8 a well-known 
angiogenic factor which in turn recruits tumor-associated macrophages and 
enhances metastatic spread to the lungs (Rolny, Capparuccia et al. 2008). 
 There are certain semaphorins which have been speculated to play anti- 
tumorigenic roles but their functions in tumorigenesis has not been completely 
explored. Sema4A, a transmembrane semaphorin that signals by interacting with 
plexin-D1, has been shown to be an inhibitor of developmental angiogenesis 
(Toyofuku, Yabuki et al. 2007) but then its role in tumor angiogenesis is unclear. 
In a panel of neurofibromas, semaphorin 4F (Sema4F) was observed to be 
downregulated thus hinting at a possible role for Sema4F in tumor progression 
(Parrinello, Noon et al. 2008). The soluble extracellular domain of Sema6A was 
shown to be anti-angiogenic to cancer cells, suggesting that they might play a part 
in tumorigenesis too (Dhanabal, Wu et al. 2005). 
 
1.5.3 Semaphorins and their receptors in gliomagenesis  
The possibility that semaphorins and their receptors could play a role in 
gliomagenesis arose from a study by Rieger et al that demonstrated the expression 
of semaphorins and their receptors in human glioma cells (Rieger, Wick et al. 
2003). Over the past decade, most of the research on semaphorins and glioma 
formation has focused primarily upon class 3 semaphorins. An increased 
expression of Sema3A was observed in a subset of human GBMs suggesting an 
oncogenic role for Sema3A in gliomas (Bagci, Wu et al. 2009). It was also 
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observed that siRNA mediated silencing of Sema3A in glioma cell lines 
suppressed glioma cell migration as well as altered the cellular morphology in a 
Rac1-dependant manner. This study highlights that Sema3A signals through 
neuropilin in an autocrine manner and enhances glioma cell infiltration (Bagci, 
Wu et al. 2009). In contrast, expression of recombinant Sema3A in glioma cell 
lines significantly reduced glioma cell proliferation as well as suppressed 
anchorage independent growth as observed by the colonies in soft agar assay 
(Sabag, Bode et al. 2012). Molecular profiling of glioblastoma patients illustrated 
that Sema3B expression was significantly increased and correlated with poor 
patient survival but unfortunately the microarray results for Sema3B was not 
confirmed using quantitative real-time PCR (Rich, Hans et al. 2005). In another 
study by Karayon-Tapon et al. an analysis performed on adult glial tumors 
demonstrated that Sema3B, Sema3G and Nrp2 were correlated with better patient 
prognosis (Karayan-Tapon, Wager et al. 2008). Interestingly, it has also been 
observed that re-expression of p53 in a p53-null glioblastoma cell line increased 
Sema3B expression thus hinting at a role for Sema3B in p53-mediated tumor 
suppression (Ochi, Mori et al. 2002).  
In a more recent and comprehensive study to elucidate the role played by 
class 3 semaphorins in glioma unearthed some interesting findings. Upon 
expression of Sema3B in U87-MG glioma cell lines, the cells were observed to 
contract but there was no reduction in proliferation in vitro nor was there any 
reduction in tumor volume upon subcutaneous implantation of Sema3B 
expressing glioma cells in nude mice. Nevertheless, upon implantation of these 
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cells into the brain cortex it resulted in potent inhibition of tumor formation 
(Sabag, Bode et al. 2012). In this study, Sema3D and Sema3E proved to be the 
most potent inhibitors of tumor development in vivo upon subcutaneous and 
intracranial implantation of the semaphorin-expressing glioma cells in 
immunocompromised mice. Interestingly, there was also a reduction of tumor 
associated microvessels in these mice suggesting an anti-angiogenic role of these 
semaphorins in counteracting glioma progression. It is noteworthy to mention that 
Sema3D and Sema3E expression also resulted in enhanced disease free survival 
of these mice (Sabag, Bode et al. 2012) . A previous study had also observed 
reduced Sema3D expression in high-grade gliomas as compared to low-grade 
gliomas (Karayan-Tapon, Wager et al. 2008).  
Addition of Sema3F to glioma cell lines induced cytoskeletal collapse and 
inhibited glioma cell migration by p190 RhoGAP mediated inactivation of RhoA 
(Shimizu, Mammoto et al. 2008). Ectopic expression of Sema3F in glioma cell 
lines has been shown to significantly reduce proliferation as well as inhibit 
anchorage-independent growth. This study also showed reduced tumor forming 
potential for Sema3F expressing glioma cells (Sabag, Bode et al. 2012). Sema3F 
gene resides at 3p21.3 which is a hot spot for loss of heterozygosity in many 
human cancers where they play a tumor suppressive role. A less studied 
semaphorin, Sema3G, was observed to elicit anti-invasive and anti-migratory 
functions upon exogenous stimulation in U251-MG glioma cell line (Zhou, Ma et 
al. 2012). While in Sabag et al.’s study, Sema3G was the only class 3 semaphorin 
where discernible tumors were observed after subcutaneous implantatation of 
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semaphorin expressing cells into nude mice but upon intracranial implantation 
these cells were unable to form tumors possibly due to the high local 
concentration of semaphorins which could have resulted in enhanced inhibition 
(Sabag, Bode et al. 2012).     
Transmembrane semaphorins have been implicated to be involved in 
gliomagenesis too. Sema6B levels were observed to be downregulated upon 
treatment with all-trans retinoic acid, an anti-tumor and differentiation-inducing 
drug thereby suggesting a role for Sema6B in glioma formation (Correa, Sasahara 
et al. 2001). Recent evidence has implicated that Sema5A can inhibit glioma cell 
motility and invasion by signaling via plexin-B3 in a Rac-1 dependant manner. It 
was also observed that a significant reduction of Sema5A protein levels was 
observed in high-grade glioblastomas (Li, Law et al. 2012). Exogenous 
stimulation of glioma cells with Sema5A resulted in morphological changes in the 
cells to a more differentiated phenotype usually associated with low-grade 
astrocytomas. These evidences suggest a possible tumor suppressor function of 
Sema5A in glioblastomas.  
The co-receptors involved in semaphorin signaling, neuropilins have also 
been implicated in gliomas. A significant increase in neuropilin-1 expression was 
observed in high-grade gliomas and this increased expression correlated with poor 
prognosis for patients (Osada, Tokunaga et al. 2004). RNAi mediated silencing of 
neuropilin-1 in a glioma cell line decreased proliferation, induced apoptosis and 
resulted in a reduction of S phase cells (Li, Tang et al. 2011). Similarly, 
overexpression of neuropilin-1 in glioma promoted tumor growth and 
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angiogenesis in vivo through activating the HGF/c-Met pathway (Hu, Guo et al. 
2007).    
1.6 Objective of the study 
Cancer is a heterogeneous disease that results from genomic instability 
and activation of aberrant signaling pathways. Semaphorins and plexins that have 
been initially identified as axon guidance molecules have recently been implicated 
in tumorigenesis as well. Sema5A is a transmembrane protein with a unique 
domain organization, it possesses both a sema domain as well as thrombospondin 
type I repeats. Its putative receptor, plexin-B3, similar to other plexins harbors a 
sema domain, cysteine-rich MRS domains (Met-related sequence) and IPT 
domains (immunoglobulin-like regions in plexins and transcription factors). There 
has been a recent interest in understanding the role played by Sema5A in cancer. 
Similar to other semaphorins, Sema5A too has been observed to exhibit 
contrasting roles in different types of cancers. In pancreatic, prostate, gastric and 
ovarian cancers Sema5A has been illustrated to behave in an oncogenic manner. 
On the other hand, publications from other research groups as well as our 
laboratory have demonstrated a tumor suppressive function for Sema5A in 
cancers of the lung, colon and high-grade gliomas. All these findings suggest that 
Sema5A may be involved in regulating certain hallmarks of cancer though the 
exact signaling mechanism is yet to be elucidated.  
 Previous publications from our laboratory have demonstrated a 
significant downregulation of Sema5A in high-grade glioblastomas. In this study, 
we embarked on performing genetic analysis on the Sema5A gene in human 
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gliomas as well as to understand the mechanism behind the downregulation of 
Sema5A in gliomas. The expression levels of Sema5A mRNA in different grades 
of glioma clinical specimens were analyzed. The Sema5A gene was also cloned 
and DNA sequencing analysis was performed to identify any genetic alterations 
of Sema5A gene in gliomas. In this study we also screened for potential 
microRNAs that could play a role in regulating Sema5A and mediating its 
downregulation in high-grade glioblastomas. Furthermore, we studied the 
biological function of Sema5A in high-grade gliomas in glioma cell proliferation. 
The downstream effectors involved in mediating the tumor suppressive function 

















MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Chemicals and Enzymes 
 Superscript III reverse transcriptase, dithiothreitol (DTT), Lipofectamine 
2000, shrimp alkaline phosphatase, the siRNA (sense and antisense strands) 
against human cullin 7 and scrambled siRNA control sequence were obtained 
from Invitrogen (Carlsbad, CA, USA). ON-TARGETplus siRNA against Sema5A 
and ON-TARGETplus control siRNA were obtained from Dharmacon (Fairfield, 
CT, USA). Pre-miR® miRNA precursors and Anti-miR® miRNA inhibitors were 
obtained from Ambion (Carlsbad, CA, USA). T4 DNA ligase, cocktail protease 
inhibitor and DAPI were from Roche Diagnostics (Penzberg, Germany). 
Oligo(dT) primers were from Integrated DNA Technologies (Coralville, IA, 
USA). Protein molecular weight ladder, 30% Acrylamide/Bis, Ethidium Bromide, 
TritonX-100, Bromophenol blue and Ethylene diamine tetraacetic acid (EDTA) 
were obtained from Bio-Rad laboratories (Hercules, CA, USA). Dimethyl 
sulfoxide (DMSO), phenylmethanesulphonylfluoride (PMSF), Trizma base, 
Paraformaldehyde (PFA), Sodium bicarbonate, MG132, Lactacystin, and 
Chloroquine were obtained from Sigma Aldrich (St. Louis, MO, USA). RNase 
inhibitor, 6X DNA loading buffer, dNTPS, DNA molecular weight standards and 
protein molecular weight standards were purchased from Promega (Madison, WI, 
USA). Taq DNA polymerase was purchased from QIAGEN (Valenica, CA, 
USA). Pfu Ultra II fusion HS DNA polymerase was purchased from Agilent 
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Technologies (Santa Clara, CA, USA). Isopropanol, 2-Mercaptoethanol, Ethanol, 
Hydrochloric acid and absolute methanol was obtained from Merck (Darmstadt, 
Germany). Ammonium persulfate (APS) and sodium dodecyl sulfate (SDS) were 
from USB Corporation (Cleveland, OH, USA). SeaKem LE Agarose was from 
Lonza (Portsmouth, NH, USA). Glycine was from VWR International (West 
Chester, PA, USA). Disodium phosphate was from SAMCHUN Chemical Co. 
Ltd. (Seoul, Korea). Restriction enzymes were obtained from NEB (Ipswich, MA, 
USA). Nonidet P-40 (NP-40) was purchased from Chemicon (Temecula, CA, 
USA). Dulbecco’s Modified Eagle’s Medium (DMEM), penicillin/streptomycin, 
Opti-MEM and trypsin/ethylene diamine tetraacetic acid (EDTA) were from 
GIBCO (Grand Island, NY, USA). Fetal bovine serum (FBS) was from Hyclone 
(Logan, UT, USA). Nitrocellulose transfer membrane was purchased from 
Whatman International Ltd (UK).  
2.1.2 Antibodies 
 Mouse anti-cMyc, mouse anti-glutathione sulfotransferase (GST), mouse 
anti-cullin 7, mouse anti-β-tubulin and rabbit anti-hemagglutinin (HA) were from 
Santa Cruz (Santa Cruz, CA, USA). Mouse anti-glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) was from Chemicon (Temecula, CA, USA). Mouse 
anti-β-Actin was from Sigma-Aldrich (St. Louis, MO, USA). Mouse anti-
hemagglutinin (HA), mouse anti-proteasome 20S alpha+beta, mouse anti-Fbxo4 
and rabbit anti-Fbxw8 were from Abcam (Cambridge, UK). Rabbit anti-cyclin 
D1, rabbit anti-phospho cyclin D1 (Thr286), rabbit anti-Erk1/2, rabbit anti-
phospho Erk1/2 (Thr 202/Tyr 204), mouse anti-ubiquitin and mouse anti-PCNA 
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were from Cell Signaling (Beverly, MA, USA). Horseradish peroxidase (HRP)-
conjugated anti-mouse and anti-rabbit secondary antibodies were from Pierce 
(Rockford, IL, USA). AlexaFluor® 488, 546 and 350 goat anti-rabbit IgG and goat 
anti-mouse IgG were from Molecular Probes (Eugene, OR, USA). 
2.1.3 Mammalian cell lines and bacterial hosts 
U-87 MG, A172, U-373 MG and HEK293 cells were obtained from 
American Type Culture Collect (ATCC) (USA). U251 was a kind gift from 
Assoc. Prof. Heng-Phon Too. E.coli bacteria BL21 and DH5α were purchased 
from Invitrogen (Grand Island, NY, USA).  
2.1.4 Kits 
 BCA assay kit and SuperSignal West Pico chemiluminescence detection 
kit, ubiquitin enrichment kit and subcellular protein fractionation kit for cultured 
cells were from Pierce (Rockford, IL, USA). RNeasy mini kit, RNeasy lipid tissue 
mini kit, QIAquick gel extraction kit, plasmid midi kit and QuantiFast SYBR 
green PCR kit were obtained from QIAGEN (Valencia, CA, USA). Illustra 
plasmidPrep mini spin kit was obtained from GE Healthcare (Buckinghamshire, 
UK). StrataClone blunt PCR cloning kit was obtained from Agilent Technologies 
(Santa Clara, CA, USA). CellTiter 96® Non-Radioactive cell proliferation assay 
(MTT) was obtained from Promega (Madison, WI, USA). Click-iT® EdU Alexa 
Fluor® 488 Flow Cytometry assay kit was obtained from Molecular Probes 
(Eugene, OR, USA). GST MicroSpin purification module were from Amersham 
Pharmacia (Milwaukee, WI, USA).  
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2.1.5 Instruments and Consumables 
pH meter and BJ15003 Balance (Sartorius AG, Germany) 
Biological safety cabinet class ІІ (Gelman BH Class ІІ Series, Germany) 
Centrifuges: CF 5804R and 5415R (Eppendorf, USA), Biofuge (Heraeus, D-
37520, Germany) 
CO2 incubator (Binder, Germany) 
SRX-101A Filmprocessor (Konica, Japan) 
Gel electrophoresis equipment, vertical gel electrophoresis and PowerPac 300 
(Bio-Rad laboratoriesm Hercules, CA, USA) 
Dry-block heaters (TECHNE,UK) 
MicroCooler ІІ (Boekel Scientific, Feasterville, PA, USA) 
Incubators (Contherm Biocell 1000, New Zealand; SANYO incubator, Japan) 
Microscopes (Leica, Nikon, Olympus) 
Microwave (SANYO, Japan) 
PCR system (Peltier Thermal Cycler PTC-100, MJ research PTC-200) 
CFL 3005 Shaker and Water bath (CFL, Germany) 
CyAnTM ADP Analyzer (Beckman Coulter, Brea, CA, USA) 
BioTek Synergy H1 Hybrid Reader (Biotek, Winooski, VT, USA) 
Sonicator (Sonics & Materials Inc., Newtown, CT, USA) 
Applied Biosystems 7500 Real-time PCR system (Applied Biosystems, Foster 
City, CA, USA) 
Vortex Mixer, Genie 2 (Fisher Scientific, USA). 
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2.1.6 Media, buffers and solutions 
Cell culture medium 
Complete DMEM 
 DMEM medium supplemented with 10% fetal bovine serum and 1% 
penicillin (100 IU/ml)/ streptomycin (100 µg/ml). 
Freezing medium 
 DMEM supplemented with 20% fetal bovine serum and 10% 
dimethylsulfoxide (DMSO). 
Buffers 
1x PBS buffer 
 0.176 mM KH2PO4, 1 mM Na2HPO4, 13.7 mM NaCl, 0.9 mM KCl, pH 
7.4. 
Trypsin-EDTA 
 0.05% trypsin and 0.02% EDTA. 
50x TAE buffer (1 litre) 
   2 mM Tris-acetate, 1 M Sodium acetate, 50 mM EDTA, pH 8.0. 
SDS-PAGE running buffer 
 25 mM Tris-HCl pH 8.3, 190 mM glycine, 0.1% SDS. 
Electroblotting buffer (Western blot) 





SDS Sample buffer (3X) for SDS-PAGE  
 0.25 mM Tris.Cl pH6.8, 0.2 M DTT, 8% SDS, 0.02% Bromophenol blue, 
0.05% β-mercaptoethanol, and 20% glycerol. 
Western blot blocking buffer 
 2% non-fat milk powder in 1x PBS. 
RIPA lysis buffer 
 50 mM Tris.Cl pH 7.4, 150 mM NaCl, 1% NP-40, 1 mM Na2P2O7, 1 mM 
NaF, 1 mM EDTA, 2 mM Na3VO4 and 1x protease inhibitor.  
 
2.2 Methods 
2.2.1 Expression constructs 
 All the sub-clones generated in this study contain fragments that were 
PCR-amplified using PfuUltra high-fidelity DNA polymerase which has 3’-5’ 
exonuclease proof reading activity thereby reducing the number of errors 
incorporated during PCR amplification.  
The expression construct pEX_hSema5A ED-Fc was generated by PCR 
amplification of the extracellular domain (ED) of human Sema5A cDNA obtained 
from a glioma biopsy. The expression constructs for expressing Sema5A splice 
variants were generated by site-directed mutagenesis and re-ligation of the PCR 
product. The expression construct pcDNA3-HA-Sema5A-myc-His was generated 
by PCR amplification of the full-length Sema5A cDNA obtained from a glioma 
biopsy. The expression construct PGEX-KGmPlexinB3CD was generated by me 
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and the expression construct harboring PlexinB3CD fragments was generated by 
Li Xinhua. Details of cloning are described in the respective sections in Chapter 
3.  
2.2.2 Polymerase Chain Reaction (PCR) 
 PCR reaction mixes for PfuUltra high-fidelity polymerase enzyme and 
Taq polymerase are listed in Table 1.1 and Table 1.2 respectively. Due to its high 
accuracy, PfuUltra was used for cloning and sequencing while the Taq 
polymerase was used for colony PCR. The thermal cycling program is listed in 
Table 1.3.  
Table 1.1 PCR reaction mix for PfuUltra DNA polymerase 
 
Components Stock Conc. Final Conc. Volume/Reaction 
Pfu Ultra ІІ buffer 10 x 1 x 5 µl 
dNTP 5 mM 200 µM 2 µl 
Forward Primer 5 µM 0.2 µM 2 µl 
Reverse Primer 5 µM 0.2 µM 2 µl 
Template DNA  2 ng/µl 100 ng 
PfuUltra DNA polymerase 2.5 U/µl 0.05 U/µl 1 µl 
H2O   Final vol of 50µl 
*Tm is determined according to each primer pair 
X* is the extension time. The extension time is 1 minute per 1000bp of the PCR 
fragment. 
 
Table 1.2. PCR reaction mix for Taq DNA polymerase 
 
Components Stock Conc. Final Conc. Volume/Reaction 
Taq buffer 10 x 1 x 2.5 µl 
dNTP 5 mM 200 µM 1 µl 
Forward Primer 5 µM 0.2 µM 1 µl 
Reverse Primer 5 µM 0.2 µM 1 µl 
Template DNA   50 ng or one bacterial colony 
Taq DNA polymerase 5 U/µl 0.025 U/µl 0.125 µl 
H2O   Final vol of 25µl 
*Tm is determined according to each primer pair 




Table 1.3. PCR thermal cycling program 
 
No. PCR step Program 
1 Initial denaturation 95°C, 2 min 
2 Denaturation 95°C, 20 s 
3 Primer Annealing Tm*, 40 s 
4 Extension 72°C, X* min 
5 Repeat steps 2-4 for 30 cycles  
6 Final Extension 72°C, 10 min 
 
 The PCR product was applied to an agarose gel and the bands of expected 
size were excised, gel-extracted and sequenced.  
2.2.3 Agarose gel electrophoresis 
 Agarose powder was dissolved in electrophoresis buffer (40 mM Tris-
acetate, 20 mM sodium acetate, 1 mM EDTA, pH 8.0) to the desired 
concentration and heated in a microwave oven until thoroughly dissolved. The gel 
solution was cooled down to 60°C, poured into a gel caster tray fitted with a 
sample comb and allowed to solidify at room temperature. Once the gel was 
solidified, the comb was removed and the gel was mounted into the 
electrophoresis tank containing electrophoresis buffer. DNA samples were mixed 
with 6x DNA loading dye (0.25% Bromophenol blue, 0.25% Xylene cyanol FF, 
30% glycerol in water) and loaded into the sample wells. After electrophoresis at 
5 volts/cm of gel, the gel was stained with ethidium bromide solution (0.5 µg/ml) 
for 10 minutes and destained in water. The gel was visualized on a ultra-violet 





2.2.4 Extraction and purification of PCR product from agarose gel 
 A chaotropic-based gel extraction kit from QIAGEN was utilized to 
extract the PCR products from agarose gels according to the manufacturer’s 
instructions. The DNA band of interest was quickly excised from agarose gel 
under minimal UV exposure to prevent DNA damage. The gel slice was 
incubated in the chaotropic buffer QG at 50°C until the gel slice was completely 
dissolved. The mixture was applied to a mini column and centrifuged at 13,200 
rpm for 1 minute at room temperature. Buffer PE was applied to wash the column 
by centrifugation at 13,200 rpm for 1 minute, and then spun one more time. DNA 
was then eluted with 30 µl of distilled water by centrifugation at 13,200 rpm for 1 
minute.  
2.2.5 Ligation reaction 
 The relative amount of digested and extracted plasmid DNA for ligation 
was determined by gel electrophoresis followed by setting up the ligation 
reaction. Typically, 100 ng of linearized vector was mixed with DNA insert at a 
molar ratio of 1:3 in a final reaction volume of 20 µl. For cloning of Sema5A 
cDNA obtained from glioma biopsies, the StrataClone blunt PCR cloning kit was 
used (Table 1.4) and ligation was carried out at room temperature for 5 minutes. 
Self-ligation reactions were carried at room temperature for 2 hours for blunt-end 
ligation for generation of Sema5A exclusion isoforms (Table 1.5). Sticky-end 




Table 1.4. StrataClone blunt PCR cloning kit ligation reaction 
 
Reagent Volume 
StrataClone blunt cloning buffer 3 µl 
DNA extraction products 4 µl 
StrataClone blunt vector mix 1 µl 
 
Table 1.5. Self-ligation reaction 
 
Reagent Volume 
10x T4 ligation buffer 2 µl 
DNA extraction products 10 µl 
T4 DNA ligase 1 µl 
dd H2O 7 µl 
 
Table 1.6. Sticky-end ligation reaction 
 
Reagent Volume 
10x T4 ligation buffer 2 µl 
DNA extraction products 8 µl 
Vector backbone 2 µl 
T4 DNA ligase 1 µl 
dd H2O 7 µl 
 
2.2.6 Bacterial transformation 
 Chemocompetent E.coli bacteria were thawed on ice for 5-10 min 
followed by mixing with ligation product or plasmid and incubated for 30 minutes 
on ice. When DH5α competent cells were used for transformation, the mixture 
was incubated on ice for 30 minutes, heat shocked for 90 seconds at 42°C in a 
water-bath. When BL21 or StrataClone competent cells were used, the mixture 
was incubated on ice for 20 minutes followed by heat shock for 45 seconds at 
42°C in a water-bath and the mixture was rapidly cooled on ice. 350 µl 
(StrataClone) or 1 ml (DH5α, BL21) of LB broth was added to the mixture and 
incubated for 1 hour at 37°C with shaking (200 rpm). The bacterial culture was 
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plated onto LB agar plates containing appropriate antibiotics and incubated 
overnight at 37°C.  
2.2.7 Isolation of plasmid DNA from bacteria using the Illustra plasmidPrep 
Mini Spin kit 
 Mini- and midi-preparation of plasmid DNA from bacteria were carried 
out using the Illustra plasmidPrep Mini Spin kit and HiSpeed Plasmid Midi kit 
respectively according to the manufacturer’s instructions. Both kits are based on a 
modified alkaline lysis procedure, followed by binding of plasmid DNA to an 
anion-exchange resin column under appropriate low salt and pH conditions. The 
concentration of plasmid DNA was determined by measuring the absorbance at 
260 nm (A260) with a spectrophotometer (ND-1000, NanoDrop).  
2.2.8 Isolation of total RNA from brain tissue using the Qiagen RNeasy® 
lipid tissue mini kit 
 Total RNA was isolated from glioma biopsies using the RNeasy lipid 
tissue mini kit according to the manufacturer’s instructions. The RNeasy lipid 
tissue mini kit is specially designed for optimal lysis of tissues rich in fat such as 
brain tissue and purification of high-quality RNA. 30 mg of starting tissue is 
excised and weighed and the tissue was placed in a Dounce homogenizer along 
with 1 ml of QIAzol lysis reagent. The tissue was thoroughly homogenized and 
the homogenate was incubated for 5 minutes at room temperature. 200 µl of 
chloroform was added to the homogenized lysate and shaken vigorously. The tube 
containing the homogenate was incubated for 2-3 minutes at room temperature. 
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The homogenate was centrifuged at 13,200 rpm for 15 minutes at 4°C to enable 
separation of the sample into 3 phases. The upper aqueous phase was then 
transferred to a new tube and 600 µl of 70% ethanol was added and mixed 
thoroughly. The sample was then transferred to a RNeasy mini spin column and 
centrifuged at 13,200 rpm for 1 minute to allow RNA binding to the column. The 
flow-through was discarded and on-column DNase digestion was performed.  
 Buffer RW1 was added to wash the column by centrifugation at 13,200 
rpm for 1 minute. DNase incubation mix was prepared containing 10 µl DNase I 
stock solution and 80 µl of buffer RDD and this mix was applied directly to the 
spin column and incubated at room temperature for 15 minutes. Buffer RW1 and 
RPE were successively added to wash the column by centrifugation at 13,200 rpm 
for 1 minute. Multiple washes with buffer RPE was performed so as to ensure 
high-quality RNA extraction. To elute, 30 µl of RNase-free water was added 
directly to the RNeasy silica gel-membrane and allowed to flow through the 
membrane by centrifugation at 13,200 rpm for 1 minute. The elution step was 
repeated to increase RNA yield. The concentration of RNA was determined by 
spectrophotometric measurement of absorbance at 260 nm (A260).  
2.2.9 Reverse transcription of total RNA using the Invitrogen SuperScript™ 
III Reverse Transcriptase 
 cDNA was prepared using Superscript ІІІ reverse transcriptase 




First-strand cDNA synthesis from total RNA 
 2 µg of total RNA, 0.5 µl of 0.5 µg/µl Oligo dT (Sigma Proligo, 
Singapore) and 2 µl of dNTP mix (5mM) were mixed with RNase free water to a 
total volume of 13.5 µl. The sample was incubated at 65 °C for 5 min for primer 
hybridization and chilled on ice for 2 min. Samples were centrifuged briefly and 
added with 4 µl of 5x first strand buffer (Invitrogen), 1 µl of DTT (0.1M), 1 µl of 
RNAse inhibitor (RNasin Plus 40 U/µl) and 1 µl of Superscript ІІІ RT (200 U/µl). 
The sample was incubated at 50°C for 60 min and the reaction was inactivated by 
incubating at 70°C for 15 min. The resulting cDNA was stored at -20°C until 
further use.  
PCR amplification of cDNA 
2µl of cDNA was used for PCR amplification using specific primer pairs. The 
final reaction volume was 50 µl.  





The amplification of PCR product was carried out according to the PCR 
conditions described in Chapter 2.2.2 Polymerase Chain Reaction (page 83). The 
PCR products were agarose gel extracted.  
Reagent Volume 
cDNA 2 µl 
Forward primer (5 pmol) 2 µl 
Reverse primer (5 pmol) 2 µl 
dNTPs (5mM) 2 µl 
PfuUltra ІІ HS buffer (10x) 5 µl 
PfuUltra ІІ HS Polymerase (2.5U/µl) 1 µl 
dd H2O 38 µl 
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2.2.10 Quantitative real-time PCR 
 Quantitative real-time PCR was performed using the QuantiFast SYBR 
Green PCR kit (Qiagen) according to the manufacturer’s instructions. The 
QuantiFast SYBR green master mix contains HotStarTaq Plus DNA Polymerase 
for high PCR specificity and accurate quantification while the hot start capability 
enables the reaction to be set up at room temperature. The SYBR green master 
mix also contains SYBR green, SYBR green PCR buffer and a passive reference 
dye such as ROX. To set up the reaction, a master mix containing QuantiFast 
SYBR green master mix, specific primer pairs and RNase free water are prepared. 
22.5 µl of the master mix is dispensed into each well of a 96-well real-time PCR 
plate followed by addition of 2.5 µl of template cDNA. The thermal cycler is 
programmed as appropriate for the specific primers being used and a melting 
curve analysis is included in the program so as to ensure specificity of primers.  




2.2.11 Plasmid Constructs 
pEXHA_hSema5AED_Fc: In the plasmid construct, an HA epitope (27 bp) was 
engineered at the N-terminus of hSema5A. Adult human brain cDNA was used as 
a DNA template for PCR amplification of the extracellular domain of hSema5A 
cDNA using the forward primer hSema5AEDF1 (5’-CTAAG CTTAA CTCAG 
Reagent Volume 
QuantiFast SYBR green master mix (2x) 12.5 µl 
Forward primer (10 pmol) 0.625 µl 
Reverse primer (10 pmol) 0.625 µl 
Template cDNA 2.5 µl 
RNase free water 8.75 µl 
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TGCCA GAGAA CCGA-3’) and reverse primer hSema5AEDR1 (5’-GCTCT 
AGAGT TGAAC TCTCC ACACC TTTTC-3’). PCR product was purified from 
agarose gel and cloned into pEXHA/Fc vector via HindІІІ and XbaІ restriction 
sites. The hSema5AED sequence was confirmed with sequencing.  
 The Sema5A exon 4, exon 7 and exon 11 exclusion isoforms were 
generated by Site-Directed Mutagenesis. The plasmid pEXHA_hSema5AED_Fc 
was used as DNA template and amplified using PfuUltra ІІ HS polymerase with 
the phosphorylated primers mentioned in Table 1.8 so as to delete exon 4, exon 7 
and exon 11 from the hSema5AED sequence. The amplified PCR products were 
restriction digested using DpnІ restriction enzyme so as to digest the parental 
template and to select for the mutation-containing newly synthesized DNA. The 
DpnІ treated DNA was then purified and re-ligated, and the ligation product was 
transformed into StrataClone competent cells to generate 
pEXHA_hSem5AdEx4_Fc, pEXHA_hSema5AdEx7_Fc and 
pEXHA_hSema5AdEx11_Fc, respectively. Correct cloning of the isoforms was 
confirmed by DNA sequencing.  
 The Sema5A intron 2a inclusion isoform was generated by PCR 
amplification of one of the bacterial clones obtained from a glioma cell line 
bearing the Sema5A intron 2a inclusion isoform. The bacterial clone harboring 
the Sema5A intron 2a inclusion isoform was used as a DNA template and 
amplified using PfuUltra ІІ HS polymerase using a forward primer 
hSema5AIn3aF1 (5’-ATAAG CTTCT GTGTT GGTGT GTGAG AC-3’) and a 
reverse primer hSema5AIn3aR1 (5’-CAGGG GTACC CGCAC TTTCT TAAT-
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3’). The amplified PCR product was cloned into pEXHA/hSema5AED/Fc via 
HindІІІ and KpnІ restriction sites to generate the plasmid 
pEXHA/hSema5Aint2a/Fc. Correct cloning of the sequence was confirmed by 
sequencing.  
pcDNA3.1HA/hSema5A: In the plasmid construct pcDNA3.1, an HA epitope tag 
(27 bp) was engineered at the N-terminus of hSema5A downstream of the signal 
peptide. The hSema5A full length cDNA obtained from adult human brain cDNA 
was used as a DNA template for PCR amplification of hSema5A using the 
forward primer hSema5AF2 (5’ -CTGTG TTGGT GTGTG AGACT- 3’) and the 
reverse primer hSema5AR2 (5’ -CCAAA CTTCG ACTCT GAAGC- 3’), the 
PCR product was purified and cloned into pcDNA3.1HA/Myc-His(A) via HindІІІ 
and XbaІ restriction sites. Correct cloning was confirmed by sequencing.  
2.2.12 Determination of protein concentration by Bicinchoninic Acid 
(BCA) protein assay 
 The BCA assay kit obtained from Pierce was used to determine the protein 
concentration using manufacturer’s instructions. Serial dilutions of BSA standards 
were prepared in lysis buffer at the following concentrations: 0 µg/ml, 25 µg/ml, 
125 µg/ml, 250 µg/ml, 500 µg/ml, 750 µg/ml, 1 mg/ml, 1.5 mg/ml and 2 mg/ml. 
Each protein sample to be used was diluted in lysis buffer at the two ratios: 1:24 
and 3:22. BCA standard working solutions were prepared by mixing reagent A 
and reagenet B in the ratio 50:1. 200 µl of BCA standard working solutions was 
added to 25 µl of each diluted BCA standard and protein sample in a 96 well 
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format. The mixtures were incubated at 37°C for 30 mins until purple colored 
product was formed. The absorbance was measured at 570 nm by Synergy H1 
hybrid multi-mode Microplate reader. The results were analyzed using Graphpad 
prism to generate the standard curve and to calculate the protein concentration of 
each sample.  
2.2.13 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) and Western blot 
 The protein samples resuspended in 3x protein loading dye (62.5 mM Tris 
Cl pH 6.8, 25% glycerol, 2% SDS, 5% β-mercaptoethanol, 0.05% bromophenol 
blue) were boiled at 95°C for 10 minutes and loaded onto a SDS-PAGE gel. The 
protein samples were resolved by SDS-PAGE gel (8-15% separating gel) at 160V 
for 1 hour. For Western blot, the SDS-PAGE gel separated proteins were 
transferred to a nitrocellulose membrane or PVDF membrane in immunoblotting 
buffer (25 mM Tris, 192 mM glycine, 20% methanol, pH 8.0) at a constant 
voltage of 100V for 1.5 hrs at 4°C in the electrotransfer unit (Bio-Rad). When 
using PVDF membrane for western blotting, the membrane needs to be activated 
by pre-wetting the membrane in 100% methanol followed by equilibration in 
transfer buffer for a few minutes before using it for western blot. After transfer of 
proteins, the nitrocellulose membranes were blocked in 2% milk phosphate-
buffered saline (MPBS) (2% non-fat milk powder dissolved in 1x PBS) at room 
temperature for 1 hr, and incubated overnight with primary antibody diluted in 
3% BSA at 4°C by gentle shaking. The membrane is then washed three times with 
1x PBS and incubated with horseradish peroxidase-conjugated secondary 
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antibody for 1 hour at room temperature. For proteins transferred on to PVDF 
membrane, blocking is carried out using 3% BSA while all the washes are carried 
out using 1x PBS supplemented with 0.1% Tween-20. The membranes are then 
washed three times followed by incubation with chemiluminescent substrate 
(SuperSignal West Pico chemiluminescence detection kit, Pierce). Protein bands 
were detected by exposure to X-ray film  and the densities of the signals were 
quantified using ImageJ software.  
2.2.14. Stripping and re-probing the nitrocellulose membrane  
 Stripping the membrane is carried out so as to remove antibodies from the 
membrane so that the membrane could be probed with another antibody. The 
membrane was stripped by incubating with stripping buffer for 10 mins, the 
stripping buffer contains 0.5 M NaCl and 2.8% acetic acid. The membrane was 
washed well using 0.1 M Tris Cl, pH 8.0, followed by two washes with 1x PBS at 
room temperature. After blocking with 2% MPBS for 1 hr the membrane was 
incubated with new antibodies.  
2.2.15 Expression and purification of GST protein in bacteria 
The GST Microspin purification module was used to purify GST and GST 
recombinant proteins according to the manufacturer’s instructions. For bacterial 
expression of GST recombinant proteins, a bacterial clone E.coli BL21 strain 
harboring the GST fusion plasmid was cultured in 3ml of LB broth supplemented 
with ampicillin (50 µg/ml) and the culture was incubated overnight at 37°C with 
constant shaking. The next day, 2 ml of LB broth containing 50 µg/ml of 
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ampicillin was inoculated with 1 ml of overnight bacterial culture. The expression 
of GST fusion protein was induced by supplementing the LB broth with 
isopropyl-β-D-thiogalactopyranoside (IPTG) to yield a final concentration of 0.5 
mM. The culture was then incubated for an additional 1 hour at 37°C with 
constant shaking. The bacterial cells were then pelleted by centrifugation at 
16,000 xg for 1 min at 4°C. The bacterial pellet was resuspended in 300 µl of ice-
cold 1x PBS and the cells were lysed by sonication at 15 seconds with 10 seconds 
interval at 4°C using a 2 mm probe. The procedure was repeated 5-8 times until 
the turbid bacterial suspension became clear. The insoluble components were 
removed by centrifugation at 16,000 xg for 10 mins at 4°C. The cleared crude 
lysate was subjected to purification using the GST Microspin column. 
 The Microspin column containing the glutathione Sepharose 4B beads 
were centrifuged at 3000 rpm for 1 min at room temperature so as to remove the 
storage buffer. The beads were then washed with 600 µl of ice-cold 1x PBS and 
centrifuged at 3000 rpm for 1 min at room temperature. To purify the GST 
proteins, the cleared crude lysate was incubated with glutathione Sepharose 4B 
beads in Microspin column for 2 hours with gentle agitation at 4°C to allow 
binding of the GST recombinant proteins to the beads. The beads were then 
washed twice with 500 µl of ice-cold 1x PBS so as to eliminate non-specific 
protein binding and centrifuged at 3000 rpm for 1 min at room temperature. 
Finally, the GST fusion protein bound to the GSH beads were resuspended in 100 
µl of ice-cold PBS and stored at 4°C for further experiments. A small aliquot of 
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the proteins was taken and analyzed by Coomassie staining so as to check the 
purity of the GST fusion proteins.  
2.2.16 Cell culture 
 HEK293, U-87 MG, U251, A172, U373 were cultured in Dulbecco’s 
Modified Eagle’s Medium (DMEM) (GIBCO) supplemented with 10% heat-
inactivated fetal bovine serum (FBS) and 1% penicillin (100 IU/ml)/streptomycin 
(100 µg/ml). All cells were cultured in a humidified atmosphere at 5% CO2 at a 
constant temperature of 37°C.  
 For trypsinization of cells, the cells were washed twice with 1x PBS and 
dislodged by treatment with 1x trypsin/EDTA (T/E) solution which contains 
0.05% trypsin and 0.53 mM EDTA in PBS for 2-3 min at 37°C. Once the cells 
were dislodged the trypsinization was stopped by addition of fresh DMEM 
containing 10% FBS and 1% penicillin/streptomycin. Generally, the cells were 
subcultured at a ratio of 1:3 (related to area).  
 For long term storage and freezing of cultures, the cells were trypsinized, 
pelleted and resuspended in 0.3 ml complete culture medium and mixed with 0.3 
ml of 2x freezing medium, which consists of DMEM supplemented with 20% 
dimethylsulfoxide (DMSO). The cell suspension was transferred to cryovials and 
gradually frozen at -80°C for 2 days and then stored in liquid nitrogen. For 
thawing of the frozen cells, the cryovials were removed from liquid nitrogen and 
rapidly immersed in a 37°C waterbath and washed with cell culture medium 
before plating.   
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2.2.17 Transient transfection of mammalian cell lines using 
Lipofectamine™ reagents 
 The day prior to transfection, appropriate number of cells (1-3x105) were 
plated in a 6 cm cell culture dish in culture medium containing 10% FBS devoid 
of any antibiotics penicillin and streptomycin (M2 medium). The next morning, 
once the cells were grown to an ideal confluence of 70-80% they were transiently 
transfected with expression constructs using the transfection reagent, 
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions. 
About one hour before transfection, the M2 culture medium was replaced with 
DMEM so as to remove any FBS in the cell culture dish. 1.6 µg of plasmid DNA 
in 250 µl of Opti-MEM was mixed with 4 µl of Lipofectamine 2000 diluted in 
250 µl of Opti-MEM. This DNA-Lipofectamine mixture was incubated for 20 
min at room temperature so as to allow the formation of DNA-Lipofectamine 
2000 complexes. The DMEM was then removed and replaced with the DNA-
Lipofectamine 2000 mixture so to as transfect the plasmid into the mammalian 
cells. Around 3-6 hours after transfection, the DNA-lipid mixture was replaced 
with DMEM complete medium so as to allow cell recovery.  
2.2.18 Transient transfection of precursor microRNAs and inhibitor 
microRNAs into mammalian cell lines 
 On the day prior to transfection, 1x105 cells were plated in a 6 well dish in 
culture medium containing 10% FBS without any antibiotics penicillin and 
streptomycin. The next morning, once the cells were grown to 70-80% confluence 
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they were transiently transfected with precursor miRNAs or inhibitor miRNAs 
using Lipofectamine 2000. One hour before transfection, the culture medium was 
changed to DMEM so as to remove any FBS present in the culture dish. 50 nM of 
precursor miRNA or inhibitor miRNA in 250 µl of Opti-MEM was mixed with 5 
µl of Lipofectaime 2000 diluted in 250 µl of Opti-MEM. This mixture was 
incubated for 20 min at room remperature and then DMEM was removed from 
the cells and replaced with miRNA-lipofectamine mixture. Negative control 
miRNA and mock transfections were used as controls for this experiment. Around 
6-7 hours after transfection medium containing DMEM and 10% FBS was added 
to the transfected cells. The cells were incubated at 37°C and they were harvested 
at 24-96 hours post transfection. Western blot analysis was performed using the 
cell lysates so as to ascertain whether these miRNAs targeted Sema5A in glioma 
cell lines.  
2.2.19 Cell proliferation assays: MTS and Click-iT EdU flow cytometry 
assay 
MTS assay 
 We used the CellTiter 96® AQueous Non-Radioactive Cell Proliferation 
Assay kit (MTS assay) obtained from Promega so as to determine glioma cell 
viability. Glioma cells were transiently transfected with plasmids harboring full 
length Sema5A or empty vector and after transfection they were re-plated on to 
96-well culture plates at a density of 5x103 cells per well. At 24 hours, 48 hours 
and 72 hours post-transfection, the viable cells were quantified by using the MTS 
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assay kit which is composed of a tetrazolium compound (3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; MTS) and 
an electron coupling agent ((phenazine methosulfate; PMS). The MTS is reduced 
to an aqueous, soluble formazan by dehydrogenase enzymes found in 
metabolically active cells. The absorbance of the formazan can be detected at 490 
nm and it is directly proportional to the number of viable cells present in the 
culture. Briefly, 20 µl of MTS and 1µl of PMS is mixed with 100µl of DMEM 
and added to the well. The plate was incubated for 2 hours at 37°C and the 
absorbance at 490 nm was measured using a microplate reader.   
Click-iT EdU flow cytometry assay 
 Glioma cells were transfected with Sema5A or empty vector and at 24 
hours, 48 hours after transfection 10 µM of EdU was added to the culture medium 
and incubated for 2 hours at 37°C to allow uptake of EdU by the proliferating 
cells. After washing with 3% BSA in PBS, the cells were then fixed using the 
Click-iT fixative which contained 4% paraformaldehyde in PBS for 15 min at 
room temperature. To permeabilize the cells, the cells were further incubated for 
15 min at room temperature with a saponin based permeabilization reagent. The 
Click-iT reaction cocktail was then added to the cells, this contained 1x PBS, 
CuSO4 , Click-iT reaction buffer additive and Alexa647. The cells were incubated 
at room temperature for 30 min, protected from light. Upon washing twice with 
the saponin based permeabilization reagent, the cells were pelleted and the 
supernatant was removed. Finally, propidium iodide (1 µg/µl) and RNase A (10 
µg/µl) diluted in saponin based permeabilization reagent was added to the cells 
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and incubated for 30 min, protected from light. The cells were analyzed by flow 
cytometry using the CyAn™ ADP Analyzer (Beckman Coulter Inc., CA, USA).  
Standard flow cytometry methods were used to determine percentage of cells in 
S-phase in the population.  
2.2.20 Immunocytochemistry and confocal microscopy 
 Glioma cells were plated on poly-L-lysine-coated (10 µg/ml) coverslips 
and allowed to grow to until they reached a confluency of 70%. Cells were 
transfected with Sema5A exon 4 exclusion isoform and 24 hours post-
transfection, the cells were treated with the proteasomal inhibitor MG132 (5 
µg/ml) for 12 hours. Cells were then fixed with 4% paraformaldehyde for 10 min, 
followed by permeabilization by addition of 0.1% Triton X-100 in PBS for 5 min 
at room temperature. The coverslips with cells plated on them were washed three 
times with 1x PBS for 5 min and blocked for 1 hour at room temperature in 3% 
BSA in PBS. Then the cells were incubated with the corresponding primary 
antibody diluted in 3% BSA in PBS and incubated overnight at 4°C. The next 
day, the primary antibody was removed and the cells were washed three times in 
1x PBS for 5 min, followed by incubation with appropriate fluorophore 
conjugated secondary antibody diluted in 3% BSA in PBS in dark at room 
temperature for 1 hour. The cells were washed three times in 1x PBS and nucleus 
was stained with 4'-6-Diamidino-2-phenylindole (DAPI) (1 μg/ml in PBS) for 5 
min in the dark at room temperature. Once again upon washing with 1x PBS, the 
coverslips were mounted on to microscope slides using an antifade mounting 
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agent (Aqua Poly Mount, Polyscience Inc) and viewed under a Zeiss LSM 510 
confocal microscope.  
2.2.21 Gene silencing by RNA interference 
 siRNAs (sense and antisense strands) against human cullin 7 and 
scrambled siRNA controls were purchased from Invitrogen (USA). siRNAs 
(sense and antisense strands) against human Sema5A and scrambled siRNA 
controls were purchased from Dharmacon (USA). A172 glioma cells were 
transfected with siRNA against human cullin 7 or scrambled control sequence; 
U87-MG cells were transfected with siRNA against human Sema5A or scrambled 
control sequence, according to the manufacturer’s instructions. Briefly, on the day 
before transfection the cells were plated in a 6-well plate at a density of 1x105 
cells per well. On the day of transfection, 50 pMol RNAi duplex was diluted in 
250 µl of Opti-MEM and mixed with 5 µl of Lipofectamine 2000 diluted in 250 
µl of Opti-MEM. The reagent mixture was incubated at room temperature for 20 
min. The medium was removed from the cells and the RNAi-Lipofectamine 
complex was added to the cells and incubated at 37°C. About 5 hours later fresh 
DMEM supplemented with 10% FBS was added to the cells. Mock transfection 
and scrambled control sequences were used as controls for RNAi efficiency. The 
transfected cells were cultured in a CO2 incubator and the cells were harvested at 
24-96h post-transfection. The efficiency and specificity of Sema5A and cullin 7 
downregulation was assessed by Western blot analysis and compared with 
scrambled siRNA and mock transfection controls. For soft agar colony formation 
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assay involving siRNA mediated downregulation of Sema5A, only cells that had 
lapsed 72 hours after siRNA transfection were utilized.  
2.2.22 Soft agar colony formation assay 
 Firstly, 1% agarose was melted in distilled water using a microwave and 
the agarose was then cooled down to 40°C in a water bath. Culture medium was 
prepared by adding 20% FBS to 2x DMEM and this was also warmed to 40°C. 
Equal volumes of 1% agarose and 2x DMEM mixture was mixed together so as to 
yield a final concentration of 0.5% agarose in 1x DMEM supplemented with 10% 
FBS. 1 ml of this base agar was added to each well of a 6 well plate and allowed 
to set for 10 min so as to ensure the agarose has solidified. Next, 0.7% agarose 
was melted in distilled water using a microwave and was cooled down to 40°C in 
a water bath. During this time, the U87-MG cells transfected with Sema5A 
siRNA and scrambled siRNA were trypsinized and the number of cells in each 
well was counted. The cells would be plated at a density of 1x104 therefore the 
cell density was adjusted such that 0.1 ml contains 1x104 cells. 0.1 ml of the cell 
suspension was mixed with 0.4 ml of 2x DMEM supplemented with 20% FBS 
which was subsequently mixed with 0.5 ml of the 0.7% agarose. The cell-agar 
suspension was gently added on top of the base agar in each well and allowed to 
solidify for 15 min at room temperature. 2 ml of 1x DMEM supplemented with 
10% FBS was added on top of the agar and the cells were incubated at 37°C for 
14 days. Medium was changed every 3 days. After 14 days, the cells were stained 
with 0.5 ml of 0.05% crystal violet (diluted in 10% ethanol in PBS) and 
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documented by photomicrography. Colonies larger than 50 µM in size were 
scored using ImageJ software.  
2.2.23 Subcellular fractionation 
 Subcellular fractionation was carried out using the subcellular protein 
fractionation kit for cultured cells obtained from Thermo Fisher according to the 
manufacturer’s instructions. U87-MG cells were transiently transfected with full-
length Sema5A or empty vector and incubated for 24-72 hours post-transfection. 
The cells were harvested and the pellet was washed in 1x PBS and centrifuged at 
500 xg for 2 min. The supernatant was carefully removed and the 200 µl of ice-
cold cytoplasmic extraction buffer (CEB) supplemented with protease inhibitors 
was added to the cell pellet and gently mixed by pipetting. The mixture was 
incubated at 4°C for 10 min with gentle agitation. This was then centrifuged at 
500 xg for 5 min and the supernatant containing the cytoplasmic extract was 
quickly transferred to a pre-chilled tube on ice. The pellet was washed with 1x 
PBS, centrifuged at 500 xg for 2 min and the supernatant was completely 
removed. Next, 200 µl of ice-cold membrane extraction buffer (MEB) 
supplemented with protease inhibitor was added to the cell pellet. The tube was 
vortexed for 5 seconds on the highest setting and incubated at 4°C for 10 min with 
gentle agitation. The tube was then centrifuged at 3000 xg for 5 min and the 
supernatant containing the membrane extract was quickly transferred to a pre-
chilled tube on ice. The pellet was washed with 1x PBS, centrifuged at 3000 xg 
for 2 min and the supernatant was completely removed. Next, 100 µl of ice-cold 
nuclear extraction buffer (NEB) supplemented with protease inhibitor was added 
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to the cell pellet and the tube was vortexed for 15 seconds on the highest setting, 
followed by incubation at 4°C for 30 min with gentle agitation. The tube was 
centrifuged at 5000 xg for 5 min and the supernatant containing the nuclear 
extract was quickly transferred to a pre-chilled tube on ice. The pellet was washed 
with 1x PBS, centrifuged at 5000 xg for 2 min and the supernatant was 
completely removed. Next, to prepare the chromatin-bound extraction buffer, 5 µl 
of 100 mM calcium chloride was mixed with 3 µl of micrococcal nuclease and 
supplemented with protease inhibitors. This mixture was added to the cell pellet 
and vortexed for 15 seconds at the highest setting, followed by incubation at room 
temperature for 15 min. After incubation, the tube was once again vortexed for 15 
sec at the highest setting and centrifuged at 16000 xg for 5 min. The supernatant 
containing the chromatin-bound nuclear extract was quickly transferred to a pre-
chilled tube on ice. The pellet was washed with 1x PBS, centrifuged at 16000 xg 
for 2 min and the supernatant was completely removed. Finally, 100 µl of room 
temperature pellet extraction buffer (PEB) containing protease inhibitors was 
added to the cell pellet and vortexed on the highest setting for 15 seconds. The 
tube was then incubated at room temperature for 10 min, followed by 
centrifugation at 16000 xg for 5 min. The supernantant containing the cytoskeletal 
extract was then transferred to a fresh tube. The subcellular fractions were then 
analysed by Western blot analysis using appropriate antibodies.  
2.2.24 Enrichment of polyubiquitinated proteins 
 The ubiquitin enrichment kit obtained from Thermo Scientific was utilized 
for enrichment of polyubiquitinated proteins from glioma cells transfected with 
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Sema5A exon 4 exclusion isoform. Glioma cells were transiently transfected with 
Sema5A exon 4 exclusion isoform and 24 hours post-transfection the cells were 
treated with 5 µM of MG132, a proteasomal inhibitor. After 12 hours of MG132 
treatment, the cells were harvested and lysed using RIPA lysis buffer 
supplemented with protease inhibitors. The protein concentration was determined 
using the BCA assay and 0.12 mg of the protein was diluted in TBS in a spin 
column. Using a wide-bore pipette tip, 20 µl of the polyubiquitin affinity resin 
was transferred to the spin column containing the sample. The spin column was 
capped and incubated overnight at 4°C with gentle mixing so as to ensure binding 
of polyubiquitinated proteins to the resin. Next day, the plug of the spin column 
was twisted off and the column was placed in a 1.5 ml centrifuge tube followed 
by centrifugation at 5000 xg for 30 seconds. The flow-through was saved for 
further analysis. 300 µl of wash buffer was added to the spin column and mixed 
well before centrifuging at 5000 xg for 30 seconds. The washing step was 
repeated twice and 200 µl of wash buffer was finally added to the beads and the 
beads were transferred to a fresh 1.5 ml tube. The tube was centrifuged at 5000 xg 
for 30 seconds and the wash buffer was completely removed. SDS-PAGE loading 







2.2.25 Protein-protein interaction assay 
GST pull-down assay using glioma cell lysate 
 GST-pull down assay is a powerful technique to confirm protein-protein 
interactions. To prepare cell lysates for binding assay, the glioma cells were 
harvested and lysed in RIPA lysis buffer. The lysate was clarified by 
centrifugation at 16000 xg for 10 min at 4°C. Protein concentration of the lysate 
was then determined using BCA assay. For binding assay, 300 µg of cell lysate 
endogenously expressing target protein was incubated with 20 µl of GST or GST 
fusion protein pre-bound to Sepharose 4B beads overnight at 4°C with gentle 
shaking. The beads were then washed twice with ice-cold 1x PBS and boiled in 
3x SDS PAGE loading buffer at 95°C for 10 mins. The samples were then 
















 As a member of class 5 semaphorins, Sema5A is rather unique due to the 
presence of a sema domain and thrombospondin repeats in the extracellular 
moeity. These novel characteristic features of Sema5A have rendered it a 
bifunctional axon guidance cue for developing axons in the mammalian midbrain 
(Kantor, Chivatakarn et al. 2004). Early study of Sema5A was mainly restricted 
to its functions in the developing nervous system.  Recently, there have been a 
number of studies that suggest the involvement of Sema5A in tumorigenesis. The 
role played by Sema5A is rather promiscuous as it has been reported to be 
oncogenic in certain cancer types and tumor suppressive in some others.  
The first evidence that suggested the implication of Sema5A in cancer 
development was from a Drosophila screening exercise to identify genes involved 
in cancer progression and metastasis, in which Dsema-5c the Drosophila homolog 
of Sema5A was identified as a gene essential for tumorigenesis (Woodhouse, 
Fisher et al. 2003). In pancreatic cancer, elevated levels of Sema5A and its 
receptor plexin-B3 correlate with increased tumor growth, invasion, metastasis 
and enhanced tumor angiogenesis (Sadanandam, Varney et al. 2010). Similarly in 
gastric cancer Sema5A and plexin-B3 were observed to promote cancer cell 
invasion and metastasis (Pan, Lv et al. 2010). Recent research indicates increased 
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levels of Sema5A and plexin-B3 in metastatic ovarian cancer which is associated 
with poor patient survival. In vitro silencing of Sema5A suppressed migration and 
invasion of the cells (Danielson 2014).  
On the other hand, Sema5A expression level has been observed to be 
decreased in colon, lung cancer and high-grade gliomas (Lu, Tsai et al. 2010; Li, 
Law et al. 2012; Liu, Lu et al. 2012). Downregulation of Sema5A was observed 
in non-small cell lung carcinoma and it was associated with better patient survival 
(Lu, Tsai et al. 2010). Results from our laboratory have revealed the anti-
migratory and anti-invasive property in human gliomas, which is mediated 
through the inactivation of Rac1 via RhoGDIα (Li and Lee 2010). We have also 
elaborated that Sema5A inhibits actin binding by upregulating protein kinase C 
levels and enhanced fascin-1 phosphorylation in glioma cells (Li, Law et al. 
2012). To further enhance our understanding of the status of the Sema5A gene in 
glioma cells we cloned the Sema5A gene into bacterial vectors and studied the 
resultant clones for any genetic alterations.   
3.2 No significant change observed in Sema5A mRNA levels in human 
gliomas 
 Previous findings from our laboratory showed that Sema5A protein level 
is significantly downregulated towards high-grade glioblastomas (Li, Law et al. 
2012). As a first step to understand the underlying cause, the mRNA levels of 
Sema5A in these glioma biopsies were measured to determine whether Sema5A 
downregulation is regulated at the transcriptional level. Briefly, RNA was 
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extracted from glioma cell lines using the Qiagen RNeasy kit, and RNA from 
glioma biopsies was extracted by using the Qiagen RNeasy lipid tissue mini kit 
which is specifically designed to extract high-quality RNA from fatty tissues such 
as brain and adipose tissues. The RNA was then reverse transcribed and Sema5A 
mRNA levels were analyzed by using quantitative real-time PCR. The primers 
used for quantitative real-time PCR of Sema5A are shown in Table 3.1, the 
primer pair hSema5A_qRT_F1 and hSema5A_qRT_R1 binds to exons 9 and 10 
of Sema5A. The results were also verified by utilizing another primer pair that 
binds to exons 15 and 16. 
To accurately quantify gene expression levels the target genes can be 
quantified by either absolute quantification or relative quantification. In absolute 
quantification, the absolute amount of target gene present in the sample would be 
determined, while in relative quantification the ratio between the target gene and 
an endogenous reference gene such as a housekeeping gene would be calculated. 
This normalized value can then be used to study the differential target gene 
expression in different samples. In a validation experiment to check the ability to 
use the relative quantification method of analysis by ΔΔCT method, the 
amplification efficiencies of Sema5A and GAPDH, the reference gene, was 
determined. The amplification efficiencies of these genes can be ascertained by 
preparing serial dilutions of Sema5A and GAPDH cDNAs and each of the 
dilutions are amplified using quantitative real-time PCR. A standard curve for 
both Sema5A and GAPDH was generated by plotting the CT values (Y-axis) 
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against input cDNA (X-axis) and for this we utilized 5 different concentrations of 
cDNA ranging from 100 ng to 0.01 ng as shown in Fig 3.1 and Fig 3.2. 
The rationale for this experiment is that analysis of samples by the ΔΔCT 
method requires no or a very small difference in the efficiencies of amplification 
between the gene of interest and the endogenous housekeeping gene in the assays 
(Pfaffl 2001). For the standard curve assays, efficiency and R2 of Sema5A and 
GAPDH were similar as shown in Fig 3.1 and Fig 3.2. To compare the 
amplification efficiencies of Sema5A and GAPDH, the CT values of Sema5A are 
subtracted from the CT values of GAPDH, the subtracted values are then plotted 
against the log of input cDNA as shown in Fig. 3.3. If the slope of the straight line 
is less than 0.1, the amplification efficiencies are proven to be comparable and the 
ΔΔCT method could be confidently utilized to determine gene expression levels. 
As shown in Fig 3.3, the slope of the straight line was zero, suggesting that 
Sema5A mRNA levels in glioma biopsies can be determined by utilizing the 
ΔΔCT method.  
Next, we went ahead to determine the Sema5A mRNA levels in glioma 
cell lines and human glioma specimens by using quantitative real-time PCR and 
analysis by using the ΔΔCT method. The ΔCT value for Sema5A and GAPDH was 
determined for each sample by calculating the difference between the CT value of 
Sema5A and the CT value of GAPDH. The ΔΔCT value was then calculated by 
subtracting ΔCT value of the calibrator sample (normal brain) from the ΔCT value 
of the glioma specimen. As the PCR amplification efficiencies were comparable, 
the normalized Sema5A gene expression level in each glioma sample was 
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calculated using the formula 2-ΔΔCT. Interestingly, the results showed no 
statistically significant difference in Sema5A mRNA levels in glioma cell lines as 
shown in Fig 3.4A. While in the human glioma specimens, only grade IV high-
grade glioma specimens showed a significant difference in Sema5A mRNA levels 
as compared to normal brain as illustrated in Fig 3.4B.  These results suggest that 
the decline in Sema5A protein level observed in high grade gliomas are unlikely 
due to a downregulation in Sema5A gene transcription.  
These results suggest that the downregulation of Sema5A protein is due to 
other mechanisms. It is noteworthy to mention that Rich et al., had demonstrated 
an increase in Sema5A mRNA levels in gliomas by employing microarray 
analysis (Rich, Hans et al. 2005). Lower Sema5A protein levels could be caused 
by post-transcriptional mechanism, a mutation in the Sema5A gene or epigenetic 
mechanisms. We therefore embarked on characterizing the Sema5A gene so as to 
identify any mutations or alternative splicing that could account for the reduced 























hSema5A_qRT_F1 5’-GAT CTA TGG CAT CTT TAC CAC CAA -3’ 
hSema5A_qRT_R1 5’-TGG CGC TCA GGT TGA AGA C -3’ 
Table 3.1. Sequence of primers used in the quantitative real-time PCR 







Fig 3.1. Validation experiment to determine amplification efficiency of 
Sema5A primers. PCR amplification plots (A) and standard curve (B) of Sema5A. 
Slope: -3.239; R2: 0.994; Efficiency: 103.6%. In A and B, representative 
amplification curves were derived from the SYBR green assay. Vertical axes of A 
indicate the SYBR green fluorescence signal (Rn) and vertical axes of B indicate 
the threshold cycles CT (cycle number when the fluorescence reached the 





Fig 3.2. Validation experiment to determine amplification efficiency of 
GAPDH primers. PCR amplification plots (A) and standard curve (B) of GAPDH. 
Slope: -3.274; R2: 0.998; Efficiency: 102.027%. In A and B, representative 
amplification curves were derived from the SYBR green assay. Vertical axes of A 
indicate the SYBR green fluorescence signal (Rn) and vertical axes of B indicate 
the threshold cycles CT (cycle number when the fluorescence reached the 
















Fig 3.3. Amplification efficiency comparison between Sema5A and GAPDH 
primers. CT values were obtained for Sema5A and GAPDH cDNAs. The 
difference in CT values was plotted against log cDNA input. The difference in 
amplification efficiency was calculated by determining the slope of the resulting 
















Fig 3.4. Quantitative analysis of Sema5A mRNA expression by quantitative 
real-time PCR. Sema5A expression levels in (A) human glioma cell lines and (B) 
human glioma biopsies (n=11) were measured using qPCR. Expression was 
normalized to GAPDH. Fold expression was calculated relative to normal brain 
cDNA. Results were expressed as mean ± standard deviation from three 
independent experiments. Statistically significant difference between normal brain 
and Grade IV glioma biopsies. (**p<0.01 vs. normal brain (NB)).   
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3.3. Cloning of Sema5A cDNA from glioma biopsies 
 As a first step to analyze Sema5A gene in human gliomas, Sema5A cDNA 
in human glioma cell lines and glioma specimens was amplified by PCR using 
high fidelity DNA polymerases. Briefly, mRNA was extracted from human 
glioma cell lines (U87-MG, U251-MG, A172, and U373-MG) and from human 
glioma biopsies, followed by reverse transcription and PCR amplification of full-
length Sema5A cDNA using gene specific primers, hSema5A_F2 and 
hSema5A_R2 (Table 3.2). Similarly, Sema5A cDNA was amplified from normal 
human brain (MVP human brain total RNA, Agilent Technologies) as a control 
for all subsequent experiments. The PCR products were purified using gel 
extraction and cloned into the vector pSC-B-amp/kan by blunt-end ligation using 
the StrataClone Blunt PCR cloning kit. The bacterial clones bearing Sema5A 
cDNA were identified by colony PCR using the following pairs of primers: 
hSema5A_F2 and hSema5A_R3, hSema5A_F5 and hSema5A_R4 (Table 3.2). 
PCR products were then analyzed by electrophoresis. Successful cloning was 
confirmed by restriction mapping and finally the clones were analyzed by DNA 
sequencing. DNA sequencing was performed on the clones using three different 
sets of primers to detect for any mutations or alternative splicing events (Table 
3.2). The primer sets used for PCR amplification and colony PCR are shown in 
Fig 3.5A. 
The calculated size of Sema5A PCR amplicons is 3.4 kb. Nevertheless, 
Sema5A amplicons obtained from glioma cell lines and the glioma biopsies did 
not resolve into a discrete band upon agarose gel electrophoresis but appeared as a 
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diffuse thick band between 3 and 4 kb as observed in Fig 3.5B. This finding 
suggests the presence of multiple Sema5A PCR products of slightly different 
sizes. Analysis of the resulting clones by colony PCR using region-specific 
primers that amplify exon 3-10 and exon 10-16 of Sema5A revealed Sema5A 
cDNA species of different sizes as compared to full-length Sema5A (Fig 3.5C). 
DNA sequencing analysis of these Sema5A cDNA clones suggests that they are 













Fig 3.5. Cloning of Sema5A cDNA into pSC-B vector. (A) Sema5A cDNA was 
PCR amplified using the primers designated in orange and DNA sequencing was 
performed using the primers depicted in blue. (B) cDNAs from normal brain, 
glioma cell lines and human glioma biopsies were subjected to PCR amplification 
using the primers hSema5A_F2 and hSema5A_R2. cDNA obtained from glioma 
cell lines and glioma biopsies displayed a smear at the 3.4 kb while normal brain 
cDNA displayed a distinct band at the same size. Representative images of PCR 
amplicons are displayed. (C) After cloning the Sema5A cDNA into pSC-B vector 
the resulting colonies were screened for correct insertion of the insert by colony 
PCR using the primers hSema5A_F2 and hSema5A_R3 (left), hSema5A_F5 and 
hSema5A_R4 (right). Bands of varying sizes were obtained indicating deletions or 
additions in the Sema5A cDNA. Lane 1 is the control full length Sema5A cDNA 


















































Table 3.2. Sequence of primers used in the PCR amplification and DNA 
sequencing of Sema5A cDNA obtained from human glioma cell lines and 
clinical specimens.  
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3.4. Novel alternative splice variants of Sema5A identified in gliomas 
 DNA sequencing was performed on the colonies obtained using six 
primers (Table 3.2) to cover the entire coding region of human Sema5A. Four 
different splice variants of Sema5A were predominantly observed in the human 
glioma cell lines and specimens: 
a) Exclusion of exon 4 
b) Exclusion of exon 11 
c) Exclusion of exon 7 
d) a 147bp intron inclusion before exon 3 
A schematic diagram of different isoforms and the predicted protein products are 
illustrated in Fig 3.6. As shown in Table 3.3, the Sema5A exon 4 exclusion 
isoform was most commonly found to be expressed in grade III and IV gliomas. 
While the Sema5A exon 11 and exon 7 exclusion isoforms were less well-
represented across the glioma grades. Interestingly, the intron 2a inclusion 
isoform (147bp intron inclusion before exon 3) was found in all the glioma grades 
examined. It is noteworthy to mention that there were no mutations identified in 
the Sema5A cDNA examined. As Sema5A exon 4 exclusion isoform was 
commonly observed to be expressed in high-grade gliomas, we decided to 
















Fig 3.6. Schematic structure of human Sema5A and the isoforms identified. 







Exon 4 Exon 7 Exon 11 Intron 
2a 
Others 
II 20 2 0 0 7 4 
III 57 23 0 3 9 6 
















Table 3.3. The number of bacterial clones harboring splice variants according 
to tumor grade.  
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3.5. The predominant Sema5A splice variant identified is the exon 4 
deletion isoform 
 From the analysis of bacterial clones bearing Sema5A cDNA, the most 
common splice variant present in the glioma biopsies is the exon 4 deletion 
mutant. To determine the relative proportion of this splice variant in relation to 
full-length Sema5A, human glioma cell lines and biopsies were analyzed by 
quantitative real-time PCR using exon-specific primers. Few sets of exon-specific 
primers were designed to cover various lengths and percentage of exons 3 and 5. 
The primers used for quantitative real-time PCR of Sema5A exon 4 exclusion 
isoform are shown in Table 3.4, the primer pair hSema5A_dEx4_qRT_F2 and 
hSema5A_dEx4_qRT_R1 were used to determine expression levels of exon 4 
exclusion isoform. The primer hSema5A_dEx4_qRT_F2 binds to the exon 3-exon 
5 boundary with 60% of the primer sequence binding to exon 5.  As exon 4 is a 
small exon of only 100bp, the challenging part in designing these primers was to 
ensure specific amplification of the exon 4 deleted region and that the wild-type 
transcript was not amplified. A validation experiment was then performed to 
ensure that the amplification efficiency of the exon 4 deletion specific primers and 
GAPDH is comparable. For the validation experiment, serial dilutions of plasmids 
bearing the Sema5A exon 4 exclusion isoform (Sema5AdEx4) or GAPDH over a 
10 fold dilution range consisting of 7 different concentrations ranging from 100 
ng to 0.0001 ng were prepared and analyzed by qPCR as stated in the Materials 
and Methods section. From the standard curve assays, amplification efficiency 
and R2 of Sema5A exon 4 specific primers and GAPDH primers were found to be 
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similar as shown in Fig 3.7. For analysis, we were unable to use the ΔΔCT 
method because the exon 4 exclusion isoform was completely absent in normal 
brain which would have been the calibrator sample for ΔΔCT analysis. Instead we 
decided to compare the relative proportion of the Sema5A exon 4 exclusion 
isoform transcript to the Sema5A wild-type transcript.  
Similar to the previous experiments, RNA was extracted from glioma cell 
lines using the Qiagen RNeasy kit, and RNA from glioma specimens was 
extracted by using the Qiagen RNeasy lipid tissue mini kit. The RNA was then 
reverse transcribed and the relative frequency of the exon 4 exclusion isoform was 
determined by quantitative real-time PCR. The results obtained showed that the 
Sema5A exon 4 exclusion variant was completely absent in normal human brain 
as illustrated in Fig 3.8. It was also seen that there was no statistically significant 
difference in the expression of the exon 4 exclusion isoform across different 
grades of glioma specimens analyzed. Interestingly, the percentage of Sema5A 
exon 4 exclusion isoform present in the glioma specimens was found to be similar 
to the percentage of full-length Sema5A in the same sample. These findings 
confirm that the exon 4 exclusion variant was expressed at significant levels in 






















hSema5A_dEx4_qRT_F2 5’-CTC CTA TAA AGA AAC TAC CTC TTC AGG -3’ 
hSema5A_dEx4_qRT_R1 5’-GTA ACA GGC CTT TTT GGT AGC TT -3’ 
Table 3.4. Sequence of primers used in the quantitative real-time PCR 












Fig 3.7. Validation experiment to determine amplification efficiency of Sema5A 
exon 4 deletion specific primers and GAPDH primers. PCR amplification plots 
(A) and standard curve (B) of Sema5A dEx4 primers. Slope: -3.37; R2: 0.994; 
Efficiency: 98.02%, PCR amplification plots (C) and standard curve (D) of GAPDH. 
Slope: -3.259; R2: 0.995; Efficiency: 102.695%. In A and B, representative 
amplification curves were constructed by the SYBR green assay. Vertical axes of A 
and C indicate the monitored fluorescence and vertical axes of B and D indicate the 
threshold cycles (cycle number when the fluorescence reached the threshold), 
















Fig 3.8. Quantitative analysis of Sema5A exon 4 exclusion isoform transcript 
compared to Sema5A mRNA expression by real-time PCR. The level of 
Sema5A exon 4 exclusion isoform transcript normalized against GAPDH and 
relative to Sema5A mRNA expression was determined by quantitative real-time 
PCR in (A) glioma cell lines and (B) glioma biopsies. Results were expressed as 
mean ± standard deviation. Statistical analysis is based on results from three 




 In this section, the expression levels of Sema5A mRNA in glioma cell 
lines and glioma tissues were analyzed by quantitative real-time PCR. It was 
observed that there was no statistical significant difference in Sema5A mRNA 
levels in different grades of glioma while a reduction in Sema5A protein levels 
was observed. The results suggest that Sema5A expression in glioma cells could 
be regulated at post-trancriptional level. By cloning Sema5A cDNA from various 
grades of glioma specimens, DNA sequencing was performed to detect for any 
mutations or alternative splice forms of Sema5A. While no mutation was 
detected, a number of novel alternative splice variants of Sema5A, which could 
potentially give rise to truncated Sema5A proteins were identified. The 
predominant form of Sema5A splice variant identified was found to be the exon 4 
exclusion isoform. Quantitative real-time PCR analysis of the relative frequency 
of presence of this exon 4 splice variant in human glioma cell lines and clinical 
specimens revealed its expression level to be equivalent to that of full-length 
Sema5A mRNA.  Sema5A exon 4 exclusion splice variant was completely absent 
in normal brain. Results of functional characterization of these splice variants are 












 Alternative splicing was identified in the 1970s and with that it became 
clear that regulation of gene expression was way more complicated than 
previously thought to be. It is estimated that over 94% of genes in mammals are 
subjected to alternative splicing, which allows the expression of different proteins 
from the same gene in a spatial and temporal specific manner. In 
pathophysiological conditions such as cancer, dysregulation of alternative splicing 
can give rise to tumor progression. In cancers, certain genes can express splice 
variants that might favor or inhibit the growth of cancer cells. A well-known 
example is Bcl-x, a Bcl-2 family member that can be alternatively spliced to yield 
either Bcl-xS a proapoptotic splice variant or Bcl-xL an antiapoptotic splice 
variant (Boise, Gonzalez-Garcia et al. 1993). Over the past few years, it has come 
to light that several RNA-binding proteins and splice factors are dysregulated in 
cancers as well.  
 Semaphorins are known to be subjected to alternative splicing. Sema6B, a 
transmembrane semaphorin was shown to have two alternative splice variants that 
corresponded to the secreted and membrane-bound versions of the molecule 
(D'Apice, Costa et al. 2013). Sema3F was also observed to express two 
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alternatively spliced isoforms which are functionally redundant but they exhibit 
differences in spatial and temporal expression in the developing nervous system 
(Kusy, Funkelstein et al. 2003). To understand the function of Sema5A splice 
isoforms identified, we overexpressed each of the isoform proteins and the 
Sema5A wild-type protein by transient transfection into HEK293 cells using 
Lipofectamine 2000. The Sema5A wild-type protein was efficiently expressed in 
HEK293 cells while some of the isoforms were unable to be detected by Western 
blot analysis.  
4.2 Expression of Sema5A splice variants in mammalian cells 
 To characterize these splice variants, mammalian expression vectors 
encoding the extracellular domain (ED) of wild-type or splice isoforms of 
Sema5A fused with the Fc portion of human IgG at the C-terminus was generated. 
The plan was to transfect the semaphorin 5A-Fc fusion constructs into HEK293 
cells so as to obtain soluble semaphorin 5A protein or Sema5A splice isoforms 
which would be released into the cell culture medium. The resulting conditioned 
medium would then be collected and used for exogenous stimulation of glioma 
cell lines so as to study the functional effect of the Sema5A splice variants. A HA 
epitope tag was also engineered into the N-terminus of the mammalian expression 
vector as the deletion of exons 4 and 11 would result in an early termination 
codon and protein translation would be stalled. A N-terminal HA-epitope tag 
would ensure that we would be able to visualize the truncated proteins using 
Western blot analysis.  
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HEK293 cells were transfected with these expression vectors of Sema5A 
or the Sema5A isoforms: pEXHA_hSema5AED_Fc, pEXHA_hSema5AdEx4_Fc,                                                                                                
pEXHA_hSema5AdEx11_Fc, pEXHA_hSema5AdEx7_Fc and 
pEXHA_hSema5A int2a_Fc or parental vector pEX_Fc encoding a fusion protein 
of the wild-type and mutant Sema5AED and the Fc portion of human IgG. The 
supernatant and whole-cell extracts were then harvested separately at 24 hours, 48 
hours and 72 hours post-transfection.  Protein expression was determined by 
Western blotting using anti-HA antibody.  As for Sema5A wild-type ED the 
protein band observed on Western blot was larger than the predicted amino acid 
sequence. Using glycosylation prediction tools, it was observed that Sema5A 
could be subjected to N-linked glycosylation and a large proportion of the 
glycosylation consensus sequences were located in the sema domain. These 
proteins were generated in a soluble form as we had intended on using the 
conditioned medium for exogenous stimulation of glioma cells.  
Exon 4 exclusion isoform – The exclusion of exon 4 from the Sema5A transcript 
results in a frame-shift that leads to a premature stop codon, which is predicted to 
yield a truncated protein of only 11 kDa in size. DNA sequencing analysis of the 
exon 4 exclusion isoform is shown in Fig 4.1 and illustrated in Fig 4.2 is the 
protein sequence of the exon 4 exclusion isoform depicting the premature stop 
codon. Exon 4 is located at the beginning of the sema domain which is a critical 
region found in semaphorins and plexins that is essential for signaling. 
Surprisingly, transient transfection of the Sema5A exon 4 deletion construct into 
HEK293 cells resulted in negligible level of expression of the truncated protein 
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when compared to wild-type Sema5A as shown in Fig 4.3A. To understand the 
cause of absence of Sema5A dEx4 expression, we determined whether the 
corresponding mRNA transcript was expressed by RT-PCR. Briefly, mRNA was 
extracted from the lysates of transfected cells and after reverse transcription the 
cDNA was PCR amplified using region specific primers, hSema5A_F3 and 
hSema5A_R3. The mRNA transcript of exon 4 exclusion isoform was readily 
detected as observed in Fig 4.3B thus ruling out mRNA degradation. Therefore 
we speculated that this truncated mutant could be unstable or misfolded, thus 
causing them to be targeted for degradation and rapid elimination from the cell. 
This hypothesis was tested out by employing inhibitors again protein degradation 
pathways and these results would be discussed in greater detail in the next 
chapter.  
Exon 7 exclusion isoform – The exclusion of exon 7 from the Sema5A transcript 
is expected to preserve the translational reading frame and results in a slightly 
smaller protein due to the exclusion of this 100 bp exon. Ectopic expression of the 
exon 7 exclusion construct (pEXHA_hSema5AdEx7_Fc) in HEK293 cells 
yielded a protein at the expected size. The corresponding mRNA was also 
detected by RT-PCR amplification (Fig 4.4B). Nonetheless, the protein was only 
detected in the cell lysate but not in the medium as illustrated in Fig 4.4A.  
Similar to exon 4, the amino acid sequence encoded by exon 7 is also located 
within the Sema domain. The Sema domain is composed of a seven bladed β-
propeller fold (Nogi, Yasui et al. 2010). Each blade contains a four-strand 
antiparallel β-sheet. Four disulphide bonds are involved in stabilizing this β-
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propeller structure and two of these are within the second blade which is encoded 
by exon 7. These cysteine residues are highly conserved among different 
semaphorins as shown in Fig 4.5. While the exclusion of exon 7 from Sema5A 
transcript does not cause any frame-shift, the absence of two disulphide bonds in 
the β-propeller structure is expected to cause improper folding of the sema 
domain. This could possibly contribute to the aberrant targeting of this Sema5A 
isoform.  
Exon 11 exclusion isoform – Ectopic expression of the Sema5A exon 11 
exclusion construct (pEXHA_hSema5AdEx11_Fc) is expected to yield a protein 
of approximately 38 kDa due to a shift in translational reading frame and 
formation of a premature stop codon. Nonetheless, the truncated protein failed to 
be detected by Western blot analysis, though the corresponding mRNA transcript 
could be detected as shown in Fig 4.6. Exon 11 of Sema5A encodes a certain 
portion of the β-propeller fold known as the “extrusion” which is a highly 
conserved and essential part of the β-propeller (Nogi, Yasui et al. 2010). Improper 
folding of the protein could have targeted it for rapid elimination from the cells.  
Intron 2 inclusion isoform – The inclusion of intron 2a would generate 3 
additional ATG sites upstream of the putative start codon. When used these ATG 
sites will translate into extremely small peptides. Surprisingly, ectopic expression 
of this isoform in HEK293 cells produced wild-type Sema5A protein at a very 
low level (Fig 4.7). A possible reason for this observation would be that these 
upstream alternative ATG sites are skipped in a small population of cells and 
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translation starts from the putative ATG start codon used in wild-type Sema5A, 




Fig 4.1. Analysis of Sema5A exon 4 exclusion mutant. DNA sequencing of two clones obtained from cloning 
Sema5A cDNA from a glioma specimen. The chromatogram above shows a normal Sema5A cDNA comprising of 





Fig 4.2. Protein translation of Sema5A full-length and exon 4 exclusion 
isoform. The cDNA sequence and amino acid sequence of Sema5A full-length 
(A) and Sema5A exon 4 exclusion isoform (B). The canonical start site is 
depicted in red, exons 3, 4, and 5 are labeled and the premature stop codon which 
results from the deletion of exon 4 and a subsequent frame-shift in the coding 











Fig 4.3. Analysis of Sema5A exon 4 exclusion mutant. (A) Western blot 
detection of Sema5A ED and exon 4 exclusion protein in HEK293 cells after 24 
(lanes 1, 2), 48 (lanes 3, 4) and 72 (lanes 5, 6) hours post-transfection using anti-
HA antibody (M: medium, L: lysate). (B) RT-PCR analysis shows the presence 
of Sema5A ED transcript at 24 h (lane 1) and 48 h (lane 2), and Sema5A exon 4 
exclusion transcript at 24 (lane 3) and 48 h (lane 4) after ectopic expression in 
HEK293. GAPDH from Sema5A exon 4 exclusion protein transfection (lane 5) 











Fig 4.4. Analysis of Sema5A exon 7 exclusion mutant. (A) Western blot 
detection of Sema5A ED and exon 7 exclusion protein in HEK293 cells after 24 
(lanes 1, 2), 48 (lanes 3, 4) and 72 (lanes 5, 6) hours post-transfection using anti-
HA antibody (M: medium, L: lysate). (B) RT-PCR analysis shows the presence 
of Sema5A ED transcript at 24 h (lane 1), 48 h (lane 2), and 72 h (lane 3) and 
Sema5A exon 7 exclusion transcript at 24 h (lane 4), 48 h (lane 5) and 72 h (lane 
6) after ectopic expression in HEK293. GAPDH from Sema5A exon 7 exclusion 











Fig 4.5. Sequence alignment of the Sema domains of human Sema5A, 
Sema3A and Sema4D. The region encoded by exon 7 is marked within brackets. 
The conserved cysteines that are involved in disulphide bond formation are 












Fig 4.6. Analysis of Sema5A exon 11 exclusion mutant. (A) Western blot 
detection of Sema5A ED and exon 11 exclusion in HEK293 cells after 24 (lanes 
1, 2), 48 (lanes 3, 4) and 72 (lanes 5, 6) hours post-transfection using anti-HA 
antibody (M: medium, L: lysate). (B) RT-PCR analysis shows the presence of 
Sema5A ED transcript at 24 h (lane 1), 48 h (lane 2), and 72 h (lane 3) and 
Sema5A exon 11 exclusion transcript at 24 h (lane 4), 48 h (lane 5) and 72 h (lane 
6) after ectopic expression in HEK293. GAPDH from Sema5A exon 11 exclusion 











Fig 4.7. Analysis of Sema5A intron 2a inclusion mutant. (A) Western blot 
detection of Sema5A ED and intron 2a inclusion protein in HEK293 cells after 24 
(lanes 1, 2), 48 (lanes 3, 4) and 72 (lanes 5, 6) hours post-transfection using anti-
HA antibody (M: medium, L: lysate). (B) RT-PCR analysis shows the presence 
of Sema5A intron 2a inclusion transcript at 24 (lane 4), 48 h (lane 5) and 72 h 
(lane 6) after ectopic expression in HEK293. The absence of the Sema5A ED 
transcript at 24 h (lane 1), 48 h (lane 2), and 72 h (lane 3) was as expected as the 
primers bind specifically to the intronic region and GAPDH from Sema5A intron 
2a inclusion protein transfection (lane 7) serves as a RT control. 
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4.3 Sema5A exon 4 exclusion mutant protein is degraded through the 
proteasomal degradation pathway  
 The expression of Sema5A dEx4 protein isoform at negligible level but 
with normal level of transcript suggests that this protein isoform might be rapidly 
degraded and eliminated from the cell. In eukaryotes, two major pathways of 
protein degradation exist: the ubiquitin-proteasome pathway and the autophagy-
lysosome pathway. To test our hypothesis whether Sema5A dEx4 protein is 
subjected to degradation, HEK293 cells transfected with Sema5A dEx4 constructs 
were treated with the proteasomal inhibitors MG132 and lactacystin; or the 
lysosomal inhibitor choloroquine 24 hours post-transfection. The cells were 
harvested at different time points afterwards to analyze for the expression of 
Sema5A dEx4 protein by western blot.  
Ubiquitin-proteasome pathway 
 Both lactacystin and MG132 are proteasome inhibitors that binds 
covalently or reversibly to the β-subunit of the 26S proteasome, respectively. 
Apart from their proteasomal inhibition effect, MG132 and lactacystin are 
inhibitors of proteases such as cathepsin A, cathepsin B and calpain 1, 
respectively. Nevertheless, the primary activity of these inhibitors is directed 
predominantly against the proteasome.  
To explore the possibility of proteasomal degradation of Sema5A dEx4 
protein, HEK293 cells transfected with the construct were treated with 5 µM of 
MG132 and harvested at 3, 6 and 12 h. As a vehicle control the cells were treated 
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with DMSO only. Crude cell lysates were prepared and the expression of Sema5A 
dEx4 isoform was analyzed by Western blot using anti-HA antibodies. As shown 
in Fig. 4.8A, upon treatment with MG132 a gradual increase in expression of the 
Sema5A exon 4 exclusion mutant was observed at the expected size of 11 kDa. 
The expression level peaks at 12 h after MG132 treatment. The same blot was 
probed for c-Myc, a short-lived protein known to be degraded through the 
proteasomal pathway. The level of c-Myc was also seen to increase in a similar 
manner. Similar results were obtained when these experiments were performed in 
a glioma cell line, U87-MG (Fig 4.8B). A MG132 dosage dependant assay was 
also performed in which HEK293 cells transfected with Sema5A dEx4 expression 
vectors were exposed to different concentrations (1, 2.5, 5, 10 and 20 µM) of 
MG132 for 12 h. Western blot analysis of the lysates showed an increase in the 
expression of Sema5A exon 4 exclusion protein with increasing concentration of 
MG132 (Fig 4.9). 
To confirm that the increase in expression of Sema5A dEx4 isoform is due 
to effect of MG132 in blocking proteasomal degradation instead of other 
confounding effects, the experiments were repeated using lactacystin, which 
irreversibly alkylates the β subunit of the 20S proteasome. A time-course study in 
which the transfected cells were treated with 10 µM of lactacystin for 3, 6 and   
12 h showed a significant increase in the level of Sema5A exon 4 exclusion 
protein at 12 h post-transfection as demonstrated in Fig 4.10.  
The results indicate that the Sema5A exon 4 exclusion isoform is unstable 
and degraded through the ubiquitin-proteasome pathway, hence contributing to 
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the downregulation of Sema5A protein in high-grade glioblastomas (Li, Law et 
al. 2012). A decline in Sema5A protein expression in gliomas could compromise 





















Fig 4.8. Time course analysis of the effect of MG132 in preventing ubiquitin-
proteasome degradation of Sema5A exon 4 exclusion isoform. HEK293 cells 
transfected with Sema5A dEx4 construct were treated with the proteasome 
inhibitor MG132 at 5 μM for different durations, followed by western blot 
analysis using anti-HA antibody (A) c-Myc was used a positive control for 
proteasomal degradation and GAPDH was used as a protein loading control (M: 
medium; L: lysate). Results were expressed as mean ± standard deviations from 
three independent experiments. (*** p<0.001 vs. DMSO control). Similar results 
were also obtained when the experiments were repeated in U87-MG glioma cell 











Fig 4.9. Sema5A exon 4 exclusion isoform is prevented from degradation by 
the ubiquitin-proteasome inhibitor MG132 in a dose-dependent manner. 
HEK293 cells transfected with Sema5A dEx4 construct were treated with 
different dosages of the proteasome inhibitor MG132 for 12 h, followed by 
Western blot analysis using anti-HA antibody. c-Myc was used a positive control 
for proteasomal degradation and GAPDH was used as a protein loading control 
(M: medium; L: lysate). Results were expressed as mean ± standard deviations 


















Fig 4.10. Inhibition of proteasome degradation using lactacystin restores 
expression of Sema5A exon 4 exclusion mutant protein. HEK293 cells 
transfected with Sema5A dEx4 construct were treated with 10 µM of lactacystin 
for 3, 6 and 12 h and crude cell lysates were subjected to Western blot analysis 
using anti-HA antibody. c-Myc was used a positive control for proteasomal 






To examine whether the Sema5A exon 4 deletion mutant could also be 
degraded through the lysosomal pathway, HEK293 cells transfected with Sema5A 
dEx4 construct were treated with 100 µM chloroquine, a lysosomal inhibitor that 
inhibits autophagy by increasing the lysosomal pH and inhibits lysosomal protein 
degradation. A time course study was done wherein the transfected cells were 
cultured in the presence of 100 µM of chloroquine for 3, 6 and 12 h. Western blot 
analysis showed extremely low expression of exon 4 exclusion isoform, which 
remains unchanged throughout the course of chloroquine treatment (Fig 4.11A). 
By contrast, the expression level of Notch 3-ICD protein, a protein known to be 
degraded by the lysosomal pathway showed a gradual increase (Fig 4.11B). These 
results suggest that Sema5A exon 4 exclusion isoform is unlikely to be degraded 























Fig 4.11. Inhibition of lysosomal degradation using chloroquine has no effect 
on the expression of Sema5A exon 4 exclusion isoform. HEK293 cells 
transfected with Sema5A dEx4 construct were treated with the lysosome 
degradation inhibitor chloroquine at 100 µM for 0, 3, 6 and 12 h and subjected to 
Western blot analysis using anti-HA antibody (A). Notch-3ICD was used as a 
positive control for lysosomal degradation and GAPDH was used as a protein 




4.4 Sema5A exon 4 exclusion isoform could undergo ubiquitin-
independent degradation 
 Proteins targeted for degradation by the ubiquitin-proteasome pathway are 
usually tagged by chains of ubiquitin through series of enzymatic events. The 
multi-ubiquitinated protein is then recognized and degraded by the 26S 
proteasome complex, a multicatalytic protease complex. Nevertheless, certain 
proteins such as structurally abnormal or misfolded proteins can be degraded 
without prior ubiquitination (Jariel-Encontre, Bossis et al. 2008).    
 To determine whether the Sema5A exon 4 exclusion isoform is 
ubiquitinated prior to degradation in the proteasome, cells transfected with 
Sema5A dEx4 construct were treated with 5 µM MG132 for 3, 6 and 12 h. Total 
protein was extracted from the cells and poly-ubiquitinated proteins present in the 
lysate were immunoprecipitated with polyubiquitin affinity resin. 
Polyubiquitinated Sema5A dEx4 protein was then detected by Western blot 
analysis using anti-HA antibodies. Western blot analysis to detect 
polyubiquitinated proteins usually results in a high molecular weight smear which 
is caused by the different sizes of the modified proteins. An increase in poly-
ubiquitinated proteins were in fact seen from 3 h with a maximum increase 
observed at 12 h post-MG132 treatment when the blot was probed with anti-
ubiquitin antibodies (Fig 4.12A). This indicates that the immunoprecipitation of 
ubiquitinated proteins in the cell lysate was successful. It is noteworthy that when 
probing for a specific polyubiquitinated protein it would have an additional 
molecular weight of at least 32 kDa or its multiples when compared to the non-
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ubiquitinated form of the protein, when the blot was probed with anti-HA 
antibody, the non-ubiquitinated form of the 11 kDa Sema5AdEx4 isoform (with 












Fig 4.12. Absence of poly-ubiquitinated Sema5A exon 4 exclusion isoform. 
HEK293 cells transfected with Sema5A dEx4 construct were treated with MG132 
for 0, 3, 6 and 12 h. The polyubiquitinated proteins were immunoprecipitated with 
polyubiquitin affinity resin and analyzed by Western blot using anti-ubiquitin 
antibody (A) and anti-HA antibody (B).  
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4.5 The 20S proteasome is responsible for degrading Sema5A exon 4 
exclusion isoform 
 The results obtained from the MG132 and lactacystin studies suggest that 
Sema5A exon 4 exclusion isoform is degraded through the proteasomal pathway. 
To confirm this finding, immunocytochemistry was performed to determine the 
subcellular localization of Sema5A dEx4 protein and compare with that of 
proteasomal marker using confocal microscopy.  
 Briefly, HEK293 cells were plated at an appropriate cell density on to 
poly-L-lysine coated coverslips. The cells were transfected with Sema5A dEx4 
construct, treated with 5 µM MG132 and harvested at 12 h. A vehicle control was 
included in which the cells were treated with DMSO only. Cells were then 
subjected to immunofluorescence staining using anti-HA, anti-20S proteasome 
and anti-ubiquitin antibodies. Immunofluorescence staining for Sema5A exon 4 
exclusion isoform revealed an increase in signal intensity upon MG132 treatment 
as compared to untreated and vehicle control (Fig. 4.13Bi), which corroborates 
with the earlier finding that this isoform is subjected to proteasomal degradation. 
20S proteasome immunostaining for both the α and β proteasome subunits 
showed cytoplasmic localization of the 20S proteasome in cells with and without 
MG132 treatment (Fig. 4.13Aii, Bii, Cii). Interestingly, it was observed that upon 
MG132 treatment the Sema5A exon 4 exclusion isoform colocalized with the 20S 
proteasome (Fig. 4.13B). The colocalization of 20S proteasome and Sema5A 
exon 4 exclusion isoform confirms that this abnormal splice isoform is degraded 
by the proteasomal pathway.  
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When the cells were fluorescently stained with ubiquitin, there was a 
substantial increase in polyubiquitinated proteins observed but there was no 
significant colocalization of the Sema5A exon 4 isoform with ubiquitin (Fig. 
4.14B). These results suggest that the abnormal splice variant might undergo 



















Fig 4.13. Colocalization of Sema5A exon 4 exclusion isoform and 20S proteasome 
subunits. HEK293 cells were plated on poly-L-lysine coated coverslips and 
transfected with Sema5A dEx4 construct and the cells remained untreated (A), treated 
with MG132 (B) or DMSO vehicle control for 12 h. Sema5A exon 4 exclusion 
isoform was detected with anti-HA (green, i), 20S proteasome was detected with anti-
20S proteasome α + β subunits (red, ii), respectively. Nucleus was stained with DAPI 
(blue). Any colocalization of Sema5A exon 4 exclusion isoform and 20S proteasome 










Fig 4.14. Sema5A exon 4 exclusion isoform does not require prior ubiquitination 
to be targeted for degradation. HEK293 cells were plated on poly-L-lysine coated 
coverslips and transfected with Sema5A dEx4 construct and the cells remained 
untreated (A), treated with MG132 (B) or DMSO vehicle control for 12 h. Sema5A 
exon 4 exclusion isoform was detected with anti-HA (green, i), poly-ubiquitinated 
proteins were detected with anti-ubiquitin (red, ii), respectively. Nucleus was stained 
with DAPI (blue). Any colocalization of Sema5A exon 4 exclusion isoform and 




 The original aim of this chapter was to perform the functional 
characterizations of Sema5A splice variants but upon ectopic expression of the 
predominant isoforms there was very low level of protein expression seen. Thus 
we went ahead to examine the mechanism behind the regulation of these splice 
variants. Mammalian expression constructs were generated bearing the cDNA of 
each of the common splice variants and upon ectopic expression in mammalian 
cells it was observed that the Sema5A exon 4 exclusion isoform was unable to be 
detected using Western blot analysis. The Sema5A exon 7 exclusion isoform 
which does not result in a translational frame-shift yielded a protein at the 
expected size but due to its unstable nature the protein was stuck within the cell 
and expression was predominantly observed only in the cell lysate and not in the 
medium. As for the deletion of exon 11 from the Sema5A cDNA yields a smaller 
protein of 38 kDa but unfortunately we were unable to detect this protein upon 
ectopic expression in mammalian cells. It is highly likely that this truncated 
protein could have been rapidly eliminated from the cell. The Sema5A intron 2a 
inclusion isoform where a portion of intron 2 has been spliced-in to the Sema5A 
cDNA gives rise to 3 ATG start codons up stream of the endogenous start codon 
which when used would only yield a small peptide. Surprisingly transient 
transfection of this contruct yielded a protein at the same size as the endogenous 
Sema5A, a possible explanation is that the cells had skipped the extra start codons 
and instead translated from the endogenous start codon as it has the most 
conserved Kozak sequence.  
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 Next, we utilized various protein degradation inhibitors targeting the two 
common degradation pathways, the proteasomal pathway and the lysosomal 
pathway. Using these inhibitors, we were able to deduce that the Sema5A exon 4 
exclusion isoform was being degraded by the proteasomal pathway as illustrated 
using both Western blot analysis and confocal microscopy. Proteins that are 
degraded by the proteasomal pathway are usually tagged by ubiquitin prior to 
being degraded, so we embarked on determining whether Sema5A exon 4 
exclusion isoform was ubiquitinated prior to degradation. We used confocal 
microscopy and polyubiquitin enrichment kit but we were unable to observe any 
prior ubiquitination of the Sema5A exon 4 exclusion variant. There have been 
reports of ubiquitin-independent protein degradation that can occur via two 
mechanisms: through proteasome activators or by direct association of the protein 
to the 20S proteasome core. It has been deduced that structurally altered and 
abnormal proteins do tend to undergo ubiquitin-independent protein degradation 












MICRO-RNA MEDIATED REGULATION OF  
SEMAPHORIN 5A IN HUMAN GLIOMAS 
 
5.1 Introduction 
 The transmembrane protein, Sema5A has been shown to suppress 
migration and invasion in glioma cells. Published reports from our laboratory 
have shown a significant downregulation of Sema5A protein towards high grade 
glioblastomas, which plausibly leads to increased invasiveness (Li, Law et al. 
2012). In this study, we had performed a genetic analysis on the Sema5A gene in 
high grade gliomas to determine the underlying cause of its downregulation. No 
mutations were found but a number of alternative splice variants of Sema5A were 
detected. These splice variants could potentially give rise to truncated Sema5A 
proteins. The predominant species identified was the Sema5A exon 4 exclusion 
isoform. The deletion of exon 4 results in a shift in the translational reading frame 
leading to the formation of a truncated protein. The Sema5A exon 4 exclusion 
isoform was also found to be rapidly targeted for proteasomal degradation and 
eliminated from the cell, hence accounting for the downregulation of Sema5A 
protein observed in high-grade glioblastomas.  
 To explore the possibility that other mechanisms might contribute to the 
downregulation of Sema5A protein in high grade gliomas, we examined the 
potential role of miRNAs in regulating Sema5A expression at post-transcriptional 
level. Briefly, human Sema5A sequence was subjected to in silico analysis to 
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identify potential miRNA binding sites. Selected candidate miRNAs were then 
overexpressed or inactivated in glioma cell lines and their effect on Sema5A was 
examined. Among the miRNAs identified, miR-21 was known to be highly 
upregulated in high grade gliomas. The involvement of miR-21 in regulating 
Sema5A expression was therefore explored.  
5.2 In silico analysis to identify potential candidate miRNAs that can 
regulate Sema5A 
 MicroRNAs (miRNAs) are 21- to 25- nucleotide long non-coding RNA 
molecules that can form imperfect base-pairing with specific regions in target 
mRNAs and result in repressing target protein expression. These miRNAs can 
regulate gene expression through mRNA degradation/deadenylation or 
translational repression. Increasing number of reports show aberrant expression of 
certain miRNAs such as miR-21, -15, -16, -141,-107 are  involved in tumor 
growth and metastasis in different cancer types (Aigner 2011; Catto, Alcaraz et al. 
2011). Recent reports have indicated that semaphorins and their receptors could 
be regulated by miRNAs in cancer, Sema6A has been shown to be targeted by 
miR-141 in clear cell renal carcinoma (Liu, Brannon et al. 2010); miR-320a was 
observed to target Neuropilin1 in colorectal cancer (Zhang, He et al. 2012); while 
in cervical cancer plexin-B1 has been demonstrated to be regulated by miR-214 
(Qiang, Wang et al. 2011). To date, the regulation of transmembrane class 5 
semaphorins by miRNAs remains to be determined.  
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 To identify potential candidate miRNAs that target Sema5A, in silico 
prediction of miRNA binding sites were performed using three common 
databases:  miRDB, miRanda and DIANAlab. A number of putative miRNAs that 
may bind to seeding sequences in the Sema5A 3’UTR were identified. We cross-
referenced these miRNAs with online genomic profiling databases for glioma and 
selected 6 of them that potentially target Sema5A and are also highly upregulated 
in high-grade gliomas. The candidate miRNAs are miR-21, miR-155, miR-20a, 
miR-143, miR-106b and miR-519d. The most commonly upregulated miRNAs in 
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Table 5.1. miRNAs commonly upregulated in GBM. The table illustrates 
genomic profiling studies in glioma and the miRNAs commonly observed to be 
upregulated. The miRNAs highlighted in red are the ones that possess seeding 
sequences in Sema5A 3’UTR. GBM; glioblastoma multiforme, ABT; adjacent 
brain tissue, AA; anaplastic astrocytoma, DA; diffuse astrocytoma 
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5.3 MicroRNA-21 targets Sema5A in a post-transcriptional manner  
 miRNAs have been shown to regulate their target mRNAs by mRNA 
degradation, destabilization by deletion of the poly(A) tail or by translational 
repression by inhibiting the ribosome from translating the mRNA (Filipowicz, 
Bhattacharyya et al. 2008). MicroRNA-21 is one of those potential candidates 
that may act on Sema5A and is highly upregulated in high grade glioma as well as 
many other types of cancers such as prostate, breast, lung and gastric cancers 
(Chan, Wu et al. 2008; Yan, Huang et al. 2008; Guan, Mizoguchi et al. 2010; 
Reis, Pontes-Junior et al. 2012; Capodanno, Boldrini et al. 2013). These findings 
suggest that this miRNA might be a possible oncomiR and thereby a promising 
therapeutic target. MiR-21 has also been observed to regulate cellular 
proliferation, apoptosis and cell migration in cancer cell lines (Lou, Cui et al. 
2011; Yan, Wu et al. 2011; Chan, Blansit et al. 2014).  
 A common approach to identify the miRNAs that act on a target gene is to 
determine mRNA or protein expression levels of the target gene upon forced 
expression of candidate miRNA mimics or anti-miRNAs. We used this approach 
to determine whether miR-21 targets Sema5A in glioma cells in vitro. U87-MG 
and U251-MG cells were transiently transfected with miR-21 mimics or control 
miRNA mimics and the cells were harvested at 24 h and 48 h post-transfection. 
The lysates were then subjected to Western blot analysis to detect for any changes 
in Sema5A protein expression. Our results demonstrated that upon overexpression 
of miR-21 in U87-MG and U251-MG glioma cells Sema5A protein levels were 
reduced. To confirm this finding, we exogenously added miR-21 inhibitors or the 
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control miRNA inhibitor into A172 and U87-MG cell lines and we observed that 
Sema5A protein levels were now elevated upon miR-21 inhibition. As a positive 
control we utilized another tumor suppressor, Pdcd4, which is a validated target of 
miR-21 (Gaur, Holbeck et al. 2011). The same phenomenon was observed with 
Pdcd4 as well (Fig. 5.1). 
 Previous data from our laboratory has confirmed a significant 
downregulation of Sema5A protein levels towards high-grade glioma while 
Sema5A mRNA levels were not significantly changed (Li, Law et al. 2012). With 
the confirmation of the downregulation of Sema5A protein expression by miR-21, 
we hypothesized that it is mediated through translational repression instead of 
mRNA degradation. To test this hypothesis, U87-MG cells were transfected with 
miR-21 mimics and harvested at 24 h and 48 h post-transfection for quantitative 
real-time PCR analysis using Sema5A specific primers: hSema5A_qRT_F1 and 
hSema5A_qRT_R1. The results showed no significant change in Sema5A mRNA 
levels, as expected. These results suggest that Sema5A could be post-












Fig 5.1. Sema5A is regulated by miR-21 in a post-transcriptional manner. The 
human glioma cell lines, U87-MG (A,C), U251-MG (B) and A172 (D) were 
transiently transfected with miR-21 mimics (A,B) or inhibitors (C,D) as well as 
their respective control. Cells were harvested at various time points and subjected 
to Western blot analysis of Sema5A protein expression using anti-Sema5A 
antibodies. Equal loading of protein was confirmed with anti-GAPDH antibody. 
Pdcd4 was used as a positive control to confirm miR-21 inhibition in those cell 
lines. (E) Quantitative real-time PCR monitoring of Sema5A mRNA levels upon 
miR-21 overexpression in U87-MG cells. Results were expressed as mean ± 




5.4 Promotion of glioma cell viability by miR-21 is abolished by 
overexpression of Sema5A 
  As we had proven that miR-21 targets Sema5A and overexpression of 
miR-21 in glioma cells resulted in suppression of Sema5A protein. The next aim 
of our project was to understand the functional consequence of miR-21 targeting 
Sema5A. Gaur and colleagues have demonstrated that a downregulation of miR-
21 in glioblastoma-derived cell lines resulted in reduced tumor proliferation. 
Transplantation of the miR-21 deficient glioma cell line in immune-deficient mice 
resulted in reduced tumor growth (Gaur, Holbeck et al. 2011). It is therefore 
tempting to speculate that the heightened expression of miR-21 commonly found 
in glioma cells leads to a downregulation of Sema5A expression and suppression 
of its anti-proliferative effect. To validate this hypothesis, we decided to verify the 
effect of miR-21 on glioma cell proliferation before proceeding on to 
understanding its effect on Sema5A. To this end, U251-MG cells were transiently 
transfected with miR-21 mimics (Ambion) and were plated at the desired cell 
density of 5000 cells in 96-well culture dishes. Cells were allowed to grow for 48 
h before treatment of MTT. Cell viability was assessed by measurement of MTS 
to measure cell viability. As shown in Fig. 5.2B, there was a significant increase 
in cell viability observed upon forced expression of miR-21 as compared to mock 
transfection of negative miR controls. When miR-21 treated U251-MG cells were 
transfected with Sema5A, there was a significant drop in cell viability in the cells 
24 h post-transfection (Fig 5.2A and B). The hike in cell viability observed after 
miR-21 treatment was completely abolished when those cells were transfected 
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with Sema5A. In conclusion, miR-21 overexpression significantly enhanced 
glioma cell proliferation of U251 cells, while the overexpression of Sema5A 

























Fig 5.2. Promotion of glioma cell viability by miR-21 is abolished by 
overexpression of Sema5A. U251-MG cells were transiently transfected with miR-21 
mimics, the negative control miR (Neg) or mock transfected. After incubation for 24 
hours, the cells were transfected with Sema5A and were allowed to grow for a further 
24 hours. The cells were then subjected to MTS assay and absorbance at 570 nm was 
determined. (A) U251-MG cells overexpressing miR-21 (upper panels) and U251-MG 
cells overexpressing both miR-21 and Sema5A (lower panels). (B) The bar chart 
shows MTS score of U251-MG cells after transfection with miR-21 and Sema5A 
along with the controls. Results were expressed as mean ± standard deviation from 




5.5 Sema5A is not regulated by the other miRNAs tested  
 From our initial screening we had identified 6 putative miRNAs that could 
regulate Sema5A in high grade gliomas. So as to verify whether they could 
regulate Sema5A, miRNA mimics of those miRNAs: miR-21, miR-155, miR-20a, 
miR-143, miR-106b and miR-519d, were ectopically expressed in glioma cell 
lines by transient transfection.  Cells harvested at 24 h and 48 h after transfection 
were subjected to Western blot analysis to detect for any changes in Sema5A 
expression level. Interestingly, the results obtained showed no changes in 
Sema5A expression level upon exogenous addition of these miRNAs. It does 
seem that Sema5A is not regulated by these miRNAs despite the the presence of 






















Fig 5.3. Sema5A is not regulated by miR-155, miR-143, miR-106b, miR-20a 
nor miR-519d. U87-MG glioma cells were transiently transfected with miRNA 
mimics or their control. Cells were harvested at various time points for Western 
blot analysis of Sema5A protein expression levels using anti-Sema5A antibody. 
Equal loading of protein was confirmed with anti-GAPDH antibody. Similar 





  Previous data from our laboratory showed a significant downregulation of 
Sema5A protein level in high-grade gliomas. The present study has identified 
novel alternatively spliced isoforms of Sema5A in glioma cells that are rapidly 
targeted for proteasomal degradation from the cell. The aberrant splicing of 
Sema5A could therefore account for the decline in Sema5A protein level and not 
at the mRNA level. To determine for the presence of alternative mechanisms that 
lead to a reduction of Sema5A protein from low to high-grade glioma, we 
screened for potential miRNAs that could target Sema5A in high grade gliomas. 
To this end, candidate miRNAs were transfected into glioma cell lines and 
observed for changes in Sema5A protein levels. Among the miRNAs tested, miR-
21 was the only miRNA that could regulate Sema5A protein expression. Our data 
showed that upon ectopic expression of miR-21 mimics there was a reduction in 
Sema5A protein levels, whereas inhibition of miR-21 resulted in the opposite 
effect. We also observed no changes in Sema5A mRNA level upon miR-21 
overexpression together with the fact that miR-21 is upregulated from low to high 
grade glioma. These data supports the idea that Sema5A could be targeted by 
miR-21 for translational repression in gliomas which would account for the 











 A recent surge in interest in determining the roles of semaphorins in 
cancer had unearthed many interesting findings. Some semaphorins exhibit 
oncogenic while others tumor suppressor functions. Recent studies have 
suggested the involvement of Sema5A in tumorigenesis. The functional role 
played by Sema5A is rather promiscuous as it has been reported to be oncogenic 
in certain cancer types and tumor suppressive in other some other cancers. 
Elevated levels of Sema5A and its receptor plexin-B3 were observed in 
pancreative cancer and it correlated with enhanced tumor growth, invasion, 
metastasis and increased tumor angiogenesis (Sadanandam, Varney et al. 2010). 
In a similar manner, Sema5A and plexin-B3 were shown to promote cancer cell 
invasion and metastasis in gastric cancers (Pan, Lv et al. 2010). A recent study 
demonstrated enhanced levels of Sema5A and plexin-B3 in metastatic ovarian 
cancer which is associated with poor patient survival (Danielson 2014). On the 
other hand, Sema5A expression level has been found to be decreased in lung, 
colon cancer and high-grade glioblastomas (Lu, Tsai et al. 2010; Li, Law et al. 
2012; Liu, Lu et al. 2012). Downregulation of Sema5A expression was also 
observed in non-small lung carcinoma and it correlated with better patient 
survival (Lu, Tsai et al. 2010). Semaphorins, especially transmembrane 
semaphorins, have been known to elicit opposing functions in the developing 
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nervous system. Sema5A has been shown to behave as a bifunctional guidance 
cue eliciting both attractive and repulsive effects on the developing axons in a 
proteoglycan dependent manner (Kantor, Chivatakarn et al. 2004).  
 Reports from our laboratory have clearly shown reduced levels of Sema5A 
protein in high-grade glioblastomas and that in human gliomas Sema5A exhibits 
anti-migratory and anti-invasive effects. These effects are mediated through 
inactivation of a key migratory protein, Rac1 through RhoGDIα (Li and Lee 
2010). We have also shown that Sema5A can induce phosphorylation of fascin-1 
by protein kinase C and interestingly Sema5A can induce re-expression of glial 
fibrillary acidic protein (GFAP) promoting astrocytic differentiation of gliomas 
(Li, Law et al. 2012).  
 A key question to be addressed is whether the reduced levels of Sema5A 
observed in high-grade gliomas could confer a survival advantage to the glioma 
cells. It is therefore of interest to determine whether Sema5A has an inhibitory 
effect on glioma cell proliferation.  
6.2 Expression of Sema5A full-length protein in glioma cell lines 
 To examine the potential tumor suppressor role of Sema5A in glioma 
cells, a gain-of-function approach was taken. Briefly, Sema5A full-length cDNA 
was amplified by PCR from a glioma biopsy and cloned into the mammalian 
expression vector pcDNA3-HA/myc-His. The resulting pcDNA3-HA-Sema5A-
myc-His plasmid was transfected into U87-MG cells using Lipofectamine 2000. 
pcDNA3-HA/myc-His empty vector was used as a control. The transfected cells 
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were harvested at 24 h, 48 h and 72 h post-transfection, lysed and subjected to 
Western blot analysis for Sema5A expression. The full-length cDNA of human 
Sema5A is 3937 bp, which is translated into a protein of 1075 AA with a 
calculated molecular mass of 120 kDa. Immunostaining results using an anti-
human Sema5A antibody revealed a specific band of 150 kDa in the cell lysates 
of U87-MG transfected with pcDNA3-HA-Sema5A-myc-His, which was absent 
in the empty vector-transfected cells. Sema5A expression was observed to peak at 
24 h, with a slight reduction at 48 h post-transfection (Fig. 6.1A).  
 Since Sema5A is a transmembrane protein, its correct expression on the 
cell membrane as wild-type Sema5A needs to be determined. To this end, the 
transfected cells were subjected to subcellular protein fractionation into 
cytoplasmic, membrane, nuclear soluble, chromatin-bound and cytoskeletal 
fractions. The subcellular fractionation kit contains a series of reagents to be 
added in a stepwise manner, followed by centrifugation and collection of the 
supernatant. The first reagent causes selective cell membrane permeabilization 
releasing the soluble cytoplasmic fraction. The second reagent then dissolves 
plasma, mitochondria and ER/golgi membranes. The third reagent yields the 
soluble nuclear fraction while the insoluble pellet contains the cytoskeletal 
proteins. Cell lysate harboring transfected Sema5A protein was fractionated using 
the fractionation kit and the subcellular fractions were then subjected to Western 
blot analysis using the anti-human Sema5A antibody. As shown in Fig. 6.1B (lane 
3), the transfected Sema5A protein is observed in the membrane fraction with 
very little protein seen in the cytoplasmic fraction (lane 2). Relatively low levels 
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of transfected Sema5A protein was also observed in the nuclear fraction (lane 4) a 
phenomenon commonly seen in lipid based transfection of plasmid DNA. The 
presence of GAPDH protein predominantly in the cytoplasmic fraction indicates 
successful fractionation of the cell extracts. There is some contamination of 
GAPDH in the membrane and nuclear fractions but generally it is acceptable to 

























Fig 6.1. Detection and membrane localization of Sema5A protein in mammalian 
cells. (A) Detection of Sema5A expression in mammalian cells by Western blot 
analysis. The expression construct pcDNA3-HA-Sema5A-myc-His was transfected 
into U87-MG cells. The cells were transfected with empty vector pcDNA3-HA/myc-
His to serve as a negative control. 24 h, 48 h and 72 h after transfection, the cells were 
lysed and subjected to Western blot analysis. Sema5A was detected in pcDNA3-HA-
Sema5A-myc-His transfected U87-MG cells with a peak in expression at 24 h as a 
protein of 150 kDa using anti-human Sema5A antibody, but not in empty vector 
transfected U87-MG cells. (B) Membrane localization of Sema5A protein. U87-MG 
cells were transfected with pcDNA3-HA-Sema5A-myc-His and the cells were lysed 
and the subcellular fractions were separated using a commercial subcellular 
fractionation kit. As shown in the figure, Sema5A protein was detected predominantly 
in the membrane fraction (lane 3), with minimal nuclear localization (lane 4) and 
negligible cytoplasmic localization (lane 2). The unfractionated lysate (lane 1) was 
also subjected to Western blot analysis so as to compare the percentage of Sema5A 
present in each cellular compartment. GAPDH was used as a control to confirm purity 
of the fractionated extracts.         
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6.3 Sema5A inhibits glioma cell proliferation 
 Previous reports from our laboratory have unequivocally demonstrated 
that stimulation of glioma cells with exogenous Sema5A inhibited tumor cell 
invasion and migration. Along the same line, we determined whether ectopic 
expression of Sema5A in glioma cells might have an effect on glioma cell 
proliferation. To this end, the effect of Sema5A on cell viability in U87-MG, 
U251-MG and A172 cells was examined by MTS assay. This is a colorimetric 
assay that measures the activity of enzymes that reduce yellow MTS reagent to 
purple formazan. The quantity of formazan is presumed to be directly 
proportional to the number of viable cells and is measured by an absorbance at 
570 nm.  
 The Sema5A transfected U87-MG, U251-MG and A172 cells were plated 
at desired cell density in 96-well culture dishes and allowed to grow for 24 h, 48 h 
and 72 h before treatment of MTS. Cell viability was assessed by measuring the 
absorbance of formazan. As shown in Fig. 6.2, a significant reduction in cell 
viability was observed in U87-MG cells transfected with Sema5A as early as 24 
hours post-transfection, as compared to mock transfected cells. This trend 
continued until 72 h where a reduction of almost 30% was observed when 
compared to the empty vector control. Similarly, in U251-MG cells transfected 
with Sema5A there was a 32% reduction in cell viability at 24 hours after 
transfection when compared to the empty vector control, and upon further 
incubation a significant reduction in cell viability was consistently observed. As 
for A172 cells transfected with Sema5A the reduction in cell viability was quite 
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gradual and at 48 hours and 72 hours there was a significant reduction in cell 
viability. It is noteworthy that compared to U87-MG, U251-MG cells are fast 
growing cells and A172 cells are relatively slower in the doubling time. These 
results demonstrate that Sema5A significantly reduces cell viability of all the 
human glioma cell lines investigated. 
 The reduction in MTS scores in response to Sema5A overexpression 
indicates a reduction in cell number which could either be due to increased cell 
death or reduced cell proliferation. To elucidate the role of Sema5A on cell 
proliferation of U87-MG cells we used a cell proliferation assay kit, Click-iT EdU 
Alexa Fluor Flow Cytometry kit (Invitrogen). One of the most accurate methods 
for analyzing cell proliferation is direct measurement of DNA synthesis. The 
traditional method was through the incorporation of radioactive thymidine and 
later was replaced by antibody-based detection of the nucleoside analog, 
bromodeoxyuridine (BrdU). The Click-iT EdU flow cytometry assay kit utilizes a 
thymidine analog, EdU (5-ethynyl-2’-deoxyuridine) as an alternative to BrdU and 
the detection is based on “click” chemistry while the percentage of S-phase cells 
are determined using standard flow cytometry. The fluorescence data obtained is 
then analyzed using the FlowJo software.  
As a first step, any cell debris is excluded and only viable cells are gated 
which is followed by gating single cells or singlets. It is important to exclude 
doublets as a doublet of two G1 cells can be mistaken as a single G2/M cell. Once 
this data has been acquired, the number of cells within each phase of cell cycle 
can be determined. A representative dot plot to illustrate the cell cycle 
180 
 
compartments with propidium iodide (PI) across the x-axis and EdU-Alexa647 
across the y-axis is shown in Fig. 6.3. As the S-phase cells are positive for EdU 
they appear bright on the y-axis and can be separated from the G0/G1 and G2/M 
cell cycle phases.      
 U87-MG cells transfected with Sema5A were trypsinized after 24 and    
48 h and used for analysis of S-phase cells using the Click-iT Edu flow cytometry 
assay kit. The results obtained demonstrate that upon expressing Sema5A in U87-
MG cells there was a significant accumulation of cells in the G0/G1 phase at 24 
and 48 hours with an average of 75% of cells in G0/G1 compared with 53% in 
empty vector transfected cells as shown in Fig 6.4. A dramatically lower 
percentage of cells transfected with Sema5A (6%) stained positive for EdU, 
demonstrating that introduction of wild-type Sema5A into U87-MG cells prevents 
cells from entering S-phase. There was no change observed in the number of cells 
in G2/M phase in the U87MG cells expressing Sema5A and empty vector.  
The flow cytometry assay results are consistent with the decrease of MTS 
score caused by Sema5A. It is therefore concluded that ectopic expression of 
Sema5A in glioma cells caused a reduction in MTS score as well as a reduction in 
percentage of S-phase cells, and this reduction is due to decreased glioma cell 
proliferation. It was also observed that overexpression of Sema5A in glioma cells 













Fig 6.2. MTS assay for the effect of Sema5A on glioma cell viability. Human 
glioma cell lines U87-MG (A), U251-MG (B) and A172 (C) were transiently 
transfected with Sema5A or empty vector for 24, 48 and 72 h. The cells were then 
subjected to MTS assay and absorbance at 570 nm was determined. Results were 
expressed as mean ± standard deviation from three independent experiments.        





Fig 6.3. Sema5A overexpression in glioma cells blocks cell cycle progression 
from G0/G1 to S phase. (A) A representative dot plot illustrating the gating of 
different cell cycle compartments. (B) Glioma cells were transiently transfected 
with Sema5A or empty vector for 24 and 48 h. The cells were then dissociated and 
their DNA contents were measured by flow cytometry. The results shown are a 















Fig 6.4. Sema5A overexpression in glioma cells reduces S phase population as 
determined by flow cytometry. U87-MG glioma cells were transiently 
transfected with Sema5A or empty vector control for 24 and 48 h. The cells were 
then dissociated and their DNA contents were measured by flow cytometry. The 
approximate percentages of cells in each major phase of the cell cycle were 
calculated using the FlowJo software. The percentage of the cells in each cell cycle 
phase at (A) 24 h and (B) 48 h post-transfection is graphed above. Results were 
expressed as mean ± standard deviation from three independent experiments.      
(** p<0.01, *** p<0.001 vs. empty vector control) 
184 
 
6.4. Downregulation of Sema5A by RNAi-mediated gene silencing 
enhances anchorage-independent growth of glioma cells 
 The data obtained from both the MTS cell viability assay as well as the 
EdU flow cytometry assay have confirmed that Sema5A inhibits glioma cell 
proliferation. The next step was to examine the anti-tumorigenic role of Sema5A 
in glioma cells. To this end, a loss-of-function approach was taken by 
downregulating the expression of endogenous Sema5A in U87-MG cells prior to 
soft agar assay for anchorage-independent growth. We used SMARTpool siRNA 
(Dharmacon) which is a mixture of 4 independent siRNA sequences targeting 
Sema5A in U87-MG cells that caused a near complete knockdown of Sema5A 
protein expression.  
Briefly, U87-MG cells were transfected with Sema5A SMARTpool 
siRNA using Lipofectamine 2000. Cells subjected to scrambled SMARTpool 
siRNA and mock transfections were used as controls. The expression level of 
Sema5A in the transfected cells was examined by Western blot analysis at 24-96 
hours after transfection. Sema5A expression decreased from around 48 h and by 
96 h there was a reduction of almost 70% when human Sema5A specific 
SMARTpool siRNA was transfected into U87-MG cells, as indicated in Fig. 
6.5A. The half-life of cellular proteins can vary considerably and usually the 
mRNA of siRNA target proteins is significantly depleted at 24-48 hours after 
transfection. The best time-point to determine knockdown of most proteins at the 
protein level is usually 72-96 hours post-transfection.  
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We then proceeded to test the effect of Sema5A on the anchorage-
independent growth of glioma cells. To this end, U87-MG cells were transfected 
with Sema5A siRNA or scrambled siRNA control. The cells were were re-plated 
at the appropriate cell density 96 hours post-transfection and subjected to soft agar 
colony formation assays. The colonies were allowed to grow for 14 days and they 
were stained using 0.05% crystal violet and documented by photomicrography 
(Fig 6.5B). Colonies larger than 50 µm were counted using ImageJ software. As 
shown in Fig. 6.5C, we found that depletion of Sema5A potently enhanced the 
anchorage-independent growth of U87-MG cells when compared to the 
SMARTpool siRNA negative control. Silencing of Sema5A in glioma cells 
induced a nearly 85% increase in colony number of U87-MG cells. Taken 











Fig 6.5. siRNA-mediated Sema5A knockdown enhances anchorage-independent 
growth of U87-MG glioma cell line. U87-MG glioma cells were transfected with 
scrambled siRNA, Sema5A siRNA or mock transfected. (A) Western blot analysis of 
Sema5A protein expression following exposure of U87-MG cells to Sema5A-specific 
SMARTpool siRNA or to control siRNA using anti-human Sema5A antibody. Equal 
loading of protein across samples was verified by immunostaining with the internal 
control anti-GAPDH. (B) Soft agar colony formation assay to assess the effect of 
Sema5A knockdown on anchorage-independent growth. (C) Quantification of colony 
formation assay results. Results were expressed as mean ± standard deviations from two 
independent triplicate experiments. (* p<0.05, *** p<0.001 vs. scramble siRNA control)    
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6.5. Sema5A blocks S phase entry by targeting cell cycle related 
proteins 
 The eukaryotic cell cycle is divided into 4 phases: G1, S, G2 and M. 
During the G1 phase, cells receive mitogenic or growth-inhibitory signals and 
decide whether to pause, proceed or exit the cell cycle. S phase is the cell cycle 
phase where DNA replication occurs while during G2 the cell prepares for 
cellular division. M or Mitosis phase is when the replicated chromosomes 
segregate to either end and cytokinesis occurs resulting in two daughter cells. The 
main players in the cell cycle are cell cycle proteins such as cyclins and cyclin-
dependent kinases (cdks). Cell cycle regulation mostly occurs by the sequential 
activation and inactivation of cdks followed by synthesis and degradation of 
cyclins. The G1 cyclins along with their associated cdks are the critical regulators 
of G1 phase progression and prepares the cell for DNA synthesis in response to 
growth stimulatory signals. The cyclins involved in G1 progression are cyclin D1, 
D2 and D3 and these associate with either cdk4 or cdk6. These cyclin D-cdk 
complexes then proceed to phosphorylate the retinoblastoma protein, pRb as well 
as other cell cycle associated proteins. The phosphorylation of pRb results in the 
release of the E2F transcription factors and drives the cell into the S phase.  
 So as to understand the mechanism by which Sema5A induces G0/G1 
phase arrest, U87-MG cells were transiently transfected with Sema5A or empty 
vector and the cell lysates were harvested at different time points (12 h-36 h). The 
expression level of cyclin D1 was examined by Western blot analysis as it is 
essential for cell cycle progression from G1 to S phase. As shown in Fig. 6.6A, 
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the results showed that the protein level of cyclin D1 was significantly reduced in 
U87-MG cells upon Sema5A overexpression. As it is also known that sustained 
Erk1/2 levels are essential for the continued expression of cyclin D1 in G1 phase, 
we next examined the phosphorylation levels of Erk1/2. Western blot results 
demonstrated a significant reduction in phosphorylated Erk1/2 upon Sema5A 
transfection in U87MG cells while no change in total Erk1/2 was seen. We also 
examined the levels of proliferating nuclear antigen (PCNA) as it is a well-known 
marker for cellular proliferation and is the downstream effector of pRb pathway. 
PCNA levels were also observed to be significantly reduced upon Sema5A 
overexpression as shown in Fig. 6.6B. The decrease in cyclin D1 expression and 
Erk1/2 inactivation followed by PCNA downregulation by Sema5A supports at 



















Fig 6.6. Sema5A regulates cyclin D1 expression, Erk1/2 phosphorylation level and 
PCNA expression. U87-MG glioma cells were transfected with Sema5A or empty 
vector control and cells were harvested at various time points. (A) Western blot 
analysis of cyclin D1, phosphorylated Erk1/2 and total Erk1/2 after transfection with 
Sema5A or empty vector. Equal loading of protein was confirmed with anti-GAPDH 
antibody. (B) Western blot analysis of PCNA, a marker of cellular proliferation in 
U87-MG cells transfected with Sema5A expression vector or empty vector. Equal 
loading of protein was confirmed with anti-β-Actin antibody. 
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6.6 Sema5A induces cyclin D1 loss by increased T286 phosphorylation 
and proteasomal degradation of cyclin D1 
 As our previous results have shown a reduction in cyclin D1 upon 
Sema5A overexpression, we next sought to examine the underlying mechanism.  
Cyclin D1 is known to be regulated by proteasome-mediated degradation, which 
requires T286 phosphorylation. Therefore, we proceeded to test whether Sema5A-
induced cyclin D1 loss was dependent on T286 phosphorylation. With this regard, 
the U87-MG cells were transfected with Sema5A or empty vector control and 6 
hours after transfection an inhibitor of proteasomal degradation, MG132 was used 
to test whether Sema5A-induced cyclin D1 loss and G1 phase arrest can be 
abolished. As illustrated in Fig 6.7A, immunostaining performed on the cell 
lysates showed that Sema5A induces an increase in phosphorylation of cyclin D1 
on Thr286, which is known to tag this protein for ubiquitination and proteasomal 
degradation. It was also observed that MG132 blocked the ability of ectopically 
expressed Sema5A to decrease cyclin D1 levels (Fig. 6.7B). Consistent with this 
















Fig 6.7. Sema5A-mediated cyclin D1 degradation occurs through the proteasomal 
pathway. U87-MG glioma cells were transfected with Sema5A or empty vector and 6 
hours post-transfection the cells were treated with a proteasomal inhibitor, MG132 for 
6 and 12 hours. The cells were harvested for protein and RNA extraction. (A) Western 
blot analysis of phosphorylated cyclin D1 and (B) total cyclin D1 after ectopic 
expression with Sema5A (5A), empty vector (V) or mock transfected (M) and treated 
in the presence or absence of MG132 using anti-phospho cyclin D1 and anti-cyclin D1 
antibodies. Equal loading of protein was confirmed with anti-tubulin antibody and anti-
β-Actin antibody, respectively. (C) Quantitative real-time PCR monitoring of CCND1 





 In this section, a potential tumor suppressor role of Sema5A in glioma 
cells was examined. We started off with generating a vector bearing the full-
length Sema5A cDNA which was subsequently used for ectopic expression in 
glioma cell lines. We investigated the biological functions of Sema5A in glioma 
cell lines with regard to cellular proliferation. Our data suggests that Sema5A 
expression in glioma cells inhibits cell proliferation with a significant proportion 
of cells exhibiting G1 phase arrest followed by reduced number of S phase cells. 
Our results also reveal that the mechanism involved in the G1 phase arrest is due 
to Sema5A-induced cyclin D1 degradation which was confirmed by the changes 
in cyclin D1 phosphorylation mediated by Sema5A. Significantly, our results 
revealed that RNAi induced knockdown of Sema5A was able to enhance 
anchorage-independent growth in glioma cell lines. All these results suggest a 













IDENTIFICATION OF INTERACTING PARTNERS OF 
PLEXIN-B3 CYTOPLASMIC DOMAIN 
 
7.1. Introduction 
 The functional receptors for semaphorins are plexins and these 
transmembrane molecules interact with semaphorins to elicit a wide array of 
signaling cascades. Plexin-B3 is the only characterized receptor for Sema5A and 
this 207 kDa protein has been shown to be critical for neuronal development 
(Artigiani, Conrotto et al. 2004). Recent evidence suggests a potential role for 
plexin-B3 in tumorigenesis and cell migration in cancer cells (Li, Law et al. 2012; 
Danielson 2014). Previous data from our laboratory have identified Fascin-1 and 
RhoGDIα as plexin-B3 binding partners and to be involved in eliciting the 
downstream signaling pathway (Li and Lee 2010; Li, Law et al. 2012).  
 Our results have demonstrated a potential tumor suppressor role for 
Sema5A in glioma cells, which is supported by the observation of a reduction in 
proliferation upon Sema5A overexpression in human glioma cell lines. A 
significant reduction in cyclin D1 and an increase in the phosphorylated form of 
cyclin D1 was also observed upon ectopic expression of Sema5A. Interestingly, 
Nakayama et al., had reported that cullin 7, a member of the cullin E3 ubiquitin 
ligase family, might interact with plexin-B3 (Nakayama, Kikuno et al. 2002). 
Cullin 7 forms a SCF-like E3 ligase complex with FBXW8 and it could also 
interact with another cullin family member, cullin 1 (Tsunematsu, Nishiyama et 
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al. 2006). These cullins provide a scaffold that allows the recruitment of Rbx1, 
Skp1/2 and a F-box protein. This SCF-complex ubiquitinates and degrades 
cellular proteins including cyclin D1 (Alao 2007). 
 Our results demonstrated that overexpression of Sema5A in glioma cells 
causes an increase in phosphorylation of cyclin D1 at T286. Cyclin D1 is known 
to be regulated by proteasomal degradation, which requires its prior 
phosphorylation at T286. The phosphorylated form is then ubiquitinated and 
degraded in the 20S proteasome. Interestingly, the E3 ubiquitin ligase responsible 
for ubiquitinating and degrading cyclin D1 was identified to be cullin 7. To 
investigate the role of plexin-B3 in mediating Sema5A signal in promoting cyclin 
D1 degradation, we began by confirming the interaction between plexin-B3 
cytoplasmic domain (plexin-B3CD) and cullin 7 by pull-down assays, followed 
by mapping the binding site on plexin-B3CD. Furthermore, we had planned to 
identify the F-box protein involved in cyclin D1 ubiquitination and degradation in 
glioma cells. This prove to be a challenging task as none of the F-box proteins 
known to interact with cyclin D1 are expressed in glioma cells.   
7.2 Confirmation of interaction between plexin-B3CD and cullin 7 in 
mammalian cells 
 We initially sought to confirm the interaction between plexin-B3CD and 
cullin 7 by GST-pull down assay using whole cell lysate obtained from glioma 
cells which endogenously express cullin 7. All cullins are modified by 
neddylation or the addition of Nedd8 which enhances their E3 ligase activity. The 
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neddylation of cullins increases the molecular weight of the E3 ligase and they 
migrate as two bands when subjected to SDS PAGE electrophoresis, with the 
slower migrating band as the neddylated form. After confirmation of endogenous 
expression of cullin 7 in glioma cell lines (Fig. 7.1A), GST-plexin-B3CD pre-
bound to Sepharose 4B beads were subjected to GST-pull down assay with A172 
cell line and GST protein serves as a control in the assay. GST-pull down results 
demonstrated that cullin 7 could be readily precipitated by GST-plexin-B3CD as 
indicated by Western blot analysis (Fig. 7.1B), whereas GST control protein could 
not bind to cullin 7. This confirms the interaction between plexin-B3CD and 



























Fig 7.1. Interaction between plexin-B3CD and Cullin 7 in mammalian cells was 
confirmed by GST-pull down assay. (A) Expression of Cullin 7 in A172 cells was 
confirmed by Western blot analysis. A172 cells were subjected to Western blot 
analysis using anti-cullin 7 antibody. (B) GST-pull down assay confirmed the 
interaction between plexin-B3CD and cullin 7. Cell lysates endogenously expressing 
cullin 7 were incubated with GST or GST-plexin-B3CD pre-bound to glutathione 
Sepharose 4B beads in this assay. The bound samples were subjected to Western blot 
analysis using anti-cullin 7 antibody. Endogenous cullin 7 was found to bind 
specifically to GST-plexin-B3CD but not to GST protein. 
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7.3 Identification of cullin 7 binding sites on plexin-B3CD  
After confirmation of the interaction between plexin-B3CD and cullin 7, 
we proceeded onto identifying the binding sites on plexin-B3CD. The sequence of 
intracellular domain of plexins is highly conserved among all plexin family 
members. Nevertheless, each domain exhibits a different function upon 
interaction with its partners. Activation of plexins by semaphorins triggers several 
signaling pathways some of which involve regulating small GTPases. The 
RasGAP domain in plexins shares structural homology with other GTPase-
activating proteins.  The GAP activity of plexin-A1 and plexin-B1 towards R-Ras 
and M-Ras requires interaction of Rnd1 GTPases to the plexin intracellular 
domain (Rohm, Rahim et al. 2000; Bell, Aricescu et al. 2011). Members of the 
plexin-B family also possess a C-terminal PDZ-binding motif through which they 
interact with RhoGEF proteins such as LARG and PDZ-RhoGEF (Oinuma, Katoh 
et al. 2003). Interestingly, the functions of these domains are independent of each 
other, mutation in the GAP domain do not inhibit RhoA activation and deletion of 
PDZ motif does not affect GAP activity of plexins (Oinuma, Ishikawa et al. 
2004).  
 To identify the possible binding sites of cullin 7 on the intracellular moiety 
of plexin-B3, we performed domain mapping by GST-pull down assays using 
various plexin-B3CD fragments and deletion mutants previously generated in our 
laboratory. The plexin-B3CD was divided into three segments (A,B and C) with 
considerable overlap between the fragments as well as deletion mutants with each 
fragment deleted or with deletion of Rnd1, CRIB or RasGAP domain. As shown 
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in Fig. 7.2A, the plexin-B3CDA fragment consists of the RasGAP domain; 
plexin-B3CDB fragment consists of a GTPase binding site and a tyrosine 
phosphorylation site; plexin B3CDC fragment harbors a portion of the GTPase 
binding site, a R-RasGAP domain, a tyrosine phosphorylation site and the highly 
conserved PDZ interaction motif. The deletion mutant plexin-B3CDD has 
fragment A deleted; plexin-B3CDE does not possess a large part of fragment B 
but it does include the GTPase binding site; plexin-B3CDF has most of fragment 
A and fragment B deleted but retains the GTPase binding site; plexin-B3CDG 
harbors a deletion of the GTPase binding site only while retaining the rest of the 
domains; plexin-B3CDH has the CRIB domain deleted; while plexin-B3CDI has 
the R-RasGAP domain specifically deleted.  
 The cDNA of all the plexin-B3CD fragments and deletion mutants were 
cloned into pGEX-KG vector and the resulting bacterial expression constructs 
were transformed into BL21 E.coli strain. These were then generated as GST 
fusion proteins, which were purified using glutathione Sepharose 4B beads. 
Correct expression of the constructs was determined by Western blot analysis 
using anti-GST antibody as illustrated in Fig 7.1B. All of the recombinant 
proteins were successfully expressed as GST-fusion proteins at the expected sizes. 
 To identify specific domains on plexin-B3CD that interact with cullin 7, 
GST-pull down assay was performed using A172 whole cell lysate, which 
endogenously expresses cullin 7. In the assay, A172 cell lysate was incubated 
with purified GST-plexin-B3CDA, B, C, D, E, F, G, H and I fusion proteins 
respectively. GST-plexin-B3CD was also subjected to pull-down assay to serve as 
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a positive control for the interaction with cullin 7. To our surprise, all the three 
plexin-B3CD fragments A, B and C interacted with cullin 7, as shown in Fig 
7.2A. Judging from the relative signal intensities, more cullin 7 proteins seem to 
be co-precipitated with fragments A and B, lesser with fragment C. 
Comparatively, the interaction with full-length plexin-B3CD was much weaker 
suggesting that the plexin-B3CD fragments have a much higher binding affinity 
to cullin 7 than the entire plexin-B3 intracellular domain. Similarly, deletion of 
fragments A and B of plexin-B3CD showed reduced interaction while the deletion 
of both A and B has slightly higher interaction. This could be because deletion of 
both fragments A and B could have unmasked additional interaction sites present 
on fragment C. The deletion of Rnd1 and CRIB does not have much difference in 
relation to binding affinity while deletion of R-RasGAP domain possessed 
binding affinity similar to fragment C of plexin-B3CD. Taken together, all these 
results suggest cullin 7 interacts with plexin-B3CD through multiple interaction 
sites and their binding affinity could be dependent on their structural 
conformation. It is noteworthy to mention that previous published results from our 
laboratory had also observed similar findings with relation to interaction of 
plexin-B3CD with fascin-1 and RhoGDIα (Li and Lee 2010; Li, Law et al. 2012). 
As well as previous unpublished data from our laboratory have indicated that 
plexin-B3CD fragments A and B form intramolecular interactions with fragment 
C thus indicating that the N-terminus and C-terminus of plexin-B3CD do indeed 
interact. Upon activation by Sema5A, there would be a conformational change 
similar to plexin-B1 that would expose binding sites essential for interaction with 
200 
 
their partners(Antipenko, Himanen et al. 2003). This could also be the reason that 
the individual plexin-B3CD fragments possess a higher binding affinity when 






















Fig 7.2. Schematic representation of plexin-B3CD fragments and Western blot 
analysis of their expression as GST fusion proteins. (A) Schematic 
representation of various plexin-B3CD fragments. (B) Expression of the plexin-
B3CD fragments as GST fusion proteins. The plexin-B3CD fragments were cloned 
into pGEX-KG vectors and were transformed into BL21 E.coli cells. The GST 
fusion proteins were purified by glutathione Sepharose 4B beads and the resulting 
protein was verified by Western blot analysis using anti-GST antibody. 
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Fig 7.3. The cytoplasmic domain of plexin-B3 interacts with Cullin 7 through 
multiple binding sites. GST pull-down assay was performed to identify the 
interaction site of cullin 7 on plexin-B3 cytoplasmic domain. Whole cell lysate 
endogenously expressing cullin 7 was incubated with GST-plexin B3CD, GST-
plexinB3CDA-I for pull-down assay. The bound samples were subjected to 
immunoblotting and analyzed using anti-cullin 7 and anti-GST antibody.  
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7.4 RNAi-mediated downregulation of Cullin 7 in glioma cells to 
identify F-box proteins involved in cyclin D1 ubiquitination 
 Cyclin D1 is a protein with a short half-life of ~30min. During cell cycle 
progression, when the cell enters S phase cyclin D1 is phosphorylated at T286 
residue and gets exported to the cytoplasm for subsequent ubiquitination and 
proteasomal degradation (Guo, Yang et al. 2005). Several F-box proteins have 
been identified for ubiquitinating cyclin D1 and targeting it for degradation. 
Fbxw8, Fbxo4 are the main F-box proteins known to be responsible for this 
function while Fbxo31 has been observed to ubiquitinate cyclin D1 upon DNA 
damage (Lin, Barbash et al. 2006; Okabe, Lee et al. 2006; Santra, Wajapeyee et 
al. 2009). Fbxw8 binds to cullin 7 and mediates cyclin D1 degradation while 
Fbxo4 interacts with cullin 1 for the same function.  
 Now that we have proven that plexin-B3 cytoplasmic domain interacts 
with cullin 7 and as we have also demonstrated a significant increase in 
phosphorylated cyclin D1 upon Sema5A overexpression in glioma cells, the next 
step was to prove that cullin 7 was mediating the degradation of cyclin D1 upon 
Sema5A overexpression. We began by inhibiting cullin 7 expression in glioma 
cells by using specific siRNAs targeting cullin 7. A172 cells were transiently 
transfected with cullin 7 siRNA and the cells were harvested at 24 h, 48 h and 72 
h post-transfection. The lysates were then analyzed using Western blot analysis to 
detect changes in cullin 7 expression levels. The cullin 7 siRNA caused a 
significant reduction in cullin 7 protein levels from 48 h onwards as illustrated in 
Fig. 7.4.  
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 The proposed strategy was to knockdown cullin 7 in glioma cells followed 
by Sema5A overexpression, and the lysates would be collected for 
immunoprecipitation using phospho cyclin D1 antibodies followed by 
immunoblotting using antibodies specific for the F-box proteins. The speculation 
was that upon Sema5A overexpression the plexin-B3 signaling pathway would be 
triggered and by immunoprecipating phospho cyclin D1 we can identify the F-box 
protein that was involved in cyclin D1 degradation in glioma cells. Unfortunately, 
when we performed immunoblotting using glioma cell lysates to detect 
endogenous expression of the F-box proteins we were surprised to find that both 
Fbxw8 and Fbxo4 were not expressed in any of the glioma cell lines tested (Fig 
7.4B). Being unable to detect any of the known F-box proteins it proved difficult 





















Fig 7.4. RNAi-mediated knockdown of cullin 7 expression in A172 cells and 
detection of endogenous F-box proteins in glioma cell lines. (A) Western blot 
analysis to detect changes in expression levels of cullin 7 upon siRNA-mediated 
downregulation of cullin 7 in A172 glioma cell line using cullin 7 specific 
antibodies. (B) Western blot analysis to detect endogenous expression levels of 




 In this section, cullin 7 was confirmed to be a novel interacting partner of 
plexin-B3 that binds to the cytoplasmic portion of plexin-B3. Our results 
indicated that cullin 7 interact with plexin-B3 intracellular domain through 
multiple interaction sites. Plexin family members have been shown undergo 
conformational changes upon activation by Sema5A which would explain the 
observation that plexin-B3CD fragments presented with a higher affinity for 
cullin 7 than the full-length plexin-B3CD. Cullin 7, an E3 ubiquitin ligase forms a 
SCF E3 ligase complex (named after Skp 1, Cullin and an F-box protein) in which 
they interact and ubiquitinate target proteins for proteasomal degradation. To date 
there are more than 38 F-box proteins identified in mammals 3 of them have been 
demonstrated to target cyclin D1 for ubiquitination in a T286 phosphorylation- 
dependent manner. Nonetheless, negligible expression of these F-box proteins      
(Fbxw8 and Fbxo4) was found in glioma cell lines. It is tempting to speculate that 
there could be novel F-box proteins that could target cyclin D1 in glioma cells. 
Notably, a recent report has demonstrated that Fbxw8, Fbxo4 and Fbxo31 are not 
involved in cyclin D1 ubiquitination during normal cell cycle progression (Kanie, 
Onoyama et al. 2012). This observation highlights the fact that unknown F-box 









8.1 Summary of results 
 Semaphorins and plexins are classical axon guidance molecules that are 
involved in a myriad of biological functions especially during development of the 
nervous system. They have also been implicated in many aspects of tumorigenesis 
such as angiogenesis, tumor growth and metastasis, tumor cell migration and 
invasion. In this study, the role of Sema5A and its receptor plexin-B3 in human 
glioma progression was investigated. We showed that Sema5A protein levels are 
downregulated towards high-grade gliomas as with no major change in mRNA 
levels. This led to the speculation that Sema5A could be regulated in a post-
transcriptional manner in glioma cells. This hypothesis was validated by our 
discovery of novel alternatively spliced variants of Sema5A in glioma cells,which 
are translated into truncated and/or misfolded proteins rapidly targeted for 
degradation by the proteasomal pathway, hence resulting in a decline in the level 
of Sema5A protein. The other post-transcriptional regulatory mechanism of 
Sema5A expression we identified was through microRNAs. By performing in 
silico screening, we identified the oncomiR miR-21to be involved in regulating 
Sema5A expression. Interestingly, it was observed that miR-21 could target and 
downregulate Sema5A protein levels by translational repression and not by 
mRNA degradation. This finding is consistent with a decline in Sema5A protein 
observed in advanced grade glioblastomas. A significant increase in the 
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proliferation capacity of the glioma cells was observed upon overexpression of 
miR-21 which can be abolished once Sema5A was transiently transfected in the 
same glioma cells. More importantly, we studied the biological functions of 
Sema5A in human glioma progression; the results demonstrate that Sema5A 
could exhibit tumor suppressor functions in glioma by suppressing glioma cell 
proliferation. It elicits this tumor suppressive function by targeting cell cycle 
related proteins and predominantly blocking the cell cycle at G0-G1 phase. 
Further, we revealed that cullin 7 interacts with plexin-B3 and it could potentially 
be involved in the downstream signaling pathway elicited by Sema5A and plexin-
B3. We had also mapped the interaction domains of plexin-B3 and cullin 7. All 
these results together demonstrate that Sema5A and plexin-B3 play an important 
anti-tumorigenic role in human gliomas through mediating various biological 
processes.  
8.2 Post-transcriptional regulation of Sema5A in human gliomas 
8.2.1 Aberrant splicing of Sema5A mRNA in gliomas 
 The splicing of mRNAs is a highly complex process commonly occurring 
in the eukaryotic nucleus. It is a post-transcriptional mechanism that has a strong 
ability to regulate gene expression and creating protein diversity. Alternative 
splicing is the term given when a primary mRNA transcript is processed resulting 
in generating more than one mature mRNA and it has been estimated that almost 
94% of mammalian genes undergo alternative splicing. The spliceosome is 
responsible for carrying out splicing, the spliceosome is a multiprotein complex 
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that consists of small nuclear ribonucleoprotein particles and auxiliary proteins 
that possess the ability to recognize splice sites and catalyse the splicing reaction. 
Regulation of splicing can occur at various levels, such as the influence of trans 
factors and cis elements, single nucleotide polymorphisms and mutations. Most 
researchers claim that the abundance of splicing factors in a particular cell type 
can influence splicing (Chen and Manley, 2009), while others believe that the 
usage of alternative promoters would influence splicing decisions (Kornblihtt, 
2005). Despite these trans factors, there are certain cis sequences that can 
influence splicing as well. Exons are flanked by intronic sequences AG and GT 
and these sequences along with auxiliary sequences known as exon splicing 
enhancers and intronic splicing enhancers are known to regulate splicing too. 
With the recent advances in next generation sequencing it has been made possible 
to completely sequence the human genome. One of the consequences of next 
generation sequencing was the expansion of the single nucleotide polymorphism 
(SNP) database, dbSNP. As the protein-coding region of the human genome is 
estimated to be only 2% of the whole genome it is highly likely SNPs present in 
the coding region can regulate gene expression and splicing decisions. Finally, 
alternative splicing could be regulated by exonic mutations that could alter the 
translated protein by either introducing a premature termination codon (non-sense 
mutation), by causing a translation frame-shift (frameshift mutation) or by 
changing an amino acid (missense mutation). It is highly likely that synonymous 
mutations that do not alter the protein sequence could also influence protein 
structure by regulating splicing patterns (Chamary et al., 2006).  
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Recently the contribution of aberrant gene splicing to cancer development 
has received a lot of attention. Many of the cancer related splicing alterations are 
genomic splice site mutations and mutations in the AG and GT intronic 
dinucleotides usually results in exclusion of the subsequent exon. Almost 50% of 
all exonic deletions can lead to a frame-shift yielding a truncated protein and 
mutations at the AG and GT intronic regions can be as deleterious as a non-sense 
mutation. A mutation at the AG-GT splice site of the tumor suppressor hSNF5 
causes a deletion of exon 7, resulting in a frame-shift in the translational reading 
frame and a truncated protein, and this has been known to cause paediatric brain 
tumors when the other allele undergoes a “second hit” by deletion (Taylor et al., 
2000). Another mechanism by which mutations can cause aberrant splicing is by 
creation of additional cryptic splice sites. An AT to GT mutation in the estrogen 
receptor gene in breast cancer creates a cryptic 5’ splice site that leads to an 
inclusion of 69 nucleotides into the reading frame (Wang et al., 1997).  
  Published reports from our laboratory had indicated that Sema5A and its 
receptor, plexin-B3 can inhibit glioma cell invasion and migration (Li and Lee 
2010; Li, Law et al. 2012). Furthermore, they also observed a significant 
suppression of Sema5A protein levels towards high-grade gliomas (Li, Law et al. 
2012). With this data in hand, we embarked on analyzing the levels of Sema5A 
mRNA levels in high-grade glioma. No significant difference was observed in 
Sema5A mRNA levels in the grades of glioma analyzed. We utilized an approach 
of cloning the Sema5A gene obtained from glioma biopsies followed by DNA 
sequencing of the gene to identify any genetic alterations in the Sema5A gene. 
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With this approach we identified novel alternatively spliced isoforms of Sema5A 
that were specific to glioma. The most predominant isoform was the deletion of 
exon 4 from the Sema5A gene, as the deletion of exon 4 resulted in a translational 
frame shift and a premature stop codon this isoform was targeted for degradation 
by the proteasomal pathway. Our results did not reveal any mutations in the 
Sema5A coding region.  
A search on the dbSNP database revealed that there are 11658 variants in 
the human Sema5A gene sequence. Though we did not identify any glioma-
specific exonic SNPs in our analysis, it is quite possible that there might be SNPs 
present in the intronic regions could also influence Sema5A splicing patterns in 
gliomas. Another mechanism by which Sema5A undergoes aberrant splicing 
could be due to mutations in the genomic splices sites in the intronic AG and GT 
dinucleotides or intronic mutations that can cause inappropriate creation of cryptic 
splice sites. These splicing defects have been commonly observed as a means for 
cancer cells to inactivate tumor suppressors thus providing a survival advantage 
for the tumor. Mutations in the 5’ and 3’ flanking AG and GT sequences usually 
result in exon exclusion and generation of novel cryptic splices sites tend to result 
in retaining of intronic sequences. The genetic analysis of Sema5A in human 
gliomas revealed a number of alternative splice variants of Sema5A that result 
from deletions of exon 4, 7, 11 and inclusion of a portion of intron 2a upstream of 
exon 3. It would be interesting to sequence the genomic DNA of Sema5A in high-
grade glioblastomas so as to determine any mutations or SNPs in the intron-exon 
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junctions or within intronic regions which could influence splicing patterns and 
contribute to the aberrant splicing of Sema5A observed in high-grade gliomas.   
8.2.2 Significance of microRNA-21 mediated regulation of Sema5A in glioma 
 MicroRNAs are small non-coding RNAs that have the ability to bind to 
the 3’ untranslated region of genes and regulate their expression by either 
mediating mRNA degradation or translational repression. With more than 1500 
human miRNAs identified in a relatively short time-frame as well as the myriad 
numbers of predicted mRNA targets, these small RNAs seem to be pivotal in 
regulating various cellular functions. Abnormal expression of miRNAs could lead 
to several diseases such as neurodevelopmental diseases, cardiovascular diseases, 
inflammation and cancer (Ardekani and Naeini 2010). In fact, numerous studies 
have highlighted the role played by miRNAs in regulating apoptosis and cellular 
proliferation, which is often dysregulated in different cancer types.  
 The small regulatory RNA, miR-21, is encoded by the gene pri-miR-21 
which is located within the intronic sequence of TMEM49 gene (Kumarswamy, 
Volkmann et al. 2011). Interestingly, pri-miR-21 possesses its own promoter 
region and poly(A) tail through which transcription of the miRNA is initiated and 
terminated. Once pri-miR-21 is transcribed, it is then processed into mature miR-
21. Many studies have reported dysregulation of miR-21 in almost all human 
cancers, including glioblastomas. Apart from its role in cancer development, miR-
21 is also abnormally regulated in other pathological conditions such as in 
ischemic heart disease and cardiac hypertrophy (Cheng and Zhang 2010).  
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 In cancer cells, miR-21 is commonly upregulated and enable the tumor 
cells to evade apoptosis, and increase tumor cell invasion and metastasis. In a 
recent study on pancreatic cancer it was shown that an inhibition of miR-21 
strongly suppressed cell proliferation both in vitro and in vivo and the cells died 
by mitochondrial apoptosis (Sicard, Gayral et al. 2013). Similar results were also 
obtained in an independent study performed on breast cancer cells; knockdown of 
miR-21 inhibited breast cancer cell proliferation in vivo and in vitro as well as 
inhibited the in vitro migration of breast cancer cells (Yan, Wu et al. 2011). It is 
well known that each miRNA targets a plethora of genes with varying functions 
and binding efficiency. As for miR-21 it seems to consistently target genes 
involved in key tumor suppressor pathways such as components of the PTEN, 
p53, TGF-β and mitochondrial apoptosis pathways (Zhang, Wang et al. 2010; 
Buscaglia and Li 2011; Li, Zhang et al. 2013; Ma, Choudhury et al. 2013). 
 Numerous miR-21 targets have been identified in cancers and the most 
important ones are Programmed cell death 4 (Pdcd4), Sprouty family members: 
Spry1 and Spry2, PTEN and Tropomysin 1 (Tpm1) (Zhu, Si et al. 2007; 
Asangani, Rasheed et al. 2008; Thum, Gross et al. 2008; Zhang, Wang et al. 
2010; Kwak, Kim et al. 2011). In colorectal cancer cells, miR-21 post-
transcriptionally downregulates the tumor suppressor Pdcd4 and significantly 
enhances tumor cell invasion and metastasis (Asangani, Rasheed et al. 2008). In 
another study by Zhou and colleagues, inhibition of miR-21 in glioma cells by 
utilizing LNA or 2’O-Me-miR-21 led to an increase in caspase-dependent 
apoptosis (Zhou, Zhang et al. 2010). Furthermore, a recent study observed a 
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reduction in tumor growth in vivo upon miR-21 suppression in glioblastoma cells 
(Gaur, Holbeck et al. 2011).  
 In our study, we identified aberrant splicing of Sema5A to be a potential 
mechanism to account for the downregulation of Sema5A protein levels. We 
believed that there might be more than one mechanism that downregulated 
Sema5A protein expression and its tumor suppressor properties. As we had not 
observed any reduction in Sema5A mRNA levels the plausible regulatory 
mechanism would be miRNA-mediated regulation. We ventured to screen for any 
potential miRNAs that could regulate Sema5A. The miRNAs we had chosen for 
our analysis were known to behave in an oncogenic manner and their expression 
was always upregulated in glioma cells. MiR-21 was the most promising miRNA 
and it was observed to give rise to a significant reduction of Sema5A mediated by 
translation repression. It is noteworthy that the post-transcriptional 
downregulation of another miR-21 target Pdcd4 was also found to be via 
translational repression. Parallel to findings from other researchers, miR-21 
overexpression in glioma cells enhanced glioma proliferation and when Sema5A 
was ectopically expressed in these miR-21 expressing cells the proliferating effect 
was completely abolished.   
The results of these experiments allow us to reasonably conclude that 
miR-21 post-transcriptionally downregulates Sema5A and the oncogenic miR-21 
is able to stimulate glioma cell proliferation by repressing the tumor suppressive 
capability of Sema5A. It is also interesting that miR-21 is known to be activated 
by Erk1/2 upon stimulation of the Her2/EbB2 pathway (Huang, Wu et al. 2009). 
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As ErbB2 has been shown to interact with plexin-B3 (Swiercz, Kuner et al. 2004) 
and in our experiments Erk1/2 was downregulated upon ectopic expression of 
Sema5A in glioma cells, it is highly likely that there might be a feedback loop 
emerging from the ectopic expression of Sema5A that could lead to 
downregulation of Erk1/2 and subsequently target miR-21, resulting in abrogating 
the tumorigenic effects of this oncogene.  This mechanism agrees with our 
hypothesis that abnormal regulation of Sema5A could disrupt its binding to its 
receptor, plexin-B3 and result in deregulating the downstream signaling pathways 
which inhibit cancer growth. An inverse correlation of miR-21 and Sema5A 
towards high-grade glioma is seen and we have also proven that miR-21 
downregulates Sema5A in various glioma cell lines. Furthermore, we have 
elucidated the main function of miR-21 in suppressing Sema5A is to confer a 
proliferative advantage upon the cancer cells but there is still one question that 
needs to be addressed. It is critical that we prove miR-21 directly targets Sema5A 
and that the effects we have observed are through miR-21 targeting an upstream 
signaling molecule in the signaling network. To address this question, a luciferase 
reporter containing the Sema5A-3’UTR can be constructed and transiently 
transfected into HEK293 cells together with miR-21 mimics or inhibitors. A 
luciferase reporter assay would then be performed to determine the levels of 
reporter activity. With the results of those experiments we can conclusively 




8.3 Biological functions of Semaphorin 5A and plexin-B3 in 
tumorigenesis 
8.3.1 Implication of Sema5A and plexin-B3 in cancer progression 
 Accumulating evidence has revealed novel roles for semaphorins and 
plexins in tumorigenesis. They have been found to play critical functions in 
cancer cell proliferation, invasion, migration, dissemination and tumor 
angiogenesis (Rizzolio and Tamagnone 2007; Capparuccia and Tamagnone 2009; 
Neufeld, Sabag et al. 2012). Interestingly, evidence suggests that semaphorins can 
also influence cells in the tumor stroma such as lymphocytes, tumor associated 
macrophages and hematopoietic cells (Muratori and Tamagnone 2012). 
 In human cancers, semaphorins can behave either as an oncogene or a 
tumor suppressor, though there are certain semaphorins that have been shown to 
possess both functions in a tissue specific manner. Plexins are the receptors for 
semaphorins, nevertheless semaphorins have been found to interact and signal 
through other receptors and co-receptors as well. This could explain why some 
semaphorins exhibit contradictory roles in different cancer types, Sema4D, 
Sema4F and Sema5A are one of the common examples of semaphorins that could 
elicit opposing effects in a cell specific manner (Li, Law et al. 2012; Sadanandam, 
Varney et al. 2007; Swiercz, Kuner et al. 2004).  
 Sema5A along with its closely related family member Sema5B are 
members of the transmembrane class 5 semaphorins. Based on their domain 
organization these class 5 semaphorins are distinctly different from other 
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semaphorins. They possess a sema domain along with two clusters of type-1 
thrombospondin repeats (TSR). No clear function of TSR domains have been 
elucidated for Sema5A while TSR in other proteins have been observed to interact 
with molecules of the extracellular matrix (Adams and Tucker 2000). 
Interestingly, TSR domains in other proteins have been found to inhibit cancer 
progression by inhibiting angiogenesis (Zhang, Galardi et al. 2005; Zhang and 
Lawler 2007). It has been elucidated that Sema5A can behave as an inhibitory 
guidance cue that causes collapse of retinal ganglion growth cones and ensure 
correct patterning of retinal projections during neural development (Goldberg, 
Vargas et al. 2004). During the development of the fasciculus retroflexus, 
Sema5A was proven to behave as a bi-functional guidance cue eliciting both anti- 
and pro-migratory effects in developing axons depending on the type of 
proteoglycan that was involved in the interaction (Kantor, Chivatakarn et al. 
2004).  
 Similar to Sema4D, Sema5A has been observed to behave both as an 
oncogene and a tumor suppressor in different types of cancers. Sema5A was 
found to be overexpressed in highly aggressive prostate and pancreatic cancer 
(Sadanandam, Varney et al. 2007). The increased expression of Sema5A in 
gastric and prostate cancers enhanced tumor cell invasion, proliferation, migration 
and tumor growth (Pan, Ren et al. 2009; Pan, Lv et al. 2010; Sadanandam, 
Varney et al. 2010). Further it was shown that an up-regulated level of Sema5A 
reduced apoptosis in pancreatic and endothelial cells (Sadanandam, Rosenbaugh 
et al. 2010; Sadanandam, Varney et al. 2010). Contradictory to the above 
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findings, published reports from our laboratory and other laboratories have 
observed tumor suppressive functions of Sema5A in high-grade glioblastomas 
(Li, Law et al. 2012), colon cancer  (Liu, Lu et al. 2012) and non small cell lung 
carcinoma (Lu, Tsai et al. 2010). Downregulation of Sema5A expression levels 
was observed in non-small cell lung carcinoma and colon cancer, which is 
associated with poor patient survival (Lu, Tsai et al. 2010; Liu, Lu et al. 2012). 
These opposing effects are quite consistent with reports published on other 
semaphorin family members such as Sema3B and it suggests that semaphorins 
can behave in an antagonistic fashion depending on target cells. This is rather 
important with regard to cancers as cancers are heterogenous and the tumor 
microenvironment consists of various regulatory cells in addition to malignant 
cells.  
 In this study, we investigated the expression level of the Sema5A 
transcript in glioma specimens and found that despite reduction of Sema5A 
protein levels in high-grade gliomas there was no significant change observed in 
Sema5A mRNA levels. Our results demonstrate that Sema5A significantly 
inhibits proliferation of glioma cells and ectopic expression of Sema5A in glioma 
cells results in G0/G1 cell cycle phase blockade. Significantly, the downstream 
signaling involved in inhibiting proliferation results in degradation of cyclin D1 
and reduced ERK/MAPK signaling.  
 Recent results obtained from microarray analysis from EMBL where they 
had performed RNA-Seq analysis on 95 human individuals and 27 tissue types so 
as to determine tissue-specificity of protein coding genes, highlights that Sema5A 
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is highly expressed in cerebral cortex, lung, kidney, colon and endometrium. 
While reduced levels of Sema5A are observed in stomach, prostate, pancreas and 
ovaries. It is apparent that Sema5A behaves as a tumor suppressor in the types of 
cancers that arise from tissues in which Sema5A is endogenously expressed. 
While in the other cells in which Sema5A is not normally expressed, oncogenic 
functions of Sema5A have been reported. It is highly plausible that in the cells 
that endogenously express Sema5A, the functional receptor plexin-B3 would be 
present while in the other cells that do not express Sema5A, plexin-B3 would 
possibly not be present. Therefore it is tempting to speculate that Sema5A could 
interact and signal via other unidentified receptors which might possess oncogenic 
properties. Taken together, highlight the importance of Sema5A in cancer cells 
and despite its opposing functions in tumorigenesis, this molecule would receive 
significant attention in the future for its role in cancer progression.  
 The receptor for Sema5A, plexin-B3 has been observed to be widely 
expressed in a variety of cancer tissue types thus indicating a role for plexin-B3 in 
cancer progression. Elevated expression of plexin-B3 is associated with the 
aggressiveness of prostate and pancreatic cancers (Sadanandam, Varney et al. 
2010). Previous work performed in our laboratory has indicated that plexin-B3 
along with Sema5A can inhibit glioma cell invasion and migration (Li and Lee 
2010; Li, Law et al. 2012). Another closely related member of the plexin-B 
family is plexin-B1, this plexin has been studied quite extensively especially in to 
tumorigenesis. Reduced levels of plexin-B1 were found in renal cell carcinoma 
and breast cancers and loss of plexin-B1 correlated with poor patient survival 
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(Gomez Roman, Garay et al. 2008; Rody, Karn et al. 2009). In skin cancer 
increased plexin-B1 expression levels were seen in benign melanoma as 
compared to metastatic melanomas (Stevens, McClelland et al. 2010). Elevated 
levels of plexin-B1 were identified in ovarian cancer cells and RNAi-mediated 
silencing of plexin-B1 in those cells resulted in suppression of cell migration and 
invasion (Ye, Hao et al. 2010). Similarly, in tumors of the cervix and prostate 
high plexin-B1 levels were found as compared to normal cervical or prostate 
tissues, respectively (Wong, Nitkunan et al. 2007; Qiang, Wang et al. 2011). 
Interestingly, in prostate cancer Wong et al. had identified 13 somatic missense 
mutations in the plexin-B1 cytoplasmic domain. The mutations would completely 
block binding to Rac1, Rnd1 as well as inhibiting R-RasGAP and R-Ras binding 
subsequently resulting in enhanced cell migration, invasion, lamellopodia 
formation and adhesion (Wong, Nitkunan et al. 2007). Based on these findings, it 
is highly likely that similar mutations might exist in the plexin-B3 gene in human 
tumors. We had planned on screening the cDNAs obtained from human glioma 
biopsies for any mutations in the plexin-B3 gene. We did attempt to clone the 
plexin-B3 gene (data not shown) but unfortunately due to the large size of this 
gene the cloning procedure deemed to be highly challenging. Nevertheless, this is 
one of the future projects to be performed in our laboratory.  
8.3.2 Importance of the role played by Sema5A as a cell-cycle regulator 
 Semaphorins have always been identified predominantly as neuronal 
guidance molecules responsible for ensuring proper patterning of axons in the 
developing central nervous system. Semaphorins trigger multiple signaling 
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pathways and the same semaphorin could elicit opposing effects in a cell-type 
specific manner. In cancer cells, they have been observed to regulate cell 
proliferation, migration, invasion, metastatic dissemination and angiogenesis. 
Semaphorins have been found to behave as both pro- and anti-proliferative factors 
in cancer cells. A role in proliferation in non malignant cell types has also been 
elucidated for semaphorins and plexins. For example, Sema3A was found to 
inhibit proliferation of retinal pigment epithelial cells (Bai, Yu et al. 2013) and 
there is ample evidence proving that Sema3A can inhibit tumor progression 
through inhibiting tumor growth and survival by inhibiting interaction of its co-
receptor Nrp1 with VEGF (Herman and Meadows 2007; Kigel, Varshavsky et al. 
2008; Chakraborty, Kumar et al. 2012). Furthermore, Sema3D enhances 
proliferation of neural crest cells in zebrafish and the authors hypothesize that 
Sema3D lies downstream of the Wnt pathway which regulates proliferation in 
neural crest cells (Berndt and Halloran 2006). The axonal repellant Sema3E 
inhibits proliferation of airway smooth muscle in the lungs of asthmatic patients 
by suppressing Akt and ERK1/2 phosphorylation (Movassagh, Shan et al. 2014).  
 In cancer cells, most of the semaphorins have been implicated in 
regulating proliferation. Sema3C enhanced gastric tumor growth (Miyato, Tsuno 
et al. 2012); Sema4F increased proliferation of prostate cancer cells and increased 
Sema4F levels correlated with tumor recurrence (Ayala, Dai et al. 2008); Sema3E 
and Sema3D inhibited glioma cell proliferation both in vitro and in vivo (Sabag, 
Bode et al. 2012); Sema5A was observed to enhance tumor proliferation in 
gastric, prostate and pancreatic cancers (Pan, Lv et al. 2010; Sadanandam, Varney 
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et al. 2010). Not many research groups had focused on the downstream signaling 
mechanism involved in semaphorin mediated regulation of cell cycle.  
 Interestingly, the B type plexins are known to interact with tyrosine kinase 
receptors, Met and Ron (Conrotto, Corso et al. 2004); stimulation of both these 
factors would initiate invasive growth of cancer cells. While in breast cancer cells, 
plexin-B1 and B2 have also been found to interact with ErbB-2 (Swiercz, Kuner 
et al. 2004). Interestingly, following stimulation of plexin-B1 by Sema4D it can 
phosphorylate ErbB-2 and enhance tumor invasion and migration. While at the 
same time Sema4D stimulation of plexin-B1 associated with Met can inhibit 
tumor invasion and migration (Swiercz, Worzfeld et al. 2008). This is clear proof 
that the exchange of the binding partners was sufficient to shift Sema4D elicited 
response from pro- to anti-migratory. Similar to plexin-B1, plexin-B3 also has 
been observed to form complexes with Met and ErbB-2 and it would be 
interesting to determine whether binding of these tyrosine kinase receptors might 
be the reason for the antagonistic effects of Sema5A in different cancer (Artigiani, 
Conrotto et al. 2004; Swiercz, Kuner et al. 2004).  
 As for the role played by Sema5A and plexin-B3 in tumor proliferation, it 
was elucidated by Sadanandam et al. that Sema5A enhances proliferation in 
endothelial cells and the mechanism is through angiogenic factors such as 
interleukin-8 and VEGF (Sadanandam, Rosenbaugh et al. 2010). In our study, we 
studied the tumor suppressive role played by Sema5A in relation to glioma cells. 
We observed a significant reduction in proliferation induced by Sema5A, which is 
mediated by cell cycle arrest at G0/G1 phase of the cell cycle. Analysis of cell 
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cycle related proteins revealed that Sema5A causes a significant reduction in the 
level of cyclin D1 by promoting its phosphorylation. Cyclin D1 is a critical 
regulator of cell cycle, which interacts with CDK4 and CDK6 to phosphorylate 
and inactivate the tumor suppressor retinoblastoma protein (pRb) during 
progression of the cell cycle at G1 phase. Cyclin D1 signal is turned off by 
phosphorylation at Thr286 which causes ubiquitination and degradation by the 
26S proteasome in the cytoplasm. Cyclin D1 is overexpressed in many types of 
human neoplasms and it can behave as an oncogene as well. In our experiments, 
upon ectopic expression of Sema5A we observed a reduction in cyclin D1 levels 
and upon the use of proteasomal inhibitors we were able to prove that cyclin D1 
was targeted for proteasomal degradation. Furthermore, we proved that reduction 
of cyclin D1 levels resulted in reduction of PCNA, a cyclin-D1 associated protein 
and a marker for cellular proliferation.  
 Erk1/2 affects many cellular processes, the most important of which is cell 
cycle progression. In fibroblasts it was found that Erk1/2 expression was critical 
for G1/S progression and reduced Erk1/2 levels resulted in reduced cyclin D1 
mRNA levels and resulted in cell cycle arrest (Meloche and Pouyssegur 2007). 
Therefore, we examined phosphorylation status of Erk1/2 upon Sema5A 
overexpression in glioma cells and interestingly we observed a significant 
reduction in Erk1/2 phosphorylation. Erk1/2 has been observed to influence G1/S 
progression in many ways, one of which includes enhancing transcriptional 
activity of cyclin D1. In our study, this was not the case as we did not observe a 
decrease in cyclin D1 mRNA upon Sema5A overexpression. Therefore, Erk1/2 
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possibly influences cell cycle arrest by other mechanisms such as up-regulation of 
p21 or down-regulation of proliferative genes. To our knowledge, this is the first 
evidence showcasing the downstream mechanism involved in Sema5A-mediated 
cell cycle regulation. The signaling networks in cancer cells are highly complex 
and indeed there would be extensive cross talk between multiple signaling nodes. 
It would be interesting to elucidate the upstream signaling pathway especially to 
understand the role played by tyrosine kinase receptors in eliciting the Sema5A-
plexin-B3 downstream signals.   
8.4 Significance of interaction of plexin-B3 with cullin 7 
8.4.1 Significance of direct interaction between plexin-B3CD and cullin 7 
 Members of the cullin family of proteins function as scaffolding adaptors 
for RING finger type E3 ligases. In humans there are seven cullin proteins 
expressed: CUL1-3, CUL4A, CUL4B, CUL5, CUL7 and the closely related p53-
associated parkin-like cytoplasmic protein (PARC). These cullin proteins can 
form an E3 ligase complex which is similar to the typical E3 ligase-Skp1-CUL1-
F- box protein complex (SCF complex).  
 The SCF complex is composed of two regions, a substrate targeting 
component and a RING component. The substrate targeting component is known 
as the F-box protein which is characterized by a 40 amino-acid F-box domain. 
The adaptor protein Skp1 links the F-box protein to the amino-terminus of CUL1. 
While the function of the RING component is to recruit an E2 ubiquitin-
conjugating enzyme, characterized by the presence of a highly conserved 
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ubiquitin-conjugating domain. The targeted proteins are finally degraded by the 
proteasomal pathway.  
 Cullin family of proteins are involved in a wide array of cellular 
processes, such as cell-cycle regulation, DNA replication and DNA damage check 
points. There has also been some evidence to indicate their roles in cancer 
progression as well. Interestingly, these cullin proteins seem to be highly essential 
during embryonic development as it has been observed that genetic ablation of 
their genes in mice results in embryonic lethality (Dealy, Nguyen et al. 1999; 
Singer, Gurian-West et al. 1999; Arai, Kasper et al. 2003).  CUL7 knock-out mice 
exhibit neonatal lethality with smaller fetuses accompanied by abnormal placental 
development (Arai, Kasper et al. 2003). Mutations in CUL7 have been associated 
with hereditary human diseases such as 3-M syndrome and Yakult syndrome, 
which are characterized by growth retardation (Huber, Dias-Santagata et al. 2005; 
Maksimova, Hara et al. 2007). CUL7 forms SCF complexes with Fbxw8, the only 
F-box protein identified so far to interact with CUL7 (Dias, Dolios et al. 2002). 
Cullin 7 might also have other functions such as p53 regulation, cyclin D1 
degradation, apoptosis and malignant transformation mediated by simian virus-40 
(SV40) large T-antigen. Recently, accumulating evidence showed an over 
expression of CUL7 in breast carcinoma and it was demonstrated to enhance 
proliferation and invasion of breast cancer cell lines by suppressing the tumor 
suppressor p53 (Hongsheng, Fenping et al. 2014). This is rather interesting as the 
F-box mediator protein for CUL7, Fbxw8, has been hailed as a potential tumor 
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suppressor as it has been found to inhibit cancer cell proliferation through cyclin 
D1 proteolysis (Okabe, Lee et al. 2006).  
 In our experiments, we were interested in identifying unique binding 
partners to plexin-B3 and a publication by Nakayama et al had identified that 
plexin-B3 could potentially bind to cullin 7 (Nakayama, Kikuno et al. 2002). 
Interestingly, in our experiments using ectopic expression of Sema5A in glioma 
cells we had observed a significant downregulation of cyclin D1 and as cullin 7 
has been found to be involved in cyclin D1 degradation, this seemed to be the 
ideal candidate to work on. By using GST- pull down assays, we demonstrated 
that cullin 7 is an interaction partner of the cytoplasmic domain of plexin-B3. 
Direct interaction between plexin-B3 and cullin 7 provides a novel mechanism to 
account for the role played by Sema5A in cell-cycle control, and likely in cancer 
cell proliferation as well.  
 To elucidate the role played by Sema5A in cell-cycle control through 
cullin 7, the next step was to identify the F-box protein involved in the regulation 
of cyclin D1. Unfortunately, none of the known and validated F-box proteins that 
interact with cullin 7 or cullin 1 were expressed in glioma cells. A recent 
publication illustrated that none of the known F-box proteins were able to 
ubiquitinate and target cyclin D1 for degradation in mouse fibroblasts and their 
results suggest the presence of additional unidentified F-box proteins that could 
mediate cyclin D1 degradation (Kanie, Onoyama et al. 2012) . This could also be 
the case in our glioma cell lines, there might be unidentified ubiquitin ligases that 
could interact with cullin 7 and subsequently target cyclin D1 for degradation. 
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Identifying these novel ubiquitin ligases is beyond the scope of this project and it 
can be a challenging task as well. One method of identifying novel F-box binding 
partners of cullin 7 involved in cyclin D1 degradation would be by employing a 
combination of stable isotope labeling with amino acids in culture (SILAC)- 
based approach along with immunoprecipitation of GFP-tagged cullins expressed 
in glioma cell lines. This would be followed by separation of the bound proteins 
in SDS-PAGE, subsequent digestion of the protein lanes and finally identifying 
the interacting proteins by LC-MS or MS.   
8.4.2 Binding sites of cullin 7 on plexin-B3CD 
 The structure of plexins are highly conserved and the cytoplasmic domain 
of both plexin A and B family members possess R-RasGAP C1 and C2 domains 
that are separated by a small GTPase binding region. In plexin-B1, the amino-
terminal R-RasGAP C1 domain was found to interact with the carboxy-terminal 
R-RasGAP C2 domain and interestingly binding of Rnd1 to this site perturbs this 
interaction (Oinuma, Ishikawa et al. 2004). Data from our laboratory has also 
indicated an interaction between the amino-terminal C1 domain and the carboxy-
terminal C2 domain in plexin-B3 and that binding of its ligand Sema5A could 
elicit a conformational change in the structure of plexin-B3.  
 We mapped the possible binding sites of cullin 7 on plexin-B3 
cytoplasmic domain by employing GST-pull down assay using plexin-B3 domain 
deletion constructs. The results indicate that multiple regions of the plexin-B3 
cytoplasmic domain are involved in interacting with cullin 7. It is possible that 
228 
 
binding of cullin 7 could be dependent on the 3D conformational structure of 
plexin-B3CD. It was also observed that the binding affinity of plexin-B3 
fragments A and B were much higher than full-length plexin-B3CD. These results 
seem to indicate that the binding sites required for interaction with cullin 7 are 
only exposed upon plexin-B3 undergoing changes in its conformational make-up.  
8.5 Future directions 
 In this study, we have reported a tumor suppressor function of Sema5A in 
glioma cells and elucidated the anti-proliferative role of Sema5A in human 
gliomas. Contrary to our findings of Sema5A on inhibiting proliferation, other 
researchers have observed pro-tumorigenic and proliferative effects of Sema5A in 
other human cancers. Such contrasting results have also been found in other 
semaphorins such as Sema4D. It was observed in breast cancer cells that Sema4D 
stimulated plexin-B1 and forms complexes with Met to transduce the signal 
enhancing breast cancer cell migration (Conrotto, Corso et al. 2004). While 
another study had found that upon Sema4D stimulation plexin-B1 interacts with 
ErbB-2 and inhibits cancer cell migration (Swiercz, Kuner et al. 2004). The latter 
study suggests that anti- or pro-migratory effects of Sema4D in breast cancer cells 
depends on the stoichiometry of plexin-B1, Met and ErbB-2 expression levels. 
These two molecules compete for binding to plexin-B1 and are able to counteract 
each other’s effects in the same cells and result in either pro-migratory or anti-
migratory effect. As mentioned earlier, Sema5A is endogenously expressed at 
high levels in the brain, colon and lungs while negligible expression is observed 
in the pancreas and stomach. This suggests that there might be different signaling 
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mediators involved in cells that physiologically express Sema5A. It is possible 
that in those tissues that do not express Sema5A under normal conditions there 
might be other abnormal signaling partners involved in eliciting the signals. On 
the other hand, these contradictory findings could also be due the unique domain 
structure of Sema5A which has been responsible for its bi-functional role in the 
developing nervous system. One of our future tasks is to investigate the role 
played by the tyrosine kinase receptors Met, Ron and ErbB-2  in the signaling 
pathway mediated by plexin-B3 and Sema5A in glioma cells and other cancer 
types. It is likely a similar mechanism as observed with Sema4D/plexin-B1 and 
the tyrosine kinase receptors might be at play in this context as well.  
  miRNAs, are critical mediators involved in the regulation of gene 
expression by either degradation of target mRNA or translational repression. We 
have identified miR-21 to serve as a novel agent in downregulating Sema5A 
protein expression in glioma cells by translational repression. An overexpression 
of miR-21 in glioma cells is sufficient to counteract the tumor suppressor effect of 
Sema5A and enhances glioma cell proliferation. To substantiate the role of miR-
21, however further evidence to prove direct interaction between miR-21 and the 
3’UTR of Sema5A is needed. One of our future projects is to construct luciferase 
reporter constructs harboring the miR-21 seed sequence present in the Sema5A-
3’UTR as well as a mutated version of the seed sequence. A luciferase assay 
would then enable us to understand whether miR-21 directly targets Sema5A or if 
Sema5A is an intermediate target.  
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 Carcinogenesis is a multifaceted and multi-step process which involves a 
series of oncogenic hits and tumor suppressor inactivations. Cancer growth and 
proliferation is influenced by many signaling networks as well as by the 
extracellular matrix itself. In our study we have highlighted the tumor suppressor 
role played by Sema5A in glioma cells accompanied by a reduction of Sema5A 
expression levels in human glioma specimens. The final conclusive evidence to 
prove the tumor suppressor function of Sema5A in glioma cells is to validate our 
in vitro findings in in vivo models such as intracranial brain tumor model using 
immunocompromised mice. Our on-going project is to generate glioma cell lines 
stably expressing Sema5A by lentiviral transduction for intracranial injection into 
immunocompromised mice. The resulting animal model will be an invaluable tool 
to understand the tumor suppressor function and provide the rationale to develop 
Sema5A as a potential target for glioma therapy.  
8.6 Conclusions 
  Semaphorins and plexins, the canonical axon guidance molecules 
have recently been implicated in the regulation of various processes in cancer 
progression. Extensive work has elucidated their roles in cancer invasion, 
migration and angiogenesis. Nonetheless, the signaling pathways associated with 
the regulation of these processes have not been clearly elucidated. In this study, 
we aim to investigate the anti-proliferative signaling pathways mediated by 
Sema5A as well as understanding the molecular nature of the Sema5A gene in 
human gliomas.  
231 
 
 Firstly, we screened glioma biopsies for any potential debilitating 
mutations or alternative splicing and our analysis revealed novel alternative splice 
isoforms of Sema5A in human gliomas. Aberrant splicing of mRNAs is quite 
widespread in cancers and they usually confer a growth advantage to the cancer 
cells. Interestingly, these alternative splice variants of Sema5A were rapidly 
targeted for degradation from the cell, further strengthening our hypothesis that 
post-transcriptional mechanisms were at play in downregulating Sema5A protein 
levels. Furthermore, we identified that Sema5A could be targeted by miR-21 and 
that miR-21 enhances tumor proliferation by downregulating Sema5A in gliomas. 
MiR-21 has been consistently observed to be highly overexpressed in many types 
of neoplasms including gliomas. These two mechanisms account for the 
significant downregulation of Sema5A protein in high-grade glioblastomas 
without a concomitant alteration in transcripts.    
 Furthermore, the tumor suppressor effects of Sema5A in inhibiting glioma 
cell proliferation was found to be mediated through an induction of cell cycle 
arrest at G1/S transition promoting proteasomal degradation of the cell cycle 
protein, cyclin D1, which is usually overexpressed in most cancers. Further, 
Sema5A induces a significant reduction in phosphorylated Erk1/2, a critical 
regulator of G1 to S transition. Although the exact signaling mechanism still 
remains to be elucidated, we provide evidence that Sema5A regulates glioma cell 
proliferation.  
 Gliomas are highly proliferative and infiltrative by nature and this is one 
of the reasons that despite surgical resection of gliomas the rate of cancer 
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recurrence is alarmingly high. These aggressive brain tumors are also highly 
resistant to traditional chemo- and radiotherapies which makes them incredibly 
difficult to treat and renders a bleak future for the patients. The results of our 
study provide the rationale to explore the signaling mechanism mediated by 
Sema5A and plexin-B3 so that in the future it might be used as a potential anti-
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Fig S1: RNAi-mediated knockdown of Sema5A in U87-MG glioma cells. U87-MG 
glioma cells were transfected with scrambled siRNA (Scr), Sema5A siRNA or mock 
transfected. (A)Two representative rounds of Western blot analysis of Sema5A protein 
expression following exposure of U87-MG cells to Sema5A-specific SMARTpool 
siRNA or to control siRNA using anti-human Sema5A antibody. Equal loading of 
protein across samples was verified by immunostaining with the internal control anti-
GAPDH. (B) Quantification of Sema5A expression levels at 96 h post-transfection with 
Sema5A siRNA or control siRNA by densitometry of the blots. Results were expressed 
as mean ± standard deviations from two independent experiments. (* p<0.05 vs. 
scramble siRNA control)    
